Background  ||| S:24 E:43 ||| NN
Following  ||| S:43 E:53 ||| VBG
a  ||| S:53 E:55 ||| DT
classic  ||| S:55 E:63 ||| JJ
epithelial-mesenchymal  ||| S:63 E:86 ||| JJ
interaction  ||| S:86 E:106 ||| JJ
developmental  ||| S:106 E:120 ||| JJ
program ||| S:120 E:127 ||| NN
,  ||| S:127 E:129 ||| ,
the  ||| S:129 E:133 ||| DT
mouse  ||| S:133 E:139 ||| FW
neonatal  ||| S:139 E:148 ||| FW
submandibular  ||| S:148 E:170 ||| FW
salivary  ||| S:170 E:179 ||| FW
gland  ||| S:179 E:185 ||| FW
( ||| S:185 E:186 ||| -LRB-
SMG ||| S:186 E:189 ||| NNP
)  ||| S:189 E:191 ||| -RRB-
is  ||| S:191 E:194 ||| VBZ
comprised  ||| S:194 E:204 ||| VBN
of  ||| S:204 E:207 ||| IN
large  ||| S:207 E:213 ||| JJ
and  ||| S:213 E:217 ||| CC
small  ||| S:217 E:223 ||| JJ
ducts  ||| S:223 E:237 ||| NNS
which  ||| S:237 E:243 ||| WDT
terminate  ||| S:243 E:253 ||| VBZ
in  ||| S:253 E:256 ||| IN
lumen-containing ||| S:256 E:272 ||| NNP
,  ||| S:272 E:274 ||| ,
presumptive  ||| S:274 E:286 ||| JJ
acini  ||| S:286 E:292 ||| NN
that  ||| S:292 E:305 ||| WDT
express  ||| S:305 E:313 ||| VBP
embryonic  ||| S:313 E:323 ||| JJ
mucin  ||| S:323 E:329 ||| NNS
[  ||| S:329 E:331 ||| -LRB-
1  ||| S:331 E:333 ||| CD
2  ||| S:333 E:335 ||| CD
3  ||| S:335 E:337 ||| CD
4  ||| S:337 E:339 ||| CD
5  ||| S:339 E:341 ||| CD
6  ||| S:341 E:343 ||| CD
7  ||| S:343 E:345 ||| CD
8  ||| S:345 E:347 ||| CD
]  ||| S:347 E:349 ||| -RRB-
.  ||| S:349 E:351 ||| .
Progressive  ||| S:351 E:371 ||| JJ
prenatal  ||| S:371 E:380 ||| JJ
morphogenesis  ||| S:380 E:394 ||| NN
begins  ||| S:394 E:401 ||| VBZ
as  ||| S:401 E:404 ||| IN
a  ||| S:404 E:406 ||| DT
solid  ||| S:406 E:412 ||| JJ
outgrowth  ||| S:412 E:422 ||| NN
from  ||| S:422 E:427 ||| IN
the  ||| S:427 E:439 ||| DT
oral  ||| S:439 E:444 ||| JJ
epithelium  ||| S:444 E:455 ||| NN
around  ||| S:455 E:462 ||| IN
E11.5 ||| S:462 E:467 ||| NNP
,  ||| S:467 E:469 ||| ,
and  ||| S:469 E:473 ||| CC
is  ||| S:473 E:476 ||| VBZ
best  ||| S:476 E:481 ||| JJS
conceptualized  ||| S:481 E:496 ||| NN
in  ||| S:496 E:507 ||| IN
stages  ||| S:507 E:514 ||| NNS
[  ||| S:514 E:516 ||| -LRB-
9  ||| S:516 E:518 ||| CD
]  ||| S:518 E:520 ||| -RRB-
:  ||| S:520 E:531 ||| :
Initial  ||| S:531 E:539 ||| NNP
Bud ||| S:539 E:542 ||| NNP
,  ||| S:542 E:544 ||| ,
Pseudoglandular ||| S:544 E:559 ||| NNP
,  ||| S:559 E:569 ||| ,
Canalicular ||| S:569 E:580 ||| NNP
,  ||| S:580 E:582 ||| ,
and  ||| S:582 E:595 ||| CC
Terminal  ||| S:595 E:604 ||| NNP
Bud ||| S:604 E:607 ||| NNP
.  ||| S:607 E:609 ||| .
Epithelial  ||| S:609 E:620 ||| JJ
cell  ||| S:620 E:633 ||| NN
proliferation  ||| S:633 E:647 ||| NN
is  ||| S:647 E:650 ||| VBZ
found  ||| S:650 E:656 ||| VBN
in  ||| S:656 E:659 ||| IN
all  ||| S:659 E:663 ||| DT
stages ||| S:663 E:669 ||| NNS
,  ||| S:669 E:671 ||| ,
even  ||| S:671 E:676 ||| RB
after  ||| S:676 E:690 ||| IN
well-defined  ||| S:690 E:703 ||| JJ
lumen  ||| S:703 E:709 ||| JJ
formation  ||| S:709 E:719 ||| NN
in  ||| S:719 E:722 ||| IN
the  ||| S:722 E:735 ||| DT
Terminal  ||| S:735 E:744 ||| NNP
Bud  ||| S:744 E:748 ||| NNP
Stage ||| S:748 E:753 ||| NNP
.  ||| S:753 E:755 ||| .
Epithelial  ||| S:755 E:766 ||| JJ
cell  ||| S:766 E:779 ||| NN
apoptosis  ||| S:779 E:789 ||| NN
begins  ||| S:789 E:796 ||| VBZ
with  ||| S:796 E:801 ||| IN
the  ||| S:801 E:805 ||| DT
onset  ||| S:805 E:811 ||| NN
of  ||| S:811 E:814 ||| IN
lumen  ||| S:814 E:820 ||| JJ
formation  ||| S:820 E:830 ||| NN
in  ||| S:830 E:833 ||| IN
the  ||| S:833 E:846 ||| DT
Canalicular  ||| S:846 E:858 ||| NNP
Stage ||| S:858 E:863 ||| NNP
.  ||| S:863 E:873 ||| .
The  ||| S:873 E:877 ||| DT
proper  ||| S:877 E:884 ||| JJ
balance  ||| S:884 E:892 ||| NN
between  ||| S:892 E:900 ||| IN
SMG  ||| S:900 E:904 ||| NNP
epithelial  ||| S:904 E:915 ||| JJ
cell  ||| S:915 E:928 ||| NN
proliferation ||| S:928 E:941 ||| NN
,  ||| S:941 E:943 ||| ,
quiescence ||| S:943 E:953 ||| NN
,  ||| S:953 E:955 ||| ,
and  ||| S:955 E:959 ||| CC
apoptosis  ||| S:959 E:969 ||| NN
is  ||| S:969 E:972 ||| VBZ
mediated  ||| S:972 E:981 ||| VBN
by  ||| S:981 E:984 ||| IN
the  ||| S:984 E:996 ||| DT
appearance  ||| S:996 E:1007 ||| NN
of  ||| S:1007 E:1010 ||| IN
transcription  ||| S:1010 E:1024 ||| JJ
factors ||| S:1024 E:1031 ||| NNS
,  ||| S:1031 E:1033 ||| ,
growth  ||| S:1033 E:1040 ||| NN
factors ||| S:1040 E:1047 ||| NNS
,  ||| S:1047 E:1057 ||| ,
cytokines ||| S:1057 E:1066 ||| NN
,  ||| S:1066 E:1068 ||| ,
caspases ||| S:1068 E:1076 ||| NN
,  ||| S:1076 E:1078 ||| ,
etc.  ||| S:1078 E:1083 ||| FW
at  ||| S:1083 E:1086 ||| IN
specific  ||| S:1086 E:1095 ||| JJ
times  ||| S:1095 E:1101 ||| NNS
and  ||| S:1101 E:1105 ||| CC
places  ||| S:1105 E:1112 ||| NNS
[  ||| S:1112 E:1114 ||| -LRB-
10  ||| S:1114 E:1125 ||| CD
11  ||| S:1125 E:1128 ||| CD
12  ||| S:1128 E:1131 ||| CD
13  ||| S:1131 E:1134 ||| CD
14  ||| S:1134 E:1137 ||| CD
]  ||| S:1137 E:1139 ||| -RRB-
.  ||| S:1139 E:1141 ||| .
These  ||| S:1141 E:1147 ||| DT
SMG  ||| S:1147 E:1151 ||| NNP
cellular  ||| S:1151 E:1160 ||| JJ
and  ||| S:1160 E:1164 ||| CC
extracellular  ||| S:1164 E:1186 ||| JJ
components  ||| S:1186 E:1197 ||| NNS
may  ||| S:1197 E:1201 ||| MD
be  ||| S:1201 E:1204 ||| VB
visualized  ||| S:1204 E:1215 ||| VBN
as  ||| S:1215 E:1218 ||| IN
a  ||| S:1218 E:1229 ||| DT
Connections  ||| S:1229 E:1241 ||| NNP
Map  ||| S:1241 E:1245 ||| NNP
which  ||| S:1245 E:1251 ||| WDT
details  ||| S:1251 E:1259 ||| NNS
the  ||| S:1259 E:1271 ||| DT
functional  ||| S:1271 E:1282 ||| JJ
relationships  ||| S:1282 E:1296 ||| NNS
within  ||| S:1296 E:1303 ||| IN
and  ||| S:1303 E:1307 ||| CC
between  ||| S:1307 E:1315 ||| IN
pathways  ||| S:1315 E:1324 ||| NNS
( ||| S:1324 E:1325 ||| -LRB-
Fig.  ||| S:1325 E:1338 ||| CD
1 ||| S:1338 E:1339 ||| CD
) ||| S:1339 E:1340 ||| -RRB-
.  ||| S:1340 E:1350 ||| .
Complex  ||| S:1350 E:1358 ||| JJ
networks  ||| S:1358 E:1367 ||| NNS
of  ||| S:1367 E:1370 ||| IN
biological  ||| S:1370 E:1381 ||| JJ
signaling  ||| S:1381 E:1391 ||| JJ
pathways  ||| S:1391 E:1400 ||| NNS
( ||| S:1400 E:1401 ||| -LRB-
Fig.  ||| S:1401 E:1414 ||| CD
1 ||| S:1414 E:1415 ||| CD
)  ||| S:1415 E:1417 ||| -RRB-
emerge  ||| S:1417 E:1424 ||| VB
from  ||| S:1424 E:1429 ||| IN
the  ||| S:1429 E:1433 ||| DT
interconnections  ||| S:1433 E:1450 ||| NN
of  ||| S:1450 E:1453 ||| IN
simple  ||| S:1453 E:1460 ||| JJ
pathways  ||| S:1460 E:1477 ||| NN
under  ||| S:1477 E:1483 ||| IN
local  ||| S:1483 E:1489 ||| JJ
control  ||| S:1489 E:1497 ||| NN
[  ||| S:1497 E:1499 ||| -LRB-
15  ||| S:1499 E:1502 ||| CD
16  ||| S:1502 E:1505 ||| CD
17  ||| S:1505 E:1508 ||| CD
]  ||| S:1508 E:1510 ||| -RRB-
.  ||| S:1510 E:1512 ||| .
As  ||| S:1512 E:1515 ||| IN
such ||| S:1515 E:1519 ||| JJ
,  ||| S:1519 E:1521 ||| ,
these  ||| S:1521 E:1527 ||| DT
cellular  ||| S:1527 E:1544 ||| JJ
pathways  ||| S:1544 E:1553 ||| NNS
are  ||| S:1553 E:1557 ||| VBP
more  ||| S:1557 E:1562 ||| RBR
analogous  ||| S:1562 E:1572 ||| JJ
to  ||| S:1572 E:1575 ||| TO
the  ||| S:1575 E:1579 ||| DT
mostly  ||| S:1579 E:1586 ||| RB
redundant ||| S:1586 E:1595 ||| JJ
,  ||| S:1595 E:1605 ||| ,
overlapping  ||| S:1605 E:1617 ||| VBG
neural  ||| S:1617 E:1624 ||| JJ
network  ||| S:1624 E:1632 ||| NN
of  ||| S:1632 E:1635 ||| IN
the  ||| S:1635 E:1639 ||| DT
brain  ||| S:1639 E:1645 ||| NN
than  ||| S:1645 E:1650 ||| IN
to  ||| S:1650 E:1653 ||| TO
traffic  ||| S:1653 E:1669 ||| NN
grids  ||| S:1669 E:1675 ||| NN
of  ||| S:1675 E:1678 ||| IN
intersecting  ||| S:1678 E:1691 ||| JJ
streets  ||| S:1691 E:1699 ||| NNS
and  ||| S:1699 E:1703 ||| CC
interacting  ||| S:1703 E:1715 ||| JJ
vehicles ||| S:1715 E:1723 ||| NNS
.  ||| S:1723 E:1733 ||| .
There  ||| S:1733 E:1739 ||| EX
are  ||| S:1739 E:1743 ||| VBP
two  ||| S:1743 E:1747 ||| CD
general ||| S:1747 E:1754 ||| NN
,  ||| S:1754 E:1756 ||| ,
not  ||| S:1756 E:1760 ||| RB
mutually  ||| S:1760 E:1769 ||| RB
exclusive ||| S:1769 E:1778 ||| JJ
,  ||| S:1778 E:1780 ||| ,
classes  ||| S:1780 E:1788 ||| NNS
of  ||| S:1788 E:1799 ||| IN
interconnections ||| S:1799 E:1815 ||| NNS
:  ||| S:1815 E:1817 ||| :
( ||| S:1817 E:1818 ||| -LRB-
1 ||| S:1818 E:1819 ||| LS
)  ||| S:1819 E:1821 ||| -RRB-
junctions  ||| S:1821 E:1831 ||| NN
which  ||| S:1831 E:1837 ||| WDT
serve  ||| S:1837 E:1843 ||| VBP
as  ||| S:1843 E:1846 ||| RB
signal  ||| S:1846 E:1861 ||| VB
integrators  ||| S:1861 E:1873 ||| NNS
and  ||| S:1873 E:1877 ||| CC
( ||| S:1877 E:1878 ||| -LRB-
2 ||| S:1878 E:1879 ||| LS
)  ||| S:1879 E:1881 ||| -RRB-
nodes  ||| S:1881 E:1887 ||| NN
which  ||| S:1887 E:1893 ||| WDT
split  ||| S:1893 E:1899 ||| VBD
the  ||| S:1899 E:1903 ||| DT
signal  ||| S:1903 E:1910 ||| NN
and  ||| S:1910 E:1914 ||| CC
route  ||| S:1914 E:1928 ||| NN
them  ||| S:1928 E:1933 ||| PRP
to  ||| S:1933 E:1936 ||| TO
multiple  ||| S:1936 E:1945 ||| JJ
outputs  ||| S:1945 E:1953 ||| NNS
[  ||| S:1953 E:1955 ||| -LRB-
18  ||| S:1955 E:1958 ||| CD
]  ||| S:1958 E:1960 ||| -RRB-
.  ||| S:1960 E:1962 ||| .
Understanding  ||| S:1962 E:1976 ||| VBG
the  ||| S:1976 E:1988 ||| DT
nonlinear  ||| S:1988 E:1998 ||| JJ
dynamics  ||| S:1998 E:2007 ||| NNS
of  ||| S:2007 E:2010 ||| IN
these  ||| S:2010 E:2016 ||| DT
interconnections  ||| S:2016 E:2033 ||| NN
is  ||| S:2033 E:2036 ||| VBZ
intrinsic  ||| S:2036 E:2054 ||| VBN
to  ||| S:2054 E:2057 ||| TO
understanding  ||| S:2057 E:2071 ||| VB
the  ||| S:2071 E:2075 ||| DT
regulation  ||| S:2075 E:2086 ||| NN
of  ||| S:2086 E:2089 ||| IN
SMG  ||| S:2089 E:2093 ||| NNP
morphogenesis ||| S:2093 E:2106 ||| NN
.  ||| S:2106 E:2108 ||| .
This  ||| S:2108 E:2121 ||| DT
requires  ||| S:2121 E:2130 ||| VBZ
the  ||| S:2130 E:2134 ||| DT
integration  ||| S:2134 E:2146 ||| NN
of  ||| S:2146 E:2149 ||| IN
transcriptomic ||| S:2149 E:2163 ||| NN
,  ||| S:2163 E:2165 ||| ,
proteomic ||| S:2165 E:2174 ||| NN
,  ||| S:2174 E:2184 ||| ,
phenomic ||| S:2184 E:2192 ||| NN
,  ||| S:2192 E:2194 ||| ,
and  ||| S:2194 E:2198 ||| CC
bioinformatic  ||| S:2198 E:2212 ||| JJ
approaches ||| S:2212 E:2222 ||| NNS
,  ||| S:2222 E:2224 ||| ,
not  ||| S:2224 E:2228 ||| RB
least  ||| S:2228 E:2234 ||| JJS
because  ||| S:2234 E:2250 ||| IN
development ||| S:2250 E:2261 ||| NN
,  ||| S:2261 E:2263 ||| ,
in  ||| S:2263 E:2266 ||| IN
its  ||| S:2266 E:2270 ||| PRP$
most  ||| S:2270 E:2275 ||| RBS
basic  ||| S:2275 E:2281 ||| JJ
sense ||| S:2281 E:2286 ||| NN
,  ||| S:2286 E:2288 ||| ,
is  ||| S:2288 E:2291 ||| VBZ
genes  ||| S:2291 E:2297 ||| NNS
plus  ||| S:2297 E:2302 ||| CC
context  ||| S:2302 E:2318 ||| NN
[  ||| S:2318 E:2320 ||| -LRB-
19  ||| S:2320 E:2323 ||| CD
20  ||| S:2323 E:2326 ||| CD
21  ||| S:2326 E:2329 ||| CD
22  ||| S:2329 E:2332 ||| CD
]  ||| S:2332 E:2334 ||| -RRB-
.  ||| S:2334 E:2344 ||| .
With  ||| S:2344 E:2349 ||| IN
the  ||| S:2349 E:2353 ||| DT
present  ||| S:2353 E:2361 ||| JJ
experiments ||| S:2361 E:2372 ||| NNS
,  ||| S:2372 E:2374 ||| ,
we  ||| S:2374 E:2377 ||| PRP
sought  ||| S:2377 E:2384 ||| VBD
a  ||| S:2384 E:2386 ||| DT
glimpse  ||| S:2386 E:2394 ||| NN
of  ||| S:2394 E:2397 ||| IN
the  ||| S:2397 E:2409 ||| DT
extraordinarily  ||| S:2409 E:2425 ||| JJ
complex  ||| S:2425 E:2433 ||| JJ
behaviors  ||| S:2433 E:2443 ||| NN
of  ||| S:2443 E:2446 ||| IN
a  ||| S:2446 E:2448 ||| DT
focused  ||| S:2448 E:2456 ||| VBN
signaling  ||| S:2456 E:2474 ||| VBG
network  ||| S:2474 E:2482 ||| NN
( ||| S:2482 E:2483 ||| -LRB-
Fig.  ||| S:2483 E:2488 ||| CD
1 ||| S:2488 E:2489 ||| CD
) ||| S:2489 E:2490 ||| -RRB-
.  ||| S:2490 E:2492 ||| .
To  ||| S:2492 E:2495 ||| TO
this  ||| S:2495 E:2500 ||| DT
end ||| S:2500 E:2503 ||| NN
,  ||| S:2503 E:2505 ||| ,
we  ||| S:2505 E:2508 ||| PRP
studied  ||| S:2508 E:2516 ||| VBD
the  ||| S:2516 E:2520 ||| DT
molecular  ||| S:2520 E:2538 ||| JJ
patterns  ||| S:2538 E:2547 ||| NNS
and  ||| S:2547 E:2551 ||| CC
phenotypic  ||| S:2551 E:2562 ||| JJ
outcomes  ||| S:2562 E:2571 ||| NNS
of  ||| S:2571 E:2574 ||| IN
a  ||| S:2574 E:2576 ||| DT
nodal  ||| S:2576 E:2582 ||| JJ
"short  ||| S:2582 E:2597 ||| CD
circuit ||| S:2597 E:2604 ||| NN
" ||| S:2604 E:2605 ||| ''
,  ||| S:2605 E:2607 ||| ,
i.e. ||| S:2607 E:2611 ||| FW
,  ||| S:2611 E:2613 ||| ,
the  ||| S:2613 E:2617 ||| DT
inhibition  ||| S:2617 E:2628 ||| NN
of  ||| S:2628 E:2631 ||| IN
NF-κB  ||| S:2631 E:2637 ||| JJ
activation  ||| S:2637 E:2648 ||| NN
and  ||| S:2648 E:2660 ||| CC
translocation  ||| S:2660 E:2674 ||| JJ
to  ||| S:2674 E:2677 ||| TO
the  ||| S:2677 E:2681 ||| DT
nucleus  ||| S:2681 E:2689 ||| NN
to  ||| S:2689 E:2692 ||| TO
bind  ||| S:2692 E:2697 ||| VB
to  ||| S:2697 E:2700 ||| TO
NF-κB  ||| S:2700 E:2706 ||| JJ
response  ||| S:2706 E:2723 ||| NN
genes ||| S:2723 E:2728 ||| NNS
.  ||| S:2728 E:2730 ||| .
In  ||| S:2730 E:2733 ||| IN
most  ||| S:2733 E:2738 ||| JJS
cell  ||| S:2738 E:2743 ||| NN
types ||| S:2743 E:2748 ||| NNS
,  ||| S:2748 E:2750 ||| ,
the  ||| S:2750 E:2754 ||| DT
NF-κB  ||| S:2754 E:2760 ||| JJ
p50 ||| S:2760 E:2763 ||| CD
/ ||| S:2763 E:2764 ||| CD
p65  ||| S:2764 E:2768 ||| CD
heterodimer  ||| S:2768 E:2780 ||| NN
is  ||| S:2780 E:2791 ||| VBZ
maintained  ||| S:2791 E:2802 ||| VBN
as  ||| S:2802 E:2805 ||| IN
an  ||| S:2805 E:2808 ||| DT
inactive  ||| S:2808 E:2817 ||| JJ
form  ||| S:2817 E:2822 ||| NN
in  ||| S:2822 E:2825 ||| IN
the  ||| S:2825 E:2829 ||| DT
cytoplasm  ||| S:2829 E:2839 ||| NN
bound  ||| S:2839 E:2845 ||| VBN
to  ||| S:2845 E:2856 ||| TO
the  ||| S:2856 E:2860 ||| DT
inhibitory  ||| S:2860 E:2871 ||| JJ
protein  ||| S:2871 E:2879 ||| NN
IκB ||| S:2879 E:2882 ||| NN
.  ||| S:2882 E:2884 ||| .
Exposure  ||| S:2884 E:2893 ||| NN
of  ||| S:2893 E:2896 ||| IN
cells  ||| S:2896 E:2902 ||| NNS
to  ||| S:2902 E:2905 ||| TO
stimuli  ||| S:2905 E:2913 ||| VB
of  ||| S:2913 E:2924 ||| IN
NF-κB  ||| S:2924 E:2930 ||| NNP
induces  ||| S:2930 E:2938 ||| VBZ
the  ||| S:2938 E:2942 ||| DT
rapid  ||| S:2942 E:2948 ||| JJ
phosphorylation  ||| S:2948 E:2964 ||| NN
and  ||| S:2964 E:2968 ||| CC
subsequent  ||| S:2968 E:2987 ||| JJ
degradation  ||| S:2987 E:2999 ||| NN
of  ||| S:2999 E:3002 ||| IN
IκB  ||| S:3002 E:3006 ||| JJ
proteins ||| S:3006 E:3014 ||| NNS
.  ||| S:3014 E:3016 ||| .
Released  ||| S:3016 E:3025 ||| VBN
NF-κB  ||| S:3025 E:3031 ||| JJ
dimers  ||| S:3031 E:3038 ||| NNS
then  ||| S:3038 E:3051 ||| RB
translocate  ||| S:3051 E:3063 ||| VBN
to  ||| S:3063 E:3066 ||| TO
the  ||| S:3066 E:3070 ||| DT
nucleus ||| S:3070 E:3077 ||| NN
,  ||| S:3077 E:3079 ||| ,
bind  ||| S:3079 E:3084 ||| NN
to  ||| S:3084 E:3087 ||| TO
its  ||| S:3087 E:3091 ||| PRP$
cognate  ||| S:3091 E:3099 ||| JJ
DNA  ||| S:3099 E:3111 ||| NN
elements ||| S:3111 E:3119 ||| NNS
,  ||| S:3119 E:3121 ||| ,
and  ||| S:3121 E:3125 ||| CC
induce  ||| S:3125 E:3132 ||| VB
the  ||| S:3132 E:3136 ||| DT
expression  ||| S:3136 E:3147 ||| NN
of  ||| S:3147 E:3150 ||| IN
target  ||| S:3150 E:3157 ||| NN
genes  ||| S:3157 E:3163 ||| NNS
[  ||| S:3163 E:3165 ||| -LRB-
23  ||| S:3165 E:3168 ||| CD
24  ||| S:3168 E:3179 ||| CD
25  ||| S:3179 E:3182 ||| CD
]  ||| S:3182 E:3184 ||| -RRB-
.  ||| S:3184 E:3186 ||| .
Activated ||| S:3186 E:3195 ||| NNP
,  ||| S:3195 E:3197 ||| ,
nuclear  ||| S:3197 E:3205 ||| JJ
translocated ||| S:3205 E:3217 ||| NN
,  ||| S:3217 E:3219 ||| ,
NF-κB  ||| S:3219 E:3225 ||| JJ
transcription  ||| S:3225 E:3247 ||| JJ
factor  ||| S:3247 E:3254 ||| NN
has  ||| S:3254 E:3258 ||| VBZ
been  ||| S:3258 E:3263 ||| VBN
documented  ||| S:3263 E:3274 ||| VBN
in  ||| S:3274 E:3277 ||| IN
the  ||| S:3277 E:3281 ||| DT
mouse  ||| S:3281 E:3287 ||| NN
embryo  ||| S:3287 E:3294 ||| NN
from  ||| S:3294 E:3299 ||| IN
the  ||| S:3299 E:3311 ||| DT
1-cell  ||| S:3311 E:3318 ||| JJ
stage  ||| S:3318 E:3324 ||| NN
onward  ||| S:3324 E:3331 ||| NNS
[  ||| S:3331 E:3333 ||| -LRB-
26  ||| S:3333 E:3336 ||| CD
27  ||| S:3336 E:3339 ||| CD
]  ||| S:3339 E:3341 ||| -RRB-
.  ||| S:3341 E:3343 ||| .
Activated  ||| S:3343 E:3353 ||| JJ
NF-κB  ||| S:3353 E:3367 ||| JJ
translocation  ||| S:3367 E:3381 ||| NN
into  ||| S:3381 E:3386 ||| IN
the  ||| S:3386 E:3390 ||| DT
nucleus ||| S:3390 E:3397 ||| NN
,  ||| S:3397 E:3399 ||| ,
directly  ||| S:3399 E:3408 ||| RB
or  ||| S:3408 E:3411 ||| CC
indirectly ||| S:3411 E:3421 ||| RB
,  ||| S:3421 E:3431 ||| ,
effects  ||| S:3431 E:3439 ||| NNS
the  ||| S:3439 E:3443 ||| DT
transcriptional  ||| S:3443 E:3459 ||| JJ
control  ||| S:3459 E:3467 ||| NN
of  ||| S:3467 E:3470 ||| IN
over  ||| S:3470 E:3475 ||| IN
150  ||| S:3475 E:3479 ||| CD
target  ||| S:3479 E:3494 ||| NN
genes  ||| S:3494 E:3500 ||| NNS
[  ||| S:3500 E:3502 ||| -LRB-
28  ||| S:3502 E:3505 ||| CD
]  ||| S:3505 E:3507 ||| -RRB-
.  ||| S:3507 E:3509 ||| .
NF-κB  ||| S:3509 E:3515 ||| JJ
enhances  ||| S:3515 E:3524 ||| JJ
cell  ||| S:3524 E:3529 ||| NN
proliferation  ||| S:3529 E:3543 ||| NN
by  ||| S:3543 E:3554 ||| IN
stimulating  ||| S:3554 E:3566 ||| VBG
the  ||| S:3566 E:3570 ||| DT
expression  ||| S:3570 E:3581 ||| NN
of  ||| S:3581 E:3584 ||| IN
cytokines  ||| S:3584 E:3594 ||| JJ
such  ||| S:3594 E:3599 ||| JJ
as  ||| S:3599 E:3602 ||| IN
TNF ||| S:3602 E:3605 ||| NNP
,  ||| S:3605 E:3607 ||| ,
IL-1 ||| S:3607 E:3611 ||| NNP
,  ||| S:3611 E:3621 ||| ,
IL-2 ||| S:3621 E:3625 ||| NNP
,  ||| S:3625 E:3627 ||| ,
IL-6 ||| S:3627 E:3631 ||| NNP
,  ||| S:3631 E:3633 ||| ,
and  ||| S:3633 E:3637 ||| CC
IL-8 ||| S:3637 E:3641 ||| NNP
,  ||| S:3641 E:3643 ||| ,
among  ||| S:3643 E:3649 ||| IN
others  ||| S:3649 E:3656 ||| NNS
[  ||| S:3656 E:3658 ||| -LRB-
28  ||| S:3658 E:3661 ||| CD
29  ||| S:3661 E:3664 ||| CD
]  ||| S:3664 E:3666 ||| -RRB-
;  ||| S:3666 E:3668 ||| :
NF-κB  ||| S:3668 E:3682 ||| JJ
inhibits  ||| S:3682 E:3691 ||| JJ
apoptosis  ||| S:3691 E:3701 ||| NN
by  ||| S:3701 E:3704 ||| IN
inducing  ||| S:3704 E:3713 ||| VBG
TRAF  ||| S:3713 E:3718 ||| NNP
and  ||| S:3718 E:3722 ||| CC
clAP  ||| S:3722 E:3727 ||| JJ
expression  ||| S:3727 E:3746 ||| NN
which  ||| S:3746 E:3752 ||| WDT
suppresses  ||| S:3752 E:3763 ||| VBZ
Caspase  ||| S:3763 E:3771 ||| NNP
8  ||| S:3771 E:3773 ||| CD
activation  ||| S:3773 E:3784 ||| NNS
[  ||| S:3784 E:3786 ||| -LRB-
30  ||| S:3786 E:3789 ||| CD
]  ||| S:3789 E:3791 ||| -RRB-
,  ||| S:3791 E:3793 ||| ,
and  ||| S:3793 E:3797 ||| CC
by  ||| S:3797 E:3808 ||| IN
inhibition  ||| S:3808 E:3819 ||| NN
of  ||| S:3819 E:3822 ||| IN
p53  ||| S:3822 E:3826 ||| NN
transactivation  ||| S:3826 E:3842 ||| NNS
[  ||| S:3842 E:3844 ||| -LRB-
31  ||| S:3844 E:3847 ||| CD
32  ||| S:3847 E:3850 ||| CD
]  ||| S:3850 E:3852 ||| -RRB-
.  ||| S:3852 E:3862 ||| .
We  ||| S:3862 E:3865 ||| PRP
interrupted  ||| S:3865 E:3877 ||| VBD
the  ||| S:3877 E:3881 ||| DT
NF-κB  ||| S:3881 E:3887 ||| JJ
signal  ||| S:3887 E:3894 ||| NN
in  ||| S:3894 E:3897 ||| IN
embryonic  ||| S:3897 E:3907 ||| JJ
SMG  ||| S:3907 E:3919 ||| NNS
explants  ||| S:3919 E:3928 ||| VBP
using  ||| S:3928 E:3934 ||| VBG
the  ||| S:3934 E:3938 ||| DT
cell-permeable  ||| S:3938 E:3953 ||| JJ
peptide  ||| S:3953 E:3961 ||| JJ
SN50 ||| S:3961 E:3965 ||| NN
,  ||| S:3965 E:3967 ||| ,
a  ||| S:3967 E:3969 ||| DT
potent  ||| S:3969 E:3984 ||| JJ
inhibitor  ||| S:3984 E:3994 ||| NN
of  ||| S:3994 E:3997 ||| IN
NF-κB  ||| S:3997 E:4003 ||| JJ
nuclear  ||| S:4003 E:4011 ||| JJ
translocation  ||| S:4011 E:4025 ||| NNS
[  ||| S:4025 E:4027 ||| -LRB-
25  ||| S:4027 E:4030 ||| CD
26  ||| S:4030 E:4033 ||| CD
]  ||| S:4033 E:4035 ||| -RRB-
,  ||| S:4035 E:4037 ||| ,
[  ||| S:4037 E:4039 ||| -LRB-
33  ||| S:4039 E:4050 ||| CD
34  ||| S:4050 E:4053 ||| CD
35  ||| S:4053 E:4056 ||| CD
]  ||| S:4056 E:4058 ||| -RRB-
.  ||| S:4058 E:4060 ||| .
SN50-mediated  ||| S:4060 E:4074 ||| NNP
inhibition  ||| S:4074 E:4085 ||| NN
of  ||| S:4085 E:4088 ||| IN
NF-κB  ||| S:4088 E:4094 ||| JJ
nuclear  ||| S:4094 E:4110 ||| JJ
translocation  ||| S:4110 E:4124 ||| NN
in  ||| S:4124 E:4127 ||| IN
SMG  ||| S:4127 E:4131 ||| NNP
explants  ||| S:4131 E:4140 ||| NN
results  ||| S:4140 E:4148 ||| NNS
in  ||| S:4148 E:4151 ||| IN
extensive  ||| S:4151 E:4169 ||| JJ
apoptosis  ||| S:4169 E:4179 ||| NN
and  ||| S:4179 E:4183 ||| CC
a  ||| S:4183 E:4185 ||| DT
very  ||| S:4185 E:4190 ||| RB
substantial  ||| S:4190 E:4202 ||| JJ
decline  ||| S:4202 E:4210 ||| NN
in  ||| S:4210 E:4213 ||| IN
cell  ||| S:4213 E:4226 ||| NN
proliferation ||| S:4226 E:4239 ||| NN
.  ||| S:4239 E:4241 ||| .
Functional  ||| S:4241 E:4252 ||| JJ
genomic  ||| S:4252 E:4260 ||| JJ
analyses  ||| S:4260 E:4269 ||| NNS
demonstrate  ||| S:4269 E:4281 ||| VBP
that  ||| S:4281 E:4294 ||| DT
inhibition  ||| S:4294 E:4305 ||| NN
of  ||| S:4305 E:4308 ||| IN
NF-κB  ||| S:4308 E:4314 ||| JJ
signaling  ||| S:4314 E:4324 ||| NN
is  ||| S:4324 E:4327 ||| VBZ
associated  ||| S:4327 E:4338 ||| VBN
with  ||| S:4338 E:4343 ||| IN
the  ||| S:4343 E:4355 ||| DT
altered  ||| S:4355 E:4363 ||| JJ
expression  ||| S:4363 E:4374 ||| NN
of  ||| S:4374 E:4377 ||| IN
numerous  ||| S:4377 E:4386 ||| JJ
components  ||| S:4386 E:4397 ||| NNS
of  ||| S:4397 E:4400 ||| IN
the  ||| S:4400 E:4404 ||| DT
genetic  ||| S:4404 E:4420 ||| JJ
network  ||| S:4420 E:4428 ||| NN
of  ||| S:4428 E:4431 ||| IN
related  ||| S:4431 E:4439 ||| JJ
signaling  ||| S:4439 E:4449 ||| JJ
pathways ||| S:4449 E:4457 ||| NN
.  ||| S:4457 E:4459 ||| .
This  ||| S:4459 E:4464 ||| DT
modified  ||| S:4464 E:4481 ||| JJ
expression  ||| S:4481 E:4492 ||| NN
of  ||| S:4492 E:4495 ||| IN
genes  ||| S:4495 E:4501 ||| NNS
and  ||| S:4501 E:4505 ||| CC
proteins  ||| S:4505 E:4514 ||| NNS
associated  ||| S:4514 E:4525 ||| VBN
with  ||| S:4525 E:4530 ||| IN
the  ||| S:4530 E:4542 ||| DT
inhibition  ||| S:4542 E:4553 ||| NN
of  ||| S:4553 E:4556 ||| IN
the  ||| S:4556 E:4560 ||| DT
cell  ||| S:4560 E:4565 ||| NN
cycle  ||| S:4565 E:4571 ||| NN
and  ||| S:4571 E:4575 ||| CC
the  ||| S:4575 E:4579 ||| DT
induction  ||| S:4579 E:4589 ||| NN
of  ||| S:4589 E:4600 ||| IN
apoptosis ||| S:4600 E:4609 ||| NN
,  ||| S:4609 E:4611 ||| ,
as  ||| S:4611 E:4614 ||| RB
well  ||| S:4614 E:4619 ||| RB
as  ||| S:4619 E:4622 ||| IN
the  ||| S:4622 E:4626 ||| DT
increased  ||| S:4626 E:4636 ||| JJ
activation  ||| S:4636 E:4647 ||| NN
of  ||| S:4647 E:4658 ||| IN
proapoptotic  ||| S:4658 E:4671 ||| NN
and  ||| S:4671 E:4675 ||| CC
compensatory  ||| S:4675 E:4688 ||| JJ
antiapoptotic  ||| S:4688 E:4702 ||| JJ
pathways ||| S:4702 E:4710 ||| NN
,  ||| S:4710 E:4720 ||| ,
provides  ||| S:4720 E:4729 ||| VBZ
a  ||| S:4729 E:4731 ||| DT
"snapshot ||| S:4731 E:4740 ||| NN
"  ||| S:4740 E:4742 ||| ''
of  ||| S:4742 E:4745 ||| IN
the  ||| S:4745 E:4749 ||| DT
broad  ||| S:4749 E:4755 ||| JJ
primary  ||| S:4755 E:4763 ||| JJ
and  ||| S:4763 E:4767 ||| CC
secondary  ||| S:4767 E:4785 ||| JJ
effects  ||| S:4785 E:4793 ||| NNS
of  ||| S:4793 E:4796 ||| IN
NF-κB  ||| S:4796 E:4802 ||| JJ
signaling  ||| S:4802 E:4812 ||| NN
during  ||| S:4812 E:4819 ||| IN
SMG  ||| S:4819 E:4823 ||| NNP
development ||| S:4823 E:4834 ||| NN
.  ||| S:4834 E:4858 ||| .
Results  ||| S:4858 E:4866 ||| NNS
and  ||| S:4866 E:4870 ||| CC
discussion  ||| S:4870 E:4900 ||| NN
NF-κB  ||| S:4900 E:4906 ||| JJ
inhibition  ||| S:4906 E:4917 ||| NN
and  ||| S:4917 E:4921 ||| CC
SMG  ||| S:4921 E:4925 ||| NNP
phenotype  ||| S:4925 E:4945 ||| VBD
E15  ||| S:4945 E:4949 ||| NNP
SMG  ||| S:4949 E:4953 ||| NNP
primordia  ||| S:4953 E:4963 ||| NN
were  ||| S:4963 E:4968 ||| VBD
cultured  ||| S:4968 E:4977 ||| VBN
for  ||| S:4977 E:4981 ||| IN
2  ||| S:4981 E:4983 ||| CD
days  ||| S:4983 E:4988 ||| NNS
in  ||| S:4988 E:4991 ||| IN
the  ||| S:4991 E:5005 ||| DT
presence  ||| S:5005 E:5014 ||| NN
or  ||| S:5014 E:5017 ||| CC
absence  ||| S:5017 E:5025 ||| NN
of  ||| S:5025 E:5028 ||| IN
the  ||| S:5028 E:5032 ||| DT
cell-permeable  ||| S:5032 E:5047 ||| JJ
peptide  ||| S:5047 E:5055 ||| JJ
SN50 ||| S:5055 E:5059 ||| NN
,  ||| S:5059 E:5061 ||| ,
a  ||| S:5061 E:5073 ||| DT
potent  ||| S:5073 E:5080 ||| JJ
inhibitor  ||| S:5080 E:5090 ||| NN
of  ||| S:5090 E:5093 ||| IN
NF-κB  ||| S:5093 E:5099 ||| JJ
nuclear  ||| S:5099 E:5107 ||| JJ
translocation  ||| S:5107 E:5121 ||| NNS
[  ||| S:5121 E:5123 ||| -LRB-
33  ||| S:5123 E:5126 ||| CD
34  ||| S:5126 E:5139 ||| CD
35  ||| S:5139 E:5142 ||| CD
]  ||| S:5142 E:5144 ||| -RRB-
.  ||| S:5144 E:5146 ||| .
SN50  ||| S:5146 E:5151 ||| NNP
is  ||| S:5151 E:5154 ||| VBZ
composed  ||| S:5154 E:5163 ||| VBN
of  ||| S:5163 E:5166 ||| IN
a  ||| S:5166 E:5168 ||| DT
nuclear  ||| S:5168 E:5176 ||| JJ
localization  ||| S:5176 E:5199 ||| JJ
sequence  ||| S:5199 E:5208 ||| NN
( ||| S:5208 E:5209 ||| -LRB-
NLS ||| S:5209 E:5212 ||| NNP
)  ||| S:5212 E:5214 ||| -RRB-
for  ||| S:5214 E:5218 ||| IN
NF-κB  ||| S:5218 E:5224 ||| JJ
p50  ||| S:5224 E:5228 ||| NN
linked  ||| S:5228 E:5235 ||| VBN
to  ||| S:5235 E:5238 ||| TO
a  ||| S:5238 E:5240 ||| DT
cell-permeable  ||| S:5240 E:5265 ||| JJ
carrier  ||| S:5265 E:5273 ||| NN
[  ||| S:5273 E:5275 ||| -LRB-
33  ||| S:5275 E:5278 ||| CD
34  ||| S:5278 E:5281 ||| CD
35  ||| S:5281 E:5284 ||| CD
]  ||| S:5284 E:5286 ||| -RRB-
.  ||| S:5286 E:5288 ||| .
SN50  ||| S:5288 E:5293 ||| NNP
blocks  ||| S:5293 E:5300 ||| VBZ
the  ||| S:5300 E:5304 ||| DT
intracellular  ||| S:5304 E:5328 ||| JJ
recognition  ||| S:5328 E:5340 ||| NN
mechanism  ||| S:5340 E:5350 ||| NN
for  ||| S:5350 E:5354 ||| IN
the  ||| S:5354 E:5358 ||| DT
NLS  ||| S:5358 E:5362 ||| NNP
on  ||| S:5362 E:5365 ||| IN
NF-κB ||| S:5365 E:5370 ||| NNP
,  ||| S:5370 E:5372 ||| ,
thus  ||| S:5372 E:5387 ||| RB
inhibiting  ||| S:5387 E:5398 ||| JJ
NF-κB ||| S:5398 E:5403 ||| NN
's  ||| S:5403 E:5406 ||| POS
translocation  ||| S:5406 E:5420 ||| NN
through  ||| S:5420 E:5428 ||| IN
the  ||| S:5428 E:5432 ||| DT
nuclear  ||| S:5432 E:5450 ||| JJ
pore ||| S:5450 E:5454 ||| NN
.  ||| S:5454 E:5456 ||| .
After  ||| S:5456 E:5462 ||| IN
2  ||| S:5462 E:5464 ||| CD
days  ||| S:5464 E:5469 ||| NNS
in  ||| S:5469 E:5472 ||| IN
culture ||| S:5472 E:5479 ||| NN
,  ||| S:5479 E:5481 ||| ,
SN50-treated  ||| S:5481 E:5494 ||| CD
explants  ||| S:5494 E:5513 ||| NNS
exhibit  ||| S:5513 E:5521 ||| VBP
a  ||| S:5521 E:5523 ||| DT
substantial  ||| S:5523 E:5535 ||| JJ
decrease  ||| S:5535 E:5544 ||| NN
in  ||| S:5544 E:5547 ||| IN
gland  ||| S:5547 E:5553 ||| JJ
size  ||| S:5553 E:5558 ||| NN
and  ||| S:5558 E:5572 ||| CC
branching  ||| S:5572 E:5582 ||| NNS
morphogenesis  ||| S:5582 E:5596 ||| VBP
compared  ||| S:5596 E:5605 ||| VBN
to  ||| S:5605 E:5608 ||| TO
controls  ||| S:5608 E:5617 ||| NNS
( ||| S:5617 E:5618 ||| -LRB-
compare  ||| S:5618 E:5636 ||| FW
Fig.  ||| S:5636 E:5641 ||| FW
3Ato  ||| S:5641 E:5646 ||| FW
3B ||| S:5646 E:5648 ||| FW
) ||| S:5648 E:5649 ||| -RRB-
.  ||| S:5649 E:5651 ||| .
These  ||| S:5651 E:5657 ||| DT
2-day  ||| S:5657 E:5663 ||| CD
SN50-treated  ||| S:5663 E:5676 ||| CD
explants  ||| S:5676 E:5695 ||| NNS
demonstrate  ||| S:5695 E:5707 ||| VBP
a  ||| S:5707 E:5709 ||| DT
highly  ||| S:5709 E:5716 ||| RB
significant  ||| S:5716 E:5728 ||| JJ
81 ||| S:5728 E:5730 ||| CD
%  ||| S:5730 E:5732 ||| NN
decline  ||| S:5732 E:5740 ||| NN
( ||| S:5740 E:5741 ||| -LRB-
t  ||| S:5741 E:5754 ||| CD
4  ||| S:5754 E:5756 ||| CD
=  ||| S:5756 E:5758 ||| SYM
26.25 ||| S:5758 E:5763 ||| CD
;  ||| S:5763 E:5765 ||| :
p  ||| S:5765 E:5767 ||| CD
< ||| S:5767 E:5769 ||| SYM
0.001 ||| S:5769 E:5774 ||| CD
)  ||| S:5774 E:5776 ||| -RRB-
in  ||| S:5776 E:5779 ||| IN
cell  ||| S:5779 E:5794 ||| NN
proliferation  ||| S:5794 E:5808 ||| NN
( ||| S:5808 E:5809 ||| -LRB-
Fig.  ||| S:5809 E:5814 ||| NNP
3A ||| S:5814 E:5816 ||| NNP
,  ||| S:5816 E:5818 ||| ,
B ||| S:5818 E:5819 ||| NNP
;  ||| S:5819 E:5821 ||| :
Fig.  ||| S:5821 E:5826 ||| CD
4A ||| S:5826 E:5828 ||| CD
)  ||| S:5828 E:5830 ||| -RRB-
and  ||| S:5830 E:5834 ||| CC
a  ||| S:5834 E:5836 ||| DT
significant  ||| S:5836 E:5858 ||| JJ
10-fold  ||| S:5858 E:5866 ||| JJ
increase  ||| S:5866 E:5875 ||| NN
( ||| S:5875 E:5876 ||| -LRB-
t  ||| S:5876 E:5889 ||| CD
4  ||| S:5889 E:5891 ||| CD
=  ||| S:5891 E:5893 ||| SYM
7.98 ||| S:5893 E:5897 ||| CD
;  ||| S:5897 E:5899 ||| :
p  ||| S:5899 E:5901 ||| CD
< ||| S:5901 E:5903 ||| SYM
0.001 ||| S:5903 E:5908 ||| CD
)  ||| S:5908 E:5910 ||| -RRB-
in  ||| S:5910 E:5913 ||| IN
apoptosis  ||| S:5913 E:5933 ||| NNS
( ||| S:5933 E:5934 ||| -LRB-
Fig.  ||| S:5934 E:5939 ||| NNP
3C ||| S:5939 E:5941 ||| NNP
,  ||| S:5941 E:5943 ||| ,
D ||| S:5943 E:5944 ||| NNP
;  ||| S:5944 E:5946 ||| :
Fig.  ||| S:5946 E:5951 ||| CD
4B ||| S:5951 E:5953 ||| CD
) ||| S:5953 E:5954 ||| -RRB-
.  ||| S:5954 E:5956 ||| .
This  ||| S:5956 E:5961 ||| DT
substantial  ||| S:5961 E:5973 ||| JJ
increase  ||| S:5973 E:5982 ||| NN
in  ||| S:5982 E:5995 ||| IN
apoptosis  ||| S:5995 E:6005 ||| NN
is  ||| S:6005 E:6008 ||| VBZ
associated  ||| S:6008 E:6019 ||| VBN
with  ||| S:6019 E:6024 ||| IN
a  ||| S:6024 E:6026 ||| DT
highly  ||| S:6026 E:6033 ||| RB
significant  ||| S:6033 E:6045 ||| JJ
>  ||| S:6045 E:6057 ||| CD
4-fold  ||| S:6057 E:6064 ||| CD
increase  ||| S:6064 E:6073 ||| NN
( ||| S:6073 E:6074 ||| -LRB-
t  ||| S:6074 E:6087 ||| CD
4  ||| S:6087 E:6089 ||| CD
=  ||| S:6089 E:6091 ||| SYM
22.66 ||| S:6091 E:6096 ||| CD
;  ||| S:6096 E:6098 ||| :
p  ||| S:6098 E:6100 ||| CD
< ||| S:6100 E:6102 ||| SYM
0.001 ||| S:6102 E:6107 ||| CD
)  ||| S:6107 E:6109 ||| -RRB-
in  ||| S:6109 E:6123 ||| IN
activated  ||| S:6123 E:6133 ||| NNS
( ||| S:6133 E:6134 ||| -LRB-
phosphorylated ||| S:6134 E:6148 ||| LS
)  ||| S:6148 E:6150 ||| -RRB-
p53  ||| S:6150 E:6164 ||| NN
( ||| S:6164 E:6165 ||| -LRB-
Fig.  ||| S:6165 E:6170 ||| CD
5 ||| S:6170 E:6171 ||| CD
) ||| S:6171 E:6172 ||| -RRB-
.  ||| S:6172 E:6174 ||| .
This  ||| S:6174 E:6179 ||| DT
result  ||| S:6179 E:6186 ||| NN
is  ||| S:6186 E:6189 ||| VBZ
not  ||| S:6189 E:6193 ||| RB
surprising ||| S:6193 E:6203 ||| JJ
,  ||| S:6203 E:6205 ||| ,
given  ||| S:6205 E:6211 ||| VBN
that  ||| S:6211 E:6216 ||| IN
NF-κB  ||| S:6216 E:6232 ||| JJ
inactivates  ||| S:6232 E:6244 ||| JJ
p53  ||| S:6244 E:6248 ||| NN
[  ||| S:6248 E:6250 ||| -LRB-
32  ||| S:6250 E:6253 ||| CD
]  ||| S:6253 E:6255 ||| -RRB-
.  ||| S:6255 E:6267 ||| .
To  ||| S:6267 E:6270 ||| TO
demonstrate  ||| S:6270 E:6282 ||| VB
that  ||| S:6282 E:6287 ||| IN
this  ||| S:6287 E:6292 ||| DT
SN50  ||| S:6292 E:6297 ||| JJ
phenotype  ||| S:6297 E:6307 ||| NN
is  ||| S:6307 E:6310 ||| VBZ
consequent  ||| S:6310 E:6331 ||| VBN
to  ||| S:6331 E:6334 ||| TO
SN50-mediated  ||| S:6334 E:6348 ||| CD
inhibition  ||| S:6348 E:6359 ||| NN
of  ||| S:6359 E:6362 ||| IN
NF-κB  ||| S:6362 E:6368 ||| JJ
nuclear  ||| S:6368 E:6386 ||| JJ
translocation  ||| S:6386 E:6400 ||| NN
and  ||| S:6400 E:6404 ||| CC
not  ||| S:6404 E:6408 ||| RB
the  ||| S:6408 E:6412 ||| DT
nonspecific  ||| S:6412 E:6424 ||| JJ
effect  ||| S:6424 E:6431 ||| NN
of  ||| S:6431 E:6434 ||| IN
exogenous  ||| S:6434 E:6454 ||| JJ
peptide ||| S:6454 E:6461 ||| NN
,  ||| S:6461 E:6463 ||| ,
we  ||| S:6463 E:6466 ||| PRP
compared  ||| S:6466 E:6475 ||| VBD
E15  ||| S:6475 E:6479 ||| CD
+  ||| S:6479 E:6481 ||| CD
2  ||| S:6481 E:6483 ||| CD
SMG  ||| S:6483 E:6487 ||| JJ
phenotypes  ||| S:6487 E:6498 ||| NN
in  ||| S:6498 E:6501 ||| IN
explants  ||| S:6501 E:6520 ||| JJ
cultured  ||| S:6520 E:6529 ||| NN
in  ||| S:6529 E:6532 ||| IN
control  ||| S:6532 E:6540 ||| NN
media ||| S:6540 E:6545 ||| NNS
,  ||| S:6545 E:6547 ||| ,
100  ||| S:6547 E:6551 ||| CD
μg ||| S:6551 E:6553 ||| FW
/ ||| S:6553 E:6554 ||| FW
ml  ||| S:6554 E:6557 ||| FW
SN50  ||| S:6557 E:6562 ||| FW
peptide ||| S:6562 E:6569 ||| FW
,  ||| S:6569 E:6571 ||| ,
or  ||| S:6571 E:6574 ||| CC
100  ||| S:6574 E:6588 ||| CD
μg ||| S:6588 E:6590 ||| FW
/ ||| S:6590 E:6591 ||| FW
ml  ||| S:6591 E:6594 ||| FW
mutant  ||| S:6594 E:6601 ||| FW
SN50  ||| S:6601 E:6606 ||| FW
( ||| S:6606 E:6607 ||| -LRB-
mSN50 ||| S:6607 E:6612 ||| NNP
)  ||| S:6612 E:6614 ||| -RRB-
peptide ||| S:6614 E:6621 ||| NN
.  ||| S:6621 E:6623 ||| .
As  ||| S:6623 E:6626 ||| RB
expected ||| S:6626 E:6634 ||| VBN
,  ||| S:6634 E:6636 ||| ,
we  ||| S:6636 E:6639 ||| PRP
found  ||| S:6639 E:6655 ||| VBD
a  ||| S:6655 E:6657 ||| DT
marked  ||| S:6657 E:6664 ||| JJ
difference  ||| S:6664 E:6675 ||| NN
between  ||| S:6675 E:6683 ||| IN
control  ||| S:6683 E:6691 ||| NN
and  ||| S:6691 E:6695 ||| CC
SN50-treated  ||| S:6695 E:6708 ||| NNP
SMGs  ||| S:6708 E:6723 ||| NNP
but  ||| S:6723 E:6727 ||| CC
none  ||| S:6727 E:6732 ||| NN
between  ||| S:6732 E:6740 ||| IN
control  ||| S:6740 E:6748 ||| NN
and  ||| S:6748 E:6752 ||| CC
mutant  ||| S:6752 E:6759 ||| JJ
peptide-treated  ||| S:6759 E:6785 ||| JJ
explants  ||| S:6785 E:6794 ||| NNS
( ||| S:6794 E:6795 ||| -LRB-
data  ||| S:6795 E:6800 ||| NNS
not  ||| S:6800 E:6804 ||| RB
shown ||| S:6804 E:6809 ||| VBN
) ||| S:6809 E:6810 ||| -RRB-
.  ||| S:6810 E:6812 ||| .
In  ||| S:6812 E:6815 ||| IN
addition ||| S:6815 E:6823 ||| NN
,  ||| S:6823 E:6825 ||| ,
since  ||| S:6825 E:6831 ||| IN
TNF ||| S:6831 E:6834 ||| NNP
/ ||| S:6834 E:6835 ||| NNP
TNFR1  ||| S:6835 E:6851 ||| NNP
signaling  ||| S:6851 E:6861 ||| NN
has  ||| S:6861 E:6865 ||| VBZ
been  ||| S:6865 E:6870 ||| VBN
shown  ||| S:6870 E:6876 ||| VBN
to  ||| S:6876 E:6879 ||| TO
induce  ||| S:6879 E:6886 ||| VB
embryonic  ||| S:6886 E:6896 ||| JJ
SMG  ||| S:6896 E:6900 ||| NNP
cell  ||| S:6900 E:6915 ||| NN
proliferation  ||| S:6915 E:6929 ||| NN
and  ||| S:6929 E:6933 ||| CC
inhibit  ||| S:6933 E:6941 ||| VB
apoptosis  ||| S:6941 E:6962 ||| VBN
in  ||| S:6962 E:6965 ||| IN
vitro  ||| S:6965 E:6971 ||| NNS
[  ||| S:6971 E:6973 ||| -LRB-
13  ||| S:6973 E:6976 ||| CD
]  ||| S:6976 E:6978 ||| -RRB-
and  ||| S:6978 E:6982 ||| CC
TNF ||| S:6982 E:6985 ||| NNP
/ ||| S:6985 E:6986 ||| NNP
TNFR1  ||| S:6986 E:7002 ||| NNP
signal  ||| S:7002 E:7009 ||| NN
transduction  ||| S:7009 E:7022 ||| VBZ
primarily  ||| S:7022 E:7032 ||| RB
signals  ||| S:7032 E:7040 ||| VBZ
by  ||| S:7040 E:7043 ||| IN
induction  ||| S:7043 E:7053 ||| NN
of  ||| S:7053 E:7066 ||| IN
NF-κB  ||| S:7066 E:7072 ||| JJ
nuclear  ||| S:7072 E:7080 ||| JJ
translocation  ||| S:7080 E:7094 ||| NNS
[  ||| S:7094 E:7096 ||| -LRB-
36  ||| S:7096 E:7099 ||| CD
]  ||| S:7099 E:7101 ||| -RRB-
,  ||| S:7101 E:7103 ||| ,
we  ||| S:7103 E:7106 ||| PRP
postulated  ||| S:7106 E:7117 ||| VBD
that  ||| S:7117 E:7132 ||| IN
TNF  ||| S:7132 E:7136 ||| NNP
supplementation  ||| S:7136 E:7152 ||| NN
should  ||| S:7152 E:7159 ||| MD
have  ||| S:7159 E:7164 ||| VB
no  ||| S:7164 E:7167 ||| DT
inductive  ||| S:7167 E:7177 ||| JJ
effect  ||| S:7177 E:7184 ||| NN
on  ||| S:7184 E:7197 ||| IN
SN50-treated  ||| S:7197 E:7210 ||| NNP
SMGs ||| S:7210 E:7214 ||| NNP
.  ||| S:7214 E:7216 ||| .
Thus ||| S:7216 E:7220 ||| RB
,  ||| S:7220 E:7222 ||| ,
we  ||| S:7222 E:7225 ||| PRP
cultured  ||| S:7225 E:7234 ||| VBD
E15  ||| S:7234 E:7238 ||| CD
control ||| S:7238 E:7245 ||| NN
,  ||| S:7245 E:7257 ||| ,
SN50-treated ||| S:7257 E:7269 ||| NNP
,  ||| S:7269 E:7271 ||| ,
and  ||| S:7271 E:7275 ||| CC
mSN50-treated  ||| S:7275 E:7289 ||| CD
explants  ||| S:7289 E:7298 ||| NN
in  ||| S:7298 E:7301 ||| IN
the  ||| S:7301 E:7305 ||| DT
presence  ||| S:7305 E:7324 ||| NN
of  ||| S:7324 E:7327 ||| IN
TNF  ||| S:7327 E:7331 ||| NNP
( ||| S:7331 E:7332 ||| -LRB-
rTNF ||| S:7332 E:7336 ||| NNP
,  ||| S:7336 E:7338 ||| ,
10  ||| S:7338 E:7341 ||| CD
U ||| S:7341 E:7342 ||| NNP
/ ||| S:7342 E:7343 ||| CD
ml ||| S:7343 E:7345 ||| CD
)  ||| S:7345 E:7347 ||| -RRB-
supplementation  ||| S:7347 E:7363 ||| NN
for  ||| S:7363 E:7367 ||| IN
4  ||| S:7367 E:7369 ||| CD
or  ||| S:7369 E:7372 ||| CC
more  ||| S:7372 E:7387 ||| JJR
days ||| S:7387 E:7391 ||| NNS
.  ||| S:7391 E:7393 ||| .
In  ||| S:7393 E:7396 ||| IN
this  ||| S:7396 E:7401 ||| DT
set  ||| S:7401 E:7405 ||| NN
of  ||| S:7405 E:7408 ||| IN
experiments ||| S:7408 E:7419 ||| NNS
,  ||| S:7419 E:7421 ||| ,
we  ||| S:7421 E:7424 ||| PRP
extended  ||| S:7424 E:7433 ||| VBD
the  ||| S:7433 E:7437 ||| DT
culture  ||| S:7437 E:7455 ||| NN
period  ||| S:7455 E:7462 ||| NN
to  ||| S:7462 E:7465 ||| TO
provide  ||| S:7465 E:7473 ||| VB
sufficient  ||| S:7473 E:7484 ||| JJ
time  ||| S:7484 E:7489 ||| NN
to  ||| S:7489 E:7492 ||| TO
allow  ||| S:7492 E:7498 ||| VB
for  ||| S:7498 E:7502 ||| IN
possible  ||| S:7502 E:7521 ||| JJ
TNF-mediated  ||| S:7521 E:7534 ||| JJ
recovery ||| S:7534 E:7542 ||| NN
.  ||| S:7542 E:7544 ||| .
TNF  ||| S:7544 E:7548 ||| NNP
supplementation  ||| S:7548 E:7564 ||| FW
induced  ||| S:7564 E:7572 ||| FW
NF-κB  ||| S:7572 E:7588 ||| FW
( ||| S:7588 E:7589 ||| -LRB-
p50  ||| S:7589 E:7593 ||| NNP
and  ||| S:7593 E:7597 ||| CC
p65 ||| S:7597 E:7600 ||| CD
)  ||| S:7600 E:7602 ||| -RRB-
translocation  ||| S:7602 E:7616 ||| NNS
( ||| S:7616 E:7617 ||| -LRB-
Fig.  ||| S:7617 E:7622 ||| NNP
6A ||| S:7622 E:7624 ||| NNP
) ||| S:7624 E:7625 ||| -RRB-
,  ||| S:7625 E:7627 ||| ,
a  ||| S:7627 E:7629 ||| DT
marked  ||| S:7629 E:7636 ||| JJ
increase  ||| S:7636 E:7655 ||| NN
in  ||| S:7655 E:7658 ||| IN
explant  ||| S:7658 E:7666 ||| JJ
size ||| S:7666 E:7670 ||| NN
,  ||| S:7670 E:7672 ||| ,
and  ||| S:7672 E:7676 ||| CC
a  ||| S:7676 E:7678 ||| DT
notable  ||| S:7678 E:7686 ||| JJ
increase  ||| S:7686 E:7695 ||| NN
in  ||| S:7695 E:7698 ||| IN
cell  ||| S:7698 E:7713 ||| NN
proliferation  ||| S:7713 E:7727 ||| NN
( ||| S:7727 E:7728 ||| -LRB-
not  ||| S:7728 E:7732 ||| RB
shown ||| S:7732 E:7737 ||| VBN
) ||| S:7737 E:7738 ||| -RRB-
;  ||| S:7738 E:7740 ||| :
similar  ||| S:7740 E:7748 ||| JJ
results  ||| S:7748 E:7756 ||| NNS
were  ||| S:7756 E:7761 ||| VBD
seen  ||| S:7761 E:7766 ||| VBN
in  ||| S:7766 E:7779 ||| IN
TNF+  ||| S:7779 E:7784 ||| CD
mSN50-treated  ||| S:7784 E:7798 ||| CD
explants  ||| S:7798 E:7807 ||| NNS
( ||| S:7807 E:7808 ||| -LRB-
not  ||| S:7808 E:7812 ||| RB
shown ||| S:7812 E:7817 ||| VBN
) ||| S:7817 E:7818 ||| -RRB-
.  ||| S:7818 E:7820 ||| .
By  ||| S:7820 E:7823 ||| IN
contrast ||| S:7823 E:7831 ||| NN
,  ||| S:7831 E:7843 ||| ,
NF-κB  ||| S:7843 E:7849 ||| JJ
redistribution  ||| S:7849 E:7864 ||| NN
was  ||| S:7864 E:7868 ||| VBD
not  ||| S:7868 E:7872 ||| RB
found  ||| S:7872 E:7878 ||| VBN
in  ||| S:7878 E:7881 ||| IN
explants  ||| S:7881 E:7890 ||| JJ
cultured  ||| S:7890 E:7909 ||| NN
in  ||| S:7909 E:7912 ||| IN
TNF  ||| S:7912 E:7916 ||| NNP
+  ||| S:7916 E:7918 ||| NNP
SN50  ||| S:7918 E:7923 ||| NNP
( ||| S:7923 E:7924 ||| -LRB-
Fig.  ||| S:7924 E:7929 ||| NNP
6B ||| S:7929 E:7931 ||| NNP
) ||| S:7931 E:7932 ||| -RRB-
;  ||| S:7932 E:7934 ||| :
rather ||| S:7934 E:7940 ||| RB
,  ||| S:7940 E:7942 ||| ,
NF-κB  ||| S:7942 E:7948 ||| NNP
was  ||| S:7948 E:7952 ||| VBD
absent  ||| S:7952 E:7959 ||| VBN
from  ||| S:7959 E:7974 ||| IN
epithelial  ||| S:7974 E:7985 ||| JJ
cell  ||| S:7985 E:7990 ||| NN
nuclei  ||| S:7990 E:7997 ||| NNS
and  ||| S:7997 E:8001 ||| CC
exhibited  ||| S:8001 E:8011 ||| VBN
a  ||| S:8011 E:8013 ||| DT
very  ||| S:8013 E:8018 ||| RB
weak ||| S:8018 E:8022 ||| JJ
,  ||| S:8022 E:8024 ||| ,
diffuse  ||| S:8024 E:8042 ||| JJ
cytoplasmic  ||| S:8042 E:8054 ||| JJ
distribution ||| S:8054 E:8066 ||| NN
.  ||| S:8066 E:8068 ||| .
Moreover ||| S:8068 E:8076 ||| RB
,  ||| S:8076 E:8078 ||| ,
TNF  ||| S:8078 E:8082 ||| NNP
supplementation  ||| S:8082 E:8108 ||| NN
was  ||| S:8108 E:8112 ||| VBD
unable  ||| S:8112 E:8119 ||| JJ
to  ||| S:8119 E:8122 ||| TO
rescue  ||| S:8122 E:8129 ||| VB
the  ||| S:8129 E:8133 ||| DT
abnormal  ||| S:8133 E:8142 ||| JJ
SN50  ||| S:8142 E:8147 ||| CD
phenotype ||| S:8147 E:8156 ||| NNS
.  ||| S:8156 E:8168 ||| .
Finally ||| S:8168 E:8175 ||| RB
,  ||| S:8175 E:8177 ||| ,
the  ||| S:8177 E:8181 ||| DT
identical  ||| S:8181 E:8191 ||| JJ
response  ||| S:8191 E:8200 ||| NN
of  ||| S:8200 E:8203 ||| IN
control  ||| S:8203 E:8211 ||| NN
and  ||| S:8211 E:8225 ||| CC
mSN50-treated  ||| S:8225 E:8239 ||| NNP
SMG  ||| S:8239 E:8243 ||| NNP
explants  ||| S:8243 E:8252 ||| VBD
to  ||| S:8252 E:8255 ||| TO
TNF  ||| S:8255 E:8259 ||| NNP
supplementation  ||| S:8259 E:8285 ||| NN
provides  ||| S:8285 E:8294 ||| VBZ
further  ||| S:8294 E:8302 ||| JJ
evidence  ||| S:8302 E:8311 ||| NN
that  ||| S:8311 E:8316 ||| IN
this  ||| S:8316 E:8321 ||| DT
mutant  ||| S:8321 E:8328 ||| JJ
peptide  ||| S:8328 E:8336 ||| NN
had  ||| S:8336 E:8340 ||| VBD
no  ||| S:8340 E:8353 ||| DT
effect  ||| S:8353 E:8360 ||| NN
on  ||| S:8360 E:8363 ||| IN
NF-κB  ||| S:8363 E:8369 ||| JJ
activation ||| S:8369 E:8379 ||| NN
.  ||| S:8379 E:8409 ||| .
Transcriptomic  ||| S:8409 E:8424 ||| JJ
analysis  ||| S:8424 E:8443 ||| NN
To  ||| S:8443 E:8446 ||| TO
investigate  ||| S:8446 E:8458 ||| VB
transcriptional  ||| S:8458 E:8474 ||| JJ
responses  ||| S:8474 E:8484 ||| NNS
to  ||| S:8484 E:8487 ||| TO
NF-κB  ||| S:8487 E:8503 ||| JJ
inhibition ||| S:8503 E:8513 ||| NN
,  ||| S:8513 E:8515 ||| ,
we  ||| S:8515 E:8518 ||| PRP
analyzed  ||| S:8518 E:8527 ||| VBD
control  ||| S:8527 E:8535 ||| NN
and  ||| S:8535 E:8539 ||| CC
SN50-treated  ||| S:8539 E:8552 ||| CD
E15  ||| S:8552 E:8556 ||| CD
+  ||| S:8556 E:8558 ||| CD
2  ||| S:8558 E:8570 ||| CD
SMG  ||| S:8570 E:8574 ||| NNS
explants  ||| S:8574 E:8583 ||| VBP
using  ||| S:8583 E:8589 ||| VBG
cDNA  ||| S:8589 E:8594 ||| JJ
arrays ||| S:8594 E:8600 ||| NN
.  ||| S:8600 E:8602 ||| .
Of  ||| S:8602 E:8605 ||| IN
the  ||| S:8605 E:8609 ||| DT
1176  ||| S:8609 E:8614 ||| CD
transcripts  ||| S:8614 E:8636 ||| NNS
assayed  ||| S:8636 E:8644 ||| VBN
on  ||| S:8644 E:8647 ||| IN
these  ||| S:8647 E:8653 ||| DT
arrays  ||| S:8653 E:8660 ||| NN
( ||| S:8660 E:8661 ||| -LRB-
including  ||| S:8661 E:8671 ||| VBG
transcription  ||| S:8671 E:8685 ||| JJ
factors ||| S:8685 E:8692 ||| NNS
,  ||| S:8692 E:8704 ||| ,
cell  ||| S:8704 E:8709 ||| NN
cycle  ||| S:8709 E:8715 ||| NN
regulators ||| S:8715 E:8725 ||| NNS
,  ||| S:8725 E:8727 ||| ,
growth  ||| S:8727 E:8734 ||| NN
factors ||| S:8734 E:8741 ||| NNS
,  ||| S:8741 E:8743 ||| ,
etc. ||| S:8743 E:8747 ||| FW
) ||| S:8747 E:8748 ||| -RRB-
,  ||| S:8748 E:8750 ||| ,
691  ||| S:8750 E:8754 ||| CD
( ||| S:8754 E:8755 ||| -LRB-
~60 ||| S:8755 E:8758 ||| NNP
% ||| S:8758 E:8759 ||| NN
)  ||| S:8759 E:8771 ||| -RRB-
demonstrated  ||| S:8771 E:8784 ||| VBD
a  ||| S:8784 E:8786 ||| DT
1.5-fold  ||| S:8786 E:8795 ||| NNP
or  ||| S:8795 E:8798 ||| CC
greater  ||| S:8798 E:8806 ||| JJR
increase  ||| S:8806 E:8815 ||| NN
or  ||| S:8815 E:8818 ||| CC
decrease  ||| S:8818 E:8837 ||| NN
in  ||| S:8837 E:8840 ||| IN
expression  ||| S:8840 E:8851 ||| NN
with  ||| S:8851 E:8856 ||| IN
SN50-induced  ||| S:8856 E:8869 ||| CD
NF-κB  ||| S:8869 E:8875 ||| JJ
inhibition  ||| S:8875 E:8886 ||| NNS
( ||| S:8886 E:8887 ||| -LRB-
Fig.  ||| S:8887 E:8902 ||| CD
7 ||| S:8902 E:8903 ||| CD
) ||| S:8903 E:8904 ||| -RRB-
.  ||| S:8904 E:8906 ||| .
Of  ||| S:8906 E:8909 ||| IN
these ||| S:8909 E:8914 ||| DT
,  ||| S:8914 E:8916 ||| ,
we  ||| S:8916 E:8919 ||| PRP
focused  ||| S:8919 E:8927 ||| VBD
our  ||| S:8927 E:8931 ||| PRP$
attention  ||| S:8931 E:8941 ||| NN
on  ||| S:8941 E:8944 ||| IN
those  ||| S:8944 E:8950 ||| DT
signal  ||| S:8950 E:8967 ||| NN
transduction ||| S:8967 E:8979 ||| NN
,  ||| S:8979 E:8981 ||| ,
cell  ||| S:8981 E:8986 ||| NN
cycle ||| S:8986 E:8991 ||| NN
,  ||| S:8991 E:8993 ||| ,
and  ||| S:8993 E:8997 ||| CC
apoptosis  ||| S:8997 E:9007 ||| JJ
transcripts  ||| S:9007 E:9029 ||| NNS
related  ||| S:9029 E:9037 ||| VBN
to  ||| S:9037 E:9040 ||| TO
the  ||| S:9040 E:9055 ||| DT
Connections  ||| S:9055 E:9067 ||| NNP
Map  ||| S:9067 E:9071 ||| NNP
( ||| S:9071 E:9072 ||| -LRB-
Fig.  ||| S:9072 E:9077 ||| CD
1 ||| S:9077 E:9078 ||| CD
) ||| S:9078 E:9079 ||| -RRB-
.  ||| S:9079 E:9081 ||| .
With  ||| S:9081 E:9096 ||| IN
inhibition  ||| S:9096 E:9107 ||| NN
of  ||| S:9107 E:9110 ||| IN
NF-κB  ||| S:9110 E:9116 ||| JJ
translocation  ||| S:9116 E:9130 ||| NN
into  ||| S:9130 E:9135 ||| IN
the  ||| S:9135 E:9139 ||| DT
nucleus ||| S:9139 E:9146 ||| NN
,  ||| S:9146 E:9148 ||| ,
53  ||| S:9148 E:9162 ||| CD
Connections  ||| S:9162 E:9174 ||| NNP
Map  ||| S:9174 E:9178 ||| NNP
transcripts  ||| S:9178 E:9190 ||| FW
exhibit  ||| S:9190 E:9208 ||| FW
altered  ||| S:9208 E:9216 ||| FW
expression  ||| S:9216 E:9227 ||| FW
( ||| S:9227 E:9228 ||| -LRB-
Table  ||| S:9228 E:9234 ||| NNP
1 ||| S:9234 E:9235 ||| CD
) ||| S:9235 E:9236 ||| -RRB-
.  ||| S:9236 E:9238 ||| .
We  ||| S:9238 E:9241 ||| PRP
used  ||| S:9241 E:9246 ||| VBD
Probabilistic  ||| S:9246 E:9270 ||| NNP
Neural  ||| S:9270 E:9277 ||| NNP
Network  ||| S:9277 E:9285 ||| NNP
( ||| S:9285 E:9286 ||| -LRB-
PNN ||| S:9286 E:9289 ||| NNP
)  ||| S:9289 E:9291 ||| -RRB-
analyses  ||| S:9291 E:9300 ||| NNS
to  ||| S:9300 E:9303 ||| TO
determine  ||| S:9303 E:9313 ||| VB
which  ||| S:9313 E:9329 ||| WDT
transcript  ||| S:9329 E:9340 ||| VBP
changes  ||| S:9340 E:9348 ||| NNS
best  ||| S:9348 E:9353 ||| RBS
discriminate  ||| S:9353 E:9366 ||| JJ
control  ||| S:9366 E:9374 ||| NN
from  ||| S:9374 E:9389 ||| IN
SN50-treated  ||| S:9389 E:9402 ||| CD
explants ||| S:9402 E:9410 ||| NNS
.  ||| S:9410 E:9412 ||| .
These  ||| S:9412 E:9418 ||| DT
analyses  ||| S:9418 E:9427 ||| NNS
identified  ||| S:9427 E:9438 ||| VBD
those  ||| S:9438 E:9454 ||| DT
transcripts  ||| S:9454 E:9466 ||| NNS
with  ||| S:9466 E:9471 ||| IN
significant  ||| S:9471 E:9483 ||| JJ
changes  ||| S:9483 E:9491 ||| NNS
which  ||| S:9491 E:9497 ||| WDT
are  ||| S:9497 E:9501 ||| VBP
relatively  ||| S:9501 E:9522 ||| RB
more  ||| S:9522 E:9527 ||| RBR
important  ||| S:9527 E:9537 ||| JJ
in  ||| S:9537 E:9540 ||| IN
defining  ||| S:9540 E:9549 ||| VBG
the  ||| S:9549 E:9553 ||| DT
SMG  ||| S:9553 E:9557 ||| NNP
phenotype ||| S:9557 E:9566 ||| NN
,  ||| S:9566 E:9568 ||| ,
regardless  ||| S:9568 E:9589 ||| RB
of  ||| S:9589 E:9592 ||| IN
the  ||| S:9592 E:9596 ||| DT
direction  ||| S:9596 E:9606 ||| NN
( ||| S:9606 E:9607 ||| -LRB-
up  ||| S:9607 E:9610 ||| RB
or  ||| S:9610 E:9613 ||| CC
down ||| S:9613 E:9617 ||| RB
)  ||| S:9617 E:9619 ||| -RRB-
of  ||| S:9619 E:9622 ||| IN
change ||| S:9622 E:9628 ||| NN
.  ||| S:9628 E:9640 ||| .
Among  ||| S:9640 E:9646 ||| IN
the  ||| S:9646 E:9650 ||| DT
cell  ||| S:9650 E:9655 ||| NN
cycle  ||| S:9655 E:9661 ||| NN
transcripts  ||| S:9661 E:9673 ||| NNS
with  ||| S:9673 E:9678 ||| IN
altered  ||| S:9678 E:9696 ||| JJ
expression  ||| S:9696 E:9707 ||| NN
( ||| S:9707 E:9708 ||| -LRB-
Fig.  ||| S:9708 E:9713 ||| NNP
8A ||| S:9713 E:9715 ||| NNP
) ||| S:9715 E:9716 ||| -RRB-
,  ||| S:9716 E:9718 ||| ,
PNN  ||| S:9718 E:9722 ||| NNP
analysis  ||| S:9722 E:9731 ||| NN
shows  ||| S:9731 E:9737 ||| NNS
that  ||| S:9737 E:9742 ||| IN
the  ||| S:9742 E:9757 ||| DT
increased  ||| S:9757 E:9767 ||| JJ
expression  ||| S:9767 E:9778 ||| NN
of  ||| S:9778 E:9781 ||| IN
cyclin  ||| S:9781 E:9788 ||| CD
D2 ||| S:9788 E:9790 ||| CD
,  ||| S:9790 E:9802 ||| ,
p57 ||| S:9802 E:9805 ||| NNP
,  ||| S:9805 E:9807 ||| ,
and  ||| S:9807 E:9811 ||| CC
Cdc25a ||| S:9811 E:9817 ||| NNP
,  ||| S:9817 E:9819 ||| ,
as  ||| S:9819 E:9822 ||| RB
well  ||| S:9822 E:9827 ||| RB
as  ||| S:9827 E:9841 ||| IN
decreased  ||| S:9841 E:9851 ||| JJ
expression  ||| S:9851 E:9862 ||| NN
of  ||| S:9862 E:9865 ||| IN
PCNA ||| S:9865 E:9869 ||| NNP
,  ||| S:9869 E:9871 ||| ,
best  ||| S:9871 E:9886 ||| RBS
discriminate  ||| S:9886 E:9899 ||| JJ
control  ||| S:9899 E:9907 ||| NN
from  ||| S:9907 E:9912 ||| IN
SN50-treated  ||| S:9912 E:9925 ||| CD
explants ||| S:9925 E:9933 ||| NNS
.  ||| S:9933 E:9935 ||| .
Cyclin  ||| S:9935 E:9952 ||| NNP
D2 ||| S:9952 E:9954 ||| NNP
,  ||| S:9954 E:9956 ||| ,
Cdc25a ||| S:9956 E:9962 ||| NNP
,  ||| S:9962 E:9964 ||| ,
and  ||| S:9964 E:9968 ||| CC
PCNA  ||| S:9968 E:9973 ||| NNP
promote  ||| S:9973 E:9981 ||| VB
cell  ||| S:9981 E:9986 ||| NN
division ||| S:9986 E:9994 ||| NN
;  ||| S:9994 E:9996 ||| :
p57  ||| S:9996 E:10000 ||| CD
inhibits  ||| S:10000 E:10019 ||| JJ
cell  ||| S:10019 E:10024 ||| NN
division  ||| S:10024 E:10033 ||| NN
( ||| S:10033 E:10034 ||| -LRB-
Fig.  ||| S:10034 E:10039 ||| CD
1 ||| S:10039 E:10040 ||| CD
) ||| S:10040 E:10041 ||| -RRB-
.  ||| S:10041 E:10043 ||| .
The  ||| S:10043 E:10047 ||| DT
significant  ||| S:10047 E:10059 ||| JJ
decline  ||| S:10059 E:10067 ||| NN
in  ||| S:10067 E:10070 ||| IN
PCNA  ||| S:10070 E:10085 ||| NNP
transcript  ||| S:10085 E:10096 ||| NN
( ||| S:10096 E:10097 ||| -LRB-
Table  ||| S:10097 E:10103 ||| NNP
1 ||| S:10103 E:10104 ||| CD
)  ||| S:10104 E:10106 ||| -RRB-
is  ||| S:10106 E:10109 ||| VBZ
consistent  ||| S:10109 E:10120 ||| JJ
with  ||| S:10120 E:10125 ||| IN
the  ||| S:10125 E:10129 ||| DT
highly  ||| S:10129 E:10146 ||| RB
significant  ||| S:10146 E:10158 ||| JJ
( ||| S:10158 E:10159 ||| -LRB-
p  ||| S:10159 E:10161 ||| FW
< ||| S:10161 E:10163 ||| SYM
0.001 ||| S:10163 E:10168 ||| FW
)  ||| S:10168 E:10170 ||| -RRB-
decline  ||| S:10170 E:10178 ||| NN
in  ||| S:10178 E:10181 ||| IN
PCNA-defined  ||| S:10181 E:10194 ||| JJ
cell  ||| S:10194 E:10209 ||| NN
proliferation  ||| S:10209 E:10223 ||| NN
( ||| S:10223 E:10224 ||| -LRB-
Fig.  ||| S:10224 E:10229 ||| NNP
4A ||| S:10229 E:10231 ||| NNP
) ||| S:10231 E:10232 ||| -RRB-
.  ||| S:10232 E:10244 ||| .
Among  ||| S:10244 E:10250 ||| IN
apoptosis  ||| S:10250 E:10260 ||| JJ
transcripts  ||| S:10260 E:10272 ||| NNS
with  ||| S:10272 E:10277 ||| IN
altered  ||| S:10277 E:10285 ||| JJ
expression  ||| S:10285 E:10306 ||| NN
( ||| S:10306 E:10307 ||| -LRB-
Fig.  ||| S:10307 E:10312 ||| NNP
8B ||| S:10312 E:10314 ||| NNP
) ||| S:10314 E:10315 ||| -RRB-
,  ||| S:10315 E:10317 ||| ,
PNN  ||| S:10317 E:10321 ||| NNP
analysis  ||| S:10321 E:10330 ||| NN
demonstrates  ||| S:10330 E:10343 ||| VBZ
that  ||| S:10343 E:10348 ||| DT
downregulated  ||| S:10348 E:10372 ||| JJ
Caspase  ||| S:10372 E:10380 ||| NNP
1  ||| S:10380 E:10382 ||| CD
transcript ||| S:10382 E:10392 ||| NN
,  ||| S:10392 E:10394 ||| ,
almost  ||| S:10394 E:10401 ||| RB
alone ||| S:10401 E:10406 ||| RB
,  ||| S:10406 E:10408 ||| ,
best  ||| S:10408 E:10413 ||| RBS
discriminates  ||| S:10413 E:10437 ||| JJ
control  ||| S:10437 E:10445 ||| NN
from  ||| S:10445 E:10450 ||| IN
SN50-treated  ||| S:10450 E:10463 ||| CD
explants ||| S:10463 E:10471 ||| NNS
.  ||| S:10471 E:10473 ||| .
Caspase  ||| S:10473 E:10481 ||| NNP
1  ||| S:10481 E:10483 ||| CD
activates  ||| S:10483 E:10503 ||| CD
Caspase  ||| S:10503 E:10511 ||| CD
3  ||| S:10511 E:10513 ||| CD
and  ||| S:10513 E:10517 ||| CC
appears  ||| S:10517 E:10525 ||| VBZ
to  ||| S:10525 E:10528 ||| TO
promote  ||| S:10528 E:10536 ||| VB
production  ||| S:10536 E:10547 ||| NN
of  ||| S:10547 E:10550 ||| IN
the  ||| S:10550 E:10564 ||| DT
cytokine  ||| S:10564 E:10573 ||| JJ
IL-1β ||| S:10573 E:10578 ||| NN
,  ||| S:10578 E:10580 ||| ,
which  ||| S:10580 E:10586 ||| WDT
upregulates  ||| S:10586 E:10598 ||| VBZ
the  ||| S:10598 E:10602 ||| DT
transcription  ||| S:10602 E:10616 ||| NN
of  ||| S:10616 E:10629 ||| IN
both  ||| S:10629 E:10634 ||| DT
Caspases  ||| S:10634 E:10643 ||| NNP
1  ||| S:10643 E:10645 ||| CD
and  ||| S:10645 E:10649 ||| CC
3 ||| S:10649 E:10650 ||| CD
,  ||| S:10650 E:10652 ||| ,
additionally  ||| S:10652 E:10665 ||| FW
potentiating  ||| S:10665 E:10688 ||| FW
apoptosis  ||| S:10688 E:10698 ||| FW
[  ||| S:10698 E:10700 ||| -LRB-
37  ||| S:10700 E:10703 ||| CD
38  ||| S:10703 E:10706 ||| CD
]  ||| S:10706 E:10708 ||| -RRB-
.  ||| S:10708 E:10710 ||| .
Thus ||| S:10710 E:10714 ||| RB
,  ||| S:10714 E:10727 ||| ,
this  ||| S:10727 E:10732 ||| DT
regulatory  ||| S:10732 E:10743 ||| JJ
mechanism  ||| S:10743 E:10753 ||| NN
of  ||| S:10753 E:10766 ||| IN
caspase  ||| S:10766 E:10774 ||| JJ
gene  ||| S:10774 E:10779 ||| NN
expression  ||| S:10779 E:10790 ||| NN
would  ||| S:10790 E:10796 ||| MD
likely  ||| S:10796 E:10803 ||| RB
be  ||| S:10803 E:10806 ||| VB
diminished  ||| S:10806 E:10817 ||| VBN
in  ||| S:10817 E:10830 ||| IN
SN50-treated  ||| S:10830 E:10843 ||| CD
explants  ||| S:10843 E:10852 ||| NNS
were  ||| S:10852 E:10857 ||| VBD
they  ||| S:10857 E:10862 ||| PRP
allowed  ||| S:10862 E:10870 ||| VBD
to  ||| S:10870 E:10873 ||| TO
develop  ||| S:10873 E:10891 ||| VB
further  ||| S:10891 E:10899 ||| RBR
in  ||| S:10899 E:10902 ||| IN
culture ||| S:10902 E:10909 ||| NN
.  ||| S:10909 E:10911 ||| .
Contemporaneous  ||| S:10911 E:10927 ||| JJ
proteome  ||| S:10927 E:10936 ||| JJ
analysis  ||| S:10936 E:10955 ||| NN
provides  ||| S:10955 E:10964 ||| VBZ
a  ||| S:10964 E:10966 ||| DT
very  ||| S:10966 E:10971 ||| RB
different  ||| S:10971 E:10981 ||| JJ
profile  ||| S:10981 E:10989 ||| NN
( ||| S:10989 E:10990 ||| -LRB-
see  ||| S:10990 E:10994 ||| VB
Table  ||| S:10994 E:11000 ||| NNP
2and  ||| S:11000 E:11005 ||| NNP
text  ||| S:11005 E:11020 ||| NN
below ||| S:11020 E:11025 ||| IN
) ||| S:11025 E:11026 ||| -RRB-
.  ||| S:11026 E:11038 ||| .
Although  ||| S:11038 E:11047 ||| IN
many  ||| S:11047 E:11052 ||| JJ
"Ras ||| S:11052 E:11056 ||| NNP
/ ||| S:11056 E:11057 ||| NNP
Raf ||| S:11057 E:11060 ||| NNP
"  ||| S:11060 E:11062 ||| ''
growth  ||| S:11062 E:11069 ||| NN
factor  ||| S:11069 E:11076 ||| NN
pathway  ||| S:11076 E:11094 ||| NN
transcripts  ||| S:11094 E:11106 ||| NNS
were  ||| S:11106 E:11111 ||| VBD
upregulated  ||| S:11111 E:11123 ||| NNS
( ||| S:11123 E:11124 ||| -LRB-
Table  ||| S:11124 E:11130 ||| NNP
1 ||| S:11130 E:11131 ||| CD
) ||| S:11131 E:11132 ||| -RRB-
,  ||| S:11132 E:11134 ||| ,
as  ||| S:11134 E:11137 ||| IN
a  ||| S:11137 E:11139 ||| DT
group  ||| S:11139 E:11145 ||| NN
they  ||| S:11145 E:11160 ||| PRP
were  ||| S:11160 E:11165 ||| VBD
poor  ||| S:11165 E:11170 ||| JJ
predictors  ||| S:11170 E:11181 ||| NN
of  ||| S:11181 E:11184 ||| IN
SMG  ||| S:11184 E:11188 ||| NNP
phenotype  ||| S:11188 E:11198 ||| NNS
( ||| S:11198 E:11199 ||| -LRB-
control  ||| S:11199 E:11207 ||| NN
v.  ||| S:11207 E:11220 ||| CC
SN50-treated ||| S:11220 E:11232 ||| CD
) ||| S:11232 E:11233 ||| -RRB-
.  ||| S:11233 E:11235 ||| .
PNN  ||| S:11235 E:11239 ||| NNP
analysis  ||| S:11239 E:11248 ||| NN
( ||| S:11248 E:11249 ||| -LRB-
Fig.  ||| S:11249 E:11254 ||| NNP
9A ||| S:11254 E:11256 ||| NNP
)  ||| S:11256 E:11258 ||| -RRB-
shows  ||| S:11258 E:11264 ||| VBZ
that  ||| S:11264 E:11269 ||| IN
only  ||| S:11269 E:11284 ||| RB
IGF2 ||| S:11284 E:11288 ||| CD
,  ||| S:11288 E:11290 ||| ,
IGF2R ||| S:11290 E:11295 ||| NNP
,  ||| S:11295 E:11297 ||| ,
and  ||| S:11297 E:11301 ||| CC
IGFBP3  ||| S:11301 E:11308 ||| NNP
are  ||| S:11308 E:11312 ||| VBP
best  ||| S:11312 E:11317 ||| RB
at  ||| S:11317 E:11320 ||| IN
discriminating  ||| S:11320 E:11345 ||| VBG
control  ||| S:11345 E:11353 ||| NN
from  ||| S:11353 E:11358 ||| IN
SN50-treated  ||| S:11358 E:11371 ||| CD
explants ||| S:11371 E:11379 ||| NNS
.  ||| S:11379 E:11391 ||| .
TGF-β1  ||| S:11391 E:11398 ||| NNP
and  ||| S:11398 E:11402 ||| CC
TGF-β2  ||| S:11402 E:11409 ||| RB
show  ||| S:11409 E:11414 ||| VB
a  ||| S:11414 E:11416 ||| DT
2-fold  ||| S:11416 E:11423 ||| JJ
increase  ||| S:11423 E:11432 ||| NN
( ||| S:11432 E:11433 ||| -LRB-
Table  ||| S:11433 E:11439 ||| NNP
1 ||| S:11439 E:11440 ||| CD
)  ||| S:11440 E:11452 ||| -RRB-
which  ||| S:11452 E:11458 ||| WDT
is  ||| S:11458 E:11461 ||| VBZ
not  ||| S:11461 E:11465 ||| RB
unexpected  ||| S:11465 E:11476 ||| JJ
given  ||| S:11476 E:11482 ||| VBN
that  ||| S:11482 E:11487 ||| IN
TGF-β  ||| S:11487 E:11493 ||| JJ
and  ||| S:11493 E:11497 ||| CC
NF-κB  ||| S:11497 E:11503 ||| NNS
are  ||| S:11503 E:11517 ||| VBP
found  ||| S:11517 E:11523 ||| VBN
to  ||| S:11523 E:11526 ||| TO
be  ||| S:11526 E:11529 ||| VB
inversely  ||| S:11529 E:11539 ||| RB
proportional  ||| S:11539 E:11552 ||| VBN
to  ||| S:11552 E:11555 ||| TO
one  ||| S:11555 E:11559 ||| CD
another  ||| S:11559 E:11567 ||| DT
[  ||| S:11567 E:11569 ||| -LRB-
39  ||| S:11569 E:11572 ||| CD
]  ||| S:11572 E:11584 ||| -RRB-
.  ||| S:11584 E:11586 ||| .
Nevertheless ||| S:11586 E:11598 ||| RB
,  ||| S:11598 E:11600 ||| ,
among  ||| S:11600 E:11606 ||| IN
the  ||| S:11606 E:11610 ||| DT
TGF-β  ||| S:11610 E:11616 ||| JJ
family  ||| S:11616 E:11623 ||| NN
transcripts  ||| S:11623 E:11635 ||| NNS
and  ||| S:11635 E:11649 ||| CC
others  ||| S:11649 E:11656 ||| NNS
related  ||| S:11656 E:11664 ||| VBN
to  ||| S:11664 E:11667 ||| TO
their  ||| S:11667 E:11673 ||| PRP$
expression  ||| S:11673 E:11684 ||| NN
and  ||| S:11684 E:11688 ||| CC
signal  ||| S:11688 E:11705 ||| NN
transduction  ||| S:11705 E:11718 ||| NNS
( ||| S:11718 E:11719 ||| -LRB-
Fig.  ||| S:11719 E:11724 ||| NNP
9B ||| S:11724 E:11726 ||| NNP
) ||| S:11726 E:11727 ||| -RRB-
,  ||| S:11727 E:11729 ||| ,
BMP1 ||| S:11729 E:11733 ||| NNP
,  ||| S:11733 E:11735 ||| ,
BMP3b ||| S:11735 E:11740 ||| NNP
,  ||| S:11740 E:11742 ||| ,
BMP8a ||| S:11742 E:11747 ||| NNP
,  ||| S:11747 E:11749 ||| ,
Smad7 ||| S:11749 E:11754 ||| NNP
,  ||| S:11754 E:11756 ||| ,
and  ||| S:11756 E:11760 ||| CC
GR  ||| S:11760 E:11773 ||| NNP
best  ||| S:11773 E:11778 ||| RB
discriminate  ||| S:11778 E:11791 ||| JJ
control  ||| S:11791 E:11799 ||| NN
from  ||| S:11799 E:11804 ||| IN
SN50-treated  ||| S:11804 E:11817 ||| CD
explants ||| S:11817 E:11825 ||| NNS
.  ||| S:11825 E:11837 ||| .
BMPs  ||| S:11837 E:11842 ||| JJ
inhibit  ||| S:11842 E:11850 ||| JJ
cell  ||| S:11850 E:11855 ||| NN
proliferation  ||| S:11855 E:11869 ||| NN
via  ||| S:11869 E:11873 ||| IN
downstream  ||| S:11873 E:11884 ||| CD
Smad1 ||| S:11884 E:11889 ||| CD
/ ||| S:11889 E:11890 ||| CD
5 ||| S:11890 E:11891 ||| CD
/ ||| S:11891 E:11892 ||| CD
8  ||| S:11892 E:11904 ||| CD
proteins  ||| S:11904 E:11913 ||| NNS
whereas  ||| S:11913 E:11921 ||| IN
Smad7  ||| S:11921 E:11927 ||| CD
inhibits  ||| S:11927 E:11936 ||| CD
TGF-β  ||| S:11936 E:11942 ||| JJ
and  ||| S:11942 E:11946 ||| CC
activin  ||| S:11946 E:11964 ||| JJ
signaling  ||| S:11964 E:11974 ||| NNS
( ||| S:11974 E:11975 ||| -LRB-
Fig.  ||| S:11975 E:11980 ||| CD
1 ||| S:11980 E:11981 ||| CD
) ||| S:11981 E:11982 ||| -RRB-
.  ||| S:11982 E:11984 ||| .
This  ||| S:11984 E:11989 ||| DT
inhibition  ||| S:11989 E:12000 ||| NN
of  ||| S:12000 E:12003 ||| IN
TGF-β ||| S:12003 E:12008 ||| FW
/ ||| S:12008 E:12009 ||| FW
activin  ||| S:12009 E:12027 ||| FW
signaling  ||| S:12027 E:12037 ||| FW
is  ||| S:12037 E:12040 ||| VBZ
modulated  ||| S:12040 E:12050 ||| VBN
through  ||| S:12050 E:12058 ||| IN
NF-κB-dependent  ||| S:12058 E:12074 ||| JJ
inhibition  ||| S:12074 E:12095 ||| NN
of  ||| S:12095 E:12098 ||| IN
Smad7  ||| S:12098 E:12104 ||| NNP
[  ||| S:12104 E:12106 ||| -LRB-
40  ||| S:12106 E:12109 ||| CD
]  ||| S:12109 E:12111 ||| -RRB-
.  ||| S:12111 E:12113 ||| .
In  ||| S:12113 E:12116 ||| IN
addition ||| S:12116 E:12124 ||| NN
,  ||| S:12124 E:12126 ||| ,
there  ||| S:12126 E:12132 ||| EX
is  ||| S:12132 E:12135 ||| VBZ
a  ||| S:12135 E:12137 ||| DT
negative  ||| S:12137 E:12156 ||| JJ
feedback  ||| S:12156 E:12165 ||| NN
between  ||| S:12165 E:12173 ||| IN
NF-κB  ||| S:12173 E:12179 ||| JJ
and  ||| S:12179 E:12183 ||| CC
Smad7 ||| S:12183 E:12188 ||| NNP
;  ||| S:12188 E:12190 ||| :
activated  ||| S:12190 E:12200 ||| FW
NF-κB  ||| S:12200 E:12216 ||| FW
inhibits  ||| S:12216 E:12225 ||| FW
Smad7  ||| S:12225 E:12231 ||| FW
promotor  ||| S:12231 E:12240 ||| FW
activity  ||| S:12240 E:12249 ||| FW
[  ||| S:12249 E:12251 ||| -LRB-
41  ||| S:12251 E:12254 ||| CD
]  ||| S:12254 E:12256 ||| -RRB-
whereas  ||| S:12256 E:12264 ||| FW
Smad7  ||| S:12264 E:12280 ||| FW
inhibits  ||| S:12280 E:12289 ||| FW
NF-κB  ||| S:12289 E:12295 ||| FW
activation  ||| S:12295 E:12306 ||| FW
and  ||| S:12306 E:12310 ||| CC
potentiates  ||| S:12310 E:12322 ||| JJ
apoptosis  ||| S:12322 E:12332 ||| NNS
[  ||| S:12332 E:12334 ||| -LRB-
42  ||| S:12334 E:12347 ||| CD
]  ||| S:12347 E:12349 ||| -RRB-
.  ||| S:12349 E:12351 ||| .
Curiously ||| S:12351 E:12360 ||| NNP
,  ||| S:12360 E:12362 ||| ,
the  ||| S:12362 E:12377 ||| DT
relative  ||| S:12377 E:12386 ||| JJ
importance  ||| S:12386 E:12397 ||| NN
of  ||| S:12397 E:12400 ||| IN
increased  ||| S:12400 E:12420 ||| JJ
Smad7  ||| S:12420 E:12426 ||| CD
expression  ||| S:12426 E:12437 ||| NN
is  ||| S:12437 E:12440 ||| VBZ
20  ||| S:12440 E:12443 ||| CD
times  ||| S:12443 E:12449 ||| NNS
greater  ||| S:12449 E:12457 ||| JJR
than  ||| S:12457 E:12462 ||| IN
that  ||| S:12462 E:12467 ||| DT
of  ||| S:12467 E:12470 ||| IN
Smad1 ||| S:12470 E:12475 ||| CD
/ ||| S:12475 E:12476 ||| CD
5  ||| S:12476 E:12499 ||| CD
vis.  ||| S:12499 E:12504 ||| CD
defining  ||| S:12504 E:12513 ||| CD
the  ||| S:12513 E:12517 ||| DT
NF-κB-inhibited  ||| S:12517 E:12543 ||| JJ
explants ||| S:12543 E:12551 ||| NN
.  ||| S:12551 E:12553 ||| .
It  ||| S:12553 E:12556 ||| PRP
is  ||| S:12556 E:12559 ||| VBZ
likely  ||| S:12559 E:12566 ||| RB
that ||| S:12566 E:12570 ||| IN
,  ||| S:12570 E:12572 ||| ,
in  ||| S:12572 E:12575 ||| IN
the  ||| S:12575 E:12579 ||| DT
absence  ||| S:12579 E:12587 ||| NN
of  ||| S:12587 E:12590 ||| IN
NF-κB ||| S:12590 E:12595 ||| NNP
's  ||| S:12595 E:12608 ||| POS
negative  ||| S:12608 E:12617 ||| JJ
regulation ||| S:12617 E:12627 ||| NN
,  ||| S:12627 E:12629 ||| ,
Smad7  ||| S:12629 E:12635 ||| CD
signaling  ||| S:12635 E:12645 ||| NN
is  ||| S:12645 E:12648 ||| VBZ
upregulated ||| S:12648 E:12659 ||| VBN
,  ||| S:12659 E:12671 ||| ,
thereby  ||| S:12671 E:12679 ||| RB
sensitizing  ||| S:12679 E:12691 ||| JJ
cells  ||| S:12691 E:12697 ||| NNS
to  ||| S:12697 E:12700 ||| TO
apoptosis ||| S:12700 E:12709 ||| VB
.  ||| S:12709 E:12711 ||| .
Finally ||| S:12711 E:12718 ||| RB
,  ||| S:12718 E:12720 ||| ,
the  ||| S:12720 E:12734 ||| DT
nearly  ||| S:12734 E:12741 ||| RB
2-fold  ||| S:12741 E:12748 ||| CD
decrease  ||| S:12748 E:12757 ||| NN
in  ||| S:12757 E:12760 ||| IN
glucocorticoid  ||| S:12760 E:12775 ||| JJ
receptor  ||| S:12775 E:12784 ||| NN
( ||| S:12784 E:12785 ||| -LRB-
GR ||| S:12785 E:12787 ||| NNP
)  ||| S:12787 E:12789 ||| -RRB-
is  ||| S:12789 E:12802 ||| VBZ
also  ||| S:12802 E:12807 ||| RB
of  ||| S:12807 E:12810 ||| IN
high  ||| S:12810 E:12815 ||| JJ
relative  ||| S:12815 E:12824 ||| JJ
importance  ||| S:12824 E:12835 ||| NN
in  ||| S:12835 E:12838 ||| IN
defining  ||| S:12838 E:12847 ||| VBG
the  ||| S:12847 E:12861 ||| DT
SN50-treated  ||| S:12861 E:12874 ||| CD
phenotype  ||| S:12874 E:12884 ||| NNS
( ||| S:12884 E:12885 ||| -LRB-
Table  ||| S:12885 E:12891 ||| NNP
1 ||| S:12891 E:12892 ||| CD
) ||| S:12892 E:12893 ||| -RRB-
.  ||| S:12893 E:12895 ||| .
Glucocorticoids  ||| S:12895 E:12911 ||| NNP
( ||| S:12911 E:12912 ||| -LRB-
CORT ||| S:12912 E:12916 ||| NNP
)  ||| S:12916 E:12928 ||| -RRB-
function  ||| S:12928 E:12937 ||| NN
through  ||| S:12937 E:12945 ||| IN
the  ||| S:12945 E:12949 ||| DT
GR  ||| S:12949 E:12952 ||| NNP
to  ||| S:12952 E:12955 ||| TO
both  ||| S:12955 E:12960 ||| DT
activate  ||| S:12960 E:12969 ||| JJ
specific  ||| S:12969 E:12978 ||| JJ
gene  ||| S:12978 E:12993 ||| NN
expression  ||| S:12993 E:13004 ||| NN
as  ||| S:13004 E:13007 ||| IN
well  ||| S:13007 E:13012 ||| RB
as  ||| S:13012 E:13015 ||| IN
transrepress  ||| S:13015 E:13028 ||| JJ
NF-κB  ||| S:13028 E:13034 ||| NN
[  ||| S:13034 E:13036 ||| -LRB-
41  ||| S:13036 E:13039 ||| CD
]  ||| S:13039 E:13041 ||| -RRB-
.  ||| S:13041 E:13043 ||| .
Since  ||| S:13043 E:13059 ||| IN
GR  ||| S:13059 E:13062 ||| NNP
confers  ||| S:13062 E:13070 ||| VBZ
this  ||| S:13070 E:13075 ||| DT
latter  ||| S:13075 E:13082 ||| JJ
effect  ||| S:13082 E:13089 ||| NN
by  ||| S:13089 E:13092 ||| IN
associating  ||| S:13092 E:13104 ||| VBG
through  ||| S:13104 E:13122 ||| IN
protein-protein  ||| S:13122 E:13138 ||| JJ
interactions  ||| S:13138 E:13151 ||| NNS
with  ||| S:13151 E:13156 ||| IN
NF-κB  ||| S:13156 E:13162 ||| JJ
bound  ||| S:13162 E:13168 ||| NN
at  ||| S:13168 E:13171 ||| IN
κB  ||| S:13171 E:13184 ||| JJ
response  ||| S:13184 E:13193 ||| NN
elements  ||| S:13193 E:13202 ||| NNS
[  ||| S:13202 E:13204 ||| -LRB-
43  ||| S:13204 E:13207 ||| CD
44  ||| S:13207 E:13210 ||| CD
45  ||| S:13210 E:13213 ||| CD
46  ||| S:13213 E:13216 ||| CD
47  ||| S:13216 E:13219 ||| CD
]  ||| S:13219 E:13221 ||| -RRB-
,  ||| S:13221 E:13223 ||| ,
it  ||| S:13223 E:13226 ||| PRP
is  ||| S:13226 E:13229 ||| VBZ
important  ||| S:13229 E:13239 ||| JJ
to  ||| S:13239 E:13252 ||| TO
also  ||| S:13252 E:13257 ||| RB
evaluate  ||| S:13257 E:13266 ||| VB
changes  ||| S:13266 E:13274 ||| NNS
in  ||| S:13274 E:13277 ||| IN
GR  ||| S:13277 E:13280 ||| NNP
protein  ||| S:13280 E:13288 ||| NN
levels  ||| S:13288 E:13295 ||| NNS
( ||| S:13295 E:13296 ||| -LRB-
see  ||| S:13296 E:13310 ||| VB
below ||| S:13310 E:13315 ||| IN
) ||| S:13315 E:13316 ||| -RRB-
.  ||| S:13316 E:13328 ||| .
Further ||| S:13328 E:13335 ||| RB
,  ||| S:13335 E:13337 ||| ,
we  ||| S:13337 E:13340 ||| PRP
utilized  ||| S:13340 E:13349 ||| VBD
PNN  ||| S:13349 E:13353 ||| NNP
analysis  ||| S:13353 E:13362 ||| NN
to  ||| S:13362 E:13365 ||| TO
determine  ||| S:13365 E:13375 ||| VB
the  ||| S:13375 E:13389 ||| DT
iterated  ||| S:13389 E:13398 ||| JJ
composite  ||| S:13398 E:13408 ||| JJ
relative  ||| S:13408 E:13417 ||| JJ
importance  ||| S:13417 E:13428 ||| NN
among  ||| S:13428 E:13445 ||| IN
Connections  ||| S:13445 E:13457 ||| NNP
Map  ||| S:13457 E:13461 ||| NNP
( ||| S:13461 E:13462 ||| -LRB-
Fig.  ||| S:13462 E:13467 ||| CD
1 ||| S:13467 E:13468 ||| CD
)  ||| S:13468 E:13480 ||| -RRB-
transcripts  ||| S:13480 E:13492 ||| NNS
which  ||| S:13492 E:13498 ||| WDT
have  ||| S:13498 E:13503 ||| VBP
altered  ||| S:13503 E:13511 ||| VBN
expression  ||| S:13511 E:13522 ||| NN
as  ||| S:13522 E:13525 ||| IN
a  ||| S:13525 E:13537 ||| DT
consequence  ||| S:13537 E:13549 ||| NN
of  ||| S:13549 E:13552 ||| IN
inhibition  ||| S:13552 E:13563 ||| NN
of  ||| S:13563 E:13566 ||| IN
NF-κB  ||| S:13566 E:13572 ||| JJ
translocation  ||| S:13572 E:13586 ||| NN
into  ||| S:13586 E:13591 ||| IN
the  ||| S:13591 E:13605 ||| DT
nucleus  ||| S:13605 E:13613 ||| NN
( ||| S:13613 E:13614 ||| -LRB-
Fig.  ||| S:13614 E:13619 ||| CD
10 ||| S:13619 E:13621 ||| CD
) ||| S:13621 E:13622 ||| -RRB-
.  ||| S:13622 E:13624 ||| .
That  ||| S:13624 E:13629 ||| WDT
is ||| S:13629 E:13631 ||| VBZ
,  ||| S:13631 E:13633 ||| ,
we  ||| S:13633 E:13636 ||| PRP
then  ||| S:13636 E:13641 ||| RB
subjected  ||| S:13641 E:13651 ||| VBN
those  ||| S:13651 E:13667 ||| DT
transcripts  ||| S:13667 E:13679 ||| NNS
with  ||| S:13679 E:13684 ||| IN
altered  ||| S:13684 E:13692 ||| JJ
expression  ||| S:13692 E:13703 ||| NN
in  ||| S:13703 E:13706 ||| IN
each  ||| S:13706 E:13711 ||| DT
group  ||| S:13711 E:13717 ||| NN
( ||| S:13717 E:13718 ||| -LRB-
cell  ||| S:13718 E:13733 ||| NN
cycle ||| S:13733 E:13738 ||| NN
,  ||| S:13738 E:13740 ||| ,
apoptosis ||| S:13740 E:13749 ||| NN
,  ||| S:13749 E:13751 ||| ,
Ras ||| S:13751 E:13754 ||| NNP
/ ||| S:13754 E:13755 ||| NNP
Raf ||| S:13755 E:13758 ||| NNP
,  ||| S:13758 E:13760 ||| ,
TGF-β  ||| S:13760 E:13766 ||| JJ
family ||| S:13766 E:13772 ||| NN
)  ||| S:13772 E:13774 ||| -RRB-
previously  ||| S:13774 E:13785 ||| RB
shown  ||| S:13785 E:13801 ||| VBN
in  ||| S:13801 E:13804 ||| IN
Figures  ||| S:13804 E:13812 ||| NNP
7and  ||| S:13812 E:13817 ||| CD
8  ||| S:13817 E:13819 ||| CD
to  ||| S:13819 E:13822 ||| TO
be  ||| S:13822 E:13825 ||| VB
relatively  ||| S:13825 E:13836 ||| RB
important  ||| S:13836 E:13846 ||| JJ
in  ||| S:13846 E:13849 ||| IN
defining  ||| S:13849 E:13868 ||| VBG
the  ||| S:13868 E:13872 ||| DT
SN50  ||| S:13872 E:13877 ||| NNP
SMG  ||| S:13877 E:13881 ||| NNP
phenotype  ||| S:13881 E:13891 ||| VBD
to  ||| S:13891 E:13894 ||| TO
further  ||| S:13894 E:13902 ||| RBR
PNN  ||| S:13902 E:13906 ||| JJ
analysis ||| S:13906 E:13914 ||| NN
.  ||| S:13914 E:13916 ||| .
This  ||| S:13916 E:13931 ||| DT
transciptomic  ||| S:13931 E:13945 ||| JJ
analysis  ||| S:13945 E:13954 ||| NN
is  ||| S:13954 E:13957 ||| VBZ
a  ||| S:13957 E:13959 ||| DT
time-bound  ||| S:13959 E:13970 ||| JJ
"snapshot ||| S:13970 E:13979 ||| NN
"  ||| S:13979 E:13981 ||| ''
in  ||| S:13981 E:13994 ||| IN
which  ||| S:13994 E:14000 ||| WDT
gene  ||| S:14000 E:14005 ||| NN
expression  ||| S:14005 E:14016 ||| NN
is  ||| S:14016 E:14019 ||| VBZ
indicative  ||| S:14019 E:14030 ||| VBN
of  ||| S:14030 E:14033 ||| IN
possible  ||| S:14033 E:14042 ||| JJ
future  ||| S:14042 E:14059 ||| JJ
protein  ||| S:14059 E:14067 ||| NN
expression ||| S:14067 E:14077 ||| NN
.  ||| S:14077 E:14079 ||| .
It  ||| S:14079 E:14082 ||| PRP
is  ||| S:14082 E:14085 ||| VBZ
instructive  ||| S:14085 E:14097 ||| VBN
that ||| S:14097 E:14101 ||| IN
,  ||| S:14101 E:14103 ||| ,
of  ||| S:14103 E:14106 ||| IN
the  ||| S:14106 E:14110 ||| DT
53  ||| S:14110 E:14124 ||| CD
Connections  ||| S:14124 E:14136 ||| NNP
Map  ||| S:14136 E:14140 ||| NNP
transcripts  ||| S:14140 E:14152 ||| NNS
with  ||| S:14152 E:14167 ||| IN
altered  ||| S:14167 E:14175 ||| JJ
expression  ||| S:14175 E:14186 ||| NN
( ||| S:14186 E:14187 ||| -LRB-
Table  ||| S:14187 E:14193 ||| NNP
1 ||| S:14193 E:14194 ||| CD
) ||| S:14194 E:14195 ||| -RRB-
,  ||| S:14195 E:14197 ||| ,
4  ||| S:14197 E:14199 ||| CD
genes  ||| S:14199 E:14205 ||| NNS
of  ||| S:14205 E:14208 ||| IN
diverse  ||| S:14208 E:14216 ||| JJ
pathways  ||| S:14216 E:14235 ||| NN
but  ||| S:14235 E:14239 ||| CC
overlapping  ||| S:14239 E:14251 ||| NNS
function  ||| S:14251 E:14260 ||| VBP
best  ||| S:14260 E:14265 ||| RBS
discriminate  ||| S:14265 E:14278 ||| JJ
control  ||| S:14278 E:14286 ||| NN
from  ||| S:14286 E:14301 ||| IN
SN50-treated  ||| S:14301 E:14314 ||| CD
explants ||| S:14314 E:14322 ||| NNS
:  ||| S:14322 E:14324 ||| :
PCNA ||| S:14324 E:14328 ||| NNP
,  ||| S:14328 E:14330 ||| ,
GR ||| S:14330 E:14332 ||| NNP
,  ||| S:14332 E:14334 ||| ,
BMP1 ||| S:14334 E:14338 ||| NNP
,  ||| S:14338 E:14340 ||| ,
BMP3b ||| S:14340 E:14345 ||| NNP
.  ||| S:14345 E:14347 ||| .
The  ||| S:14347 E:14361 ||| DT
declining  ||| S:14361 E:14371 ||| VBG
PCNA  ||| S:14371 E:14376 ||| NNP
and  ||| S:14376 E:14380 ||| CC
GR  ||| S:14380 E:14383 ||| NNP
reflect  ||| S:14383 E:14391 ||| VBP
the  ||| S:14391 E:14395 ||| DT
sharp  ||| S:14395 E:14401 ||| JJ
decline  ||| S:14401 E:14409 ||| NN
in  ||| S:14409 E:14412 ||| IN
cell  ||| S:14412 E:14427 ||| NN
proliferation  ||| S:14427 E:14441 ||| NN
and  ||| S:14441 E:14445 ||| CC
branching ||| S:14445 E:14454 ||| NNS
;  ||| S:14454 E:14456 ||| :
the  ||| S:14456 E:14460 ||| DT
increasing  ||| S:14460 E:14471 ||| VBG
BMP1  ||| S:14471 E:14476 ||| NNP
and  ||| S:14476 E:14490 ||| CC
BMP3b  ||| S:14490 E:14496 ||| NNP
similarly  ||| S:14496 E:14506 ||| RB
reflects  ||| S:14506 E:14515 ||| VBZ
inhibition  ||| S:14515 E:14526 ||| VBN
of  ||| S:14526 E:14529 ||| IN
cell  ||| S:14529 E:14534 ||| NN
proliferation  ||| S:14534 E:14558 ||| NN
( ||| S:14558 E:14559 ||| -LRB-
Fig.  ||| S:14559 E:14564 ||| CD
1 ||| S:14564 E:14565 ||| CD
) ||| S:14565 E:14566 ||| -RRB-
.  ||| S:14566 E:14596 ||| .
Proteomic  ||| S:14596 E:14606 ||| NNP
analysis  ||| S:14606 E:14625 ||| VBD
Our  ||| S:14625 E:14629 ||| PRP$
cDNA  ||| S:14629 E:14634 ||| JJ
array  ||| S:14634 E:14640 ||| NN
analysis  ||| S:14640 E:14649 ||| NN
provides  ||| S:14649 E:14658 ||| VBZ
a  ||| S:14658 E:14671 ||| DT
good  ||| S:14671 E:14676 ||| JJ
first  ||| S:14676 E:14682 ||| JJ
approximation  ||| S:14682 E:14696 ||| NN
of  ||| S:14696 E:14710 ||| IN
likely  ||| S:14710 E:14717 ||| JJ
protein  ||| S:14717 E:14725 ||| NN
differences ||| S:14725 E:14736 ||| NNS
.  ||| S:14736 E:14748 ||| .
However ||| S:14748 E:14755 ||| RB
,  ||| S:14755 E:14757 ||| ,
one  ||| S:14757 E:14761 ||| CD
cannot  ||| S:14761 E:14768 ||| JJ
extrapolate  ||| S:14768 E:14780 ||| NN
from  ||| S:14780 E:14785 ||| IN
mRNA  ||| S:14785 E:14790 ||| JJ
abundance  ||| S:14790 E:14800 ||| NN
to  ||| S:14800 E:14813 ||| TO
relevant  ||| S:14813 E:14822 ||| JJ
protein  ||| S:14822 E:14830 ||| NN
levels  ||| S:14830 E:14837 ||| NNS
[  ||| S:14837 E:14839 ||| -LRB-
48  ||| S:14839 E:14842 ||| CD
]  ||| S:14842 E:14844 ||| -RRB-
.  ||| S:14844 E:14846 ||| .
A  ||| S:14846 E:14848 ||| DT
recent  ||| S:14848 E:14855 ||| JJ
study  ||| S:14855 E:14861 ||| NN
by  ||| S:14861 E:14874 ||| IN
Aebersole  ||| S:14874 E:14884 ||| NNP
and  ||| S:14884 E:14888 ||| CC
coworkers  ||| S:14888 E:14898 ||| NNS
[  ||| S:14898 E:14900 ||| -LRB-
48  ||| S:14900 E:14903 ||| CD
]  ||| S:14903 E:14905 ||| -RRB-
analyzing  ||| S:14905 E:14915 ||| VBG
yeast  ||| S:14915 E:14921 ||| NN
protein  ||| S:14921 E:14939 ||| NN
and  ||| S:14939 E:14943 ||| CC
mRNA  ||| S:14943 E:14948 ||| JJ
abundance  ||| S:14948 E:14958 ||| NNS
clearly  ||| S:14958 E:14966 ||| RB
showed  ||| S:14966 E:14973 ||| VBD
that  ||| S:14973 E:14978 ||| DT
mRNA  ||| S:14978 E:14983 ||| JJ
transcript  ||| S:14983 E:15004 ||| NN
levels  ||| S:15004 E:15011 ||| NNS
are  ||| S:15011 E:15026 ||| VBP
poor  ||| S:15026 E:15031 ||| JJ
predictors  ||| S:15031 E:15042 ||| NN
of  ||| S:15042 E:15045 ||| IN
protein  ||| S:15045 E:15063 ||| NN
expression ||| S:15063 E:15073 ||| NN
.  ||| S:15073 E:15075 ||| .
They  ||| S:15075 E:15080 ||| PRP
demonstrate  ||| S:15080 E:15092 ||| VBP
that  ||| S:15092 E:15097 ||| IN
some  ||| S:15097 E:15102 ||| DT
genes  ||| S:15102 E:15108 ||| NNS
with  ||| S:15108 E:15123 ||| IN
comparable  ||| S:15123 E:15134 ||| JJ
mRNA  ||| S:15134 E:15139 ||| JJ
levels  ||| S:15139 E:15146 ||| NNS
exhibited  ||| S:15146 E:15156 ||| VBP
a  ||| S:15156 E:15158 ||| DT
20-fold  ||| S:15158 E:15166 ||| JJ
difference  ||| S:15166 E:15177 ||| NN
in  ||| S:15177 E:15190 ||| IN
their  ||| S:15190 E:15196 ||| PRP$
protein  ||| S:15196 E:15204 ||| NN
expression  ||| S:15204 E:15215 ||| NN
while  ||| S:15215 E:15221 ||| IN
mRNA  ||| S:15221 E:15226 ||| JJ
levels  ||| S:15226 E:15233 ||| NNS
of  ||| S:15233 E:15236 ||| IN
comparable  ||| S:15236 E:15257 ||| JJ
protein  ||| S:15257 E:15265 ||| NN
expression  ||| S:15265 E:15276 ||| NN
varied  ||| S:15276 E:15283 ||| VBD
as  ||| S:15283 E:15286 ||| RB
much  ||| S:15286 E:15291 ||| RB
as  ||| S:15291 E:15294 ||| IN
30-fold ||| S:15294 E:15301 ||| CD
.  ||| S:15301 E:15313 ||| .
Thus ||| S:15313 E:15317 ||| RB
,  ||| S:15317 E:15319 ||| ,
we  ||| S:15319 E:15322 ||| PRP
next  ||| S:15322 E:15327 ||| RB
analyzed  ||| S:15327 E:15336 ||| VBD
SN50-treated  ||| S:15336 E:15349 ||| CD
and  ||| S:15349 E:15353 ||| CC
control  ||| S:15353 E:15361 ||| NN
E15  ||| S:15361 E:15365 ||| CD
+  ||| S:15365 E:15377 ||| CD
2  ||| S:15377 E:15379 ||| CD
SMG  ||| S:15379 E:15383 ||| NNS
explants  ||| S:15383 E:15392 ||| VBP
using  ||| S:15392 E:15398 ||| VBG
2-D  ||| S:15398 E:15402 ||| NNP
Western  ||| S:15402 E:15410 ||| NNP
Multiprotein  ||| S:15410 E:15423 ||| NNP
Arrays  ||| S:15423 E:15430 ||| NNP
to  ||| S:15430 E:15443 ||| TO
determine  ||| S:15443 E:15453 ||| VB
protein  ||| S:15453 E:15461 ||| NN
differences ||| S:15461 E:15472 ||| NNS
.  ||| S:15472 E:15474 ||| .
This  ||| S:15474 E:15479 ||| DT
technique  ||| S:15479 E:15489 ||| NN
allows  ||| S:15489 E:15496 ||| VBZ
for  ||| S:15496 E:15510 ||| IN
the  ||| S:15510 E:15514 ||| DT
densitometric  ||| S:15514 E:15528 ||| JJ
analysis  ||| S:15528 E:15537 ||| NN
of  ||| S:15537 E:15540 ||| IN
about  ||| S:15540 E:15546 ||| IN
600  ||| S:15546 E:15550 ||| CD
signal  ||| S:15550 E:15567 ||| NN
transduction  ||| S:15567 E:15580 ||| NNS
and  ||| S:15580 E:15584 ||| CC
other  ||| S:15584 E:15590 ||| JJ
proteins  ||| S:15590 E:15599 ||| NNS
simultaneously  ||| S:15599 E:15614 ||| RB
in  ||| S:15614 E:15617 ||| IN
each  ||| S:15617 E:15632 ||| DT
independent  ||| S:15632 E:15644 ||| JJ
sample  ||| S:15644 E:15651 ||| NN
( ||| S:15651 E:15652 ||| -LRB-
Fig.  ||| S:15652 E:15657 ||| CD
11 ||| S:15657 E:15659 ||| CD
) ||| S:15659 E:15660 ||| -RRB-
.  ||| S:15660 E:15662 ||| .
As  ||| S:15662 E:15665 ||| RB
shown  ||| S:15665 E:15671 ||| VBN
in  ||| S:15671 E:15674 ||| IN
Table  ||| S:15674 E:15680 ||| NNP
2 ||| S:15680 E:15681 ||| CD
,  ||| S:15681 E:15683 ||| ,
we  ||| S:15683 E:15696 ||| PRP
find  ||| S:15696 E:15701 ||| VBP
18  ||| S:15701 E:15704 ||| CD
proteins  ||| S:15704 E:15713 ||| NNS
which  ||| S:15713 E:15719 ||| WDT
have  ||| S:15719 E:15724 ||| VBP
both  ||| S:15724 E:15729 ||| PDT
a  ||| S:15729 E:15731 ||| DT
1.5-fold  ||| S:15731 E:15740 ||| NNP
or  ||| S:15740 E:15743 ||| CC
greater  ||| S:15743 E:15761 ||| JJR
change  ||| S:15761 E:15768 ||| NN
with  ||| S:15768 E:15773 ||| IN
NF-κB  ||| S:15773 E:15779 ||| JJ
inhibition  ||| S:15779 E:15801 ||| NN
and  ||| S:15801 E:15805 ||| CC
are  ||| S:15805 E:15809 ||| VBP
specifically  ||| S:15809 E:15822 ||| RB
related  ||| S:15822 E:15830 ||| VBN
to  ||| S:15830 E:15833 ||| TO
the  ||| S:15833 E:15858 ||| DT
Connections  ||| S:15858 E:15870 ||| NNP
Map  ||| S:15870 E:15874 ||| NNP
( ||| S:15874 E:15875 ||| -LRB-
Fig.  ||| S:15875 E:15880 ||| CD
1 ||| S:15880 E:15881 ||| CD
) ||| S:15881 E:15882 ||| -RRB-
.  ||| S:15882 E:15884 ||| .
They  ||| S:15884 E:15899 ||| PRP
include  ||| S:15899 E:15907 ||| VBP
signal  ||| S:15907 E:15914 ||| NN
transduction ||| S:15914 E:15926 ||| NN
,  ||| S:15926 E:15928 ||| ,
cell  ||| S:15928 E:15933 ||| NN
cycle ||| S:15933 E:15938 ||| NN
,  ||| S:15938 E:15940 ||| ,
and  ||| S:15940 E:15944 ||| CC
apoptosis  ||| S:15944 E:15964 ||| JJ
proteins  ||| S:15964 E:15973 ||| NNS
that  ||| S:15973 E:15978 ||| WDT
are  ||| S:15978 E:15982 ||| VBP
either  ||| S:15982 E:15989 ||| RB
directly  ||| S:15989 E:15998 ||| RB
or  ||| S:15998 E:16001 ||| CC
indirectly  ||| S:16001 E:16022 ||| RB
downstream  ||| S:16022 E:16033 ||| VBN
from  ||| S:16033 E:16038 ||| IN
activation  ||| S:16038 E:16049 ||| NN
of  ||| S:16049 E:16052 ||| IN
the  ||| S:16052 E:16056 ||| DT
TNF ||| S:16056 E:16059 ||| NNP
,  ||| S:16059 E:16061 ||| ,
IL-6 ||| S:16061 E:16065 ||| NNP
,  ||| S:16065 E:16067 ||| ,
EGF ||| S:16067 E:16070 ||| NNP
,  ||| S:16070 E:16072 ||| ,
IGF ||| S:16072 E:16075 ||| NNP
,  ||| S:16075 E:16087 ||| ,
and  ||| S:16087 E:16091 ||| CC
FGF  ||| S:16091 E:16095 ||| NNP
signaling  ||| S:16095 E:16105 ||| VBG
pathways ||| S:16105 E:16113 ||| NNS
.  ||| S:16113 E:16115 ||| .
The  ||| S:16115 E:16119 ||| DT
significant  ||| S:16119 E:16131 ||| JJ
decline  ||| S:16131 E:16139 ||| NN
in  ||| S:16139 E:16152 ||| IN
PCNA  ||| S:16152 E:16157 ||| NNP
protein  ||| S:16157 E:16165 ||| NN
( ||| S:16165 E:16166 ||| -LRB-
Table  ||| S:16166 E:16172 ||| NNP
2 ||| S:16172 E:16173 ||| CD
)  ||| S:16173 E:16175 ||| -RRB-
is  ||| S:16175 E:16178 ||| VBZ
consistent  ||| S:16178 E:16189 ||| JJ
with  ||| S:16189 E:16194 ||| IN
the  ||| S:16194 E:16198 ||| DT
significant  ||| S:16198 E:16220 ||| JJ
decline  ||| S:16220 E:16228 ||| NN
in  ||| S:16228 E:16231 ||| IN
PCNA  ||| S:16231 E:16236 ||| NNP
transcript  ||| S:16236 E:16247 ||| NN
( ||| S:16247 E:16248 ||| -LRB-
Table  ||| S:16248 E:16254 ||| NNP
1 ||| S:16254 E:16255 ||| CD
)  ||| S:16255 E:16257 ||| -RRB-
and  ||| S:16257 E:16261 ||| CC
PCNA-defined  ||| S:16261 E:16284 ||| JJ
cell  ||| S:16284 E:16289 ||| NN
proliferation  ||| S:16289 E:16303 ||| NN
( ||| S:16303 E:16304 ||| -LRB-
Fig.  ||| S:16304 E:16309 ||| NNP
4A ||| S:16309 E:16311 ||| NNP
) ||| S:16311 E:16312 ||| -RRB-
.  ||| S:16312 E:16324 ||| .
PNN  ||| S:16324 E:16328 ||| NNP
analysis  ||| S:16328 E:16337 ||| NN
shows  ||| S:16337 E:16343 ||| NNS
that  ||| S:16343 E:16348 ||| IN
among  ||| S:16348 E:16354 ||| IN
cell  ||| S:16354 E:16359 ||| NN
cycle  ||| S:16359 E:16365 ||| NN
proteins  ||| S:16365 E:16374 ||| NNS
with  ||| S:16374 E:16389 ||| IN
altered  ||| S:16389 E:16397 ||| JJ
expression  ||| S:16397 E:16408 ||| NN
( ||| S:16408 E:16409 ||| -LRB-
Fig.  ||| S:16409 E:16414 ||| NNP
12A ||| S:16414 E:16417 ||| NNP
) ||| S:16417 E:16418 ||| -RRB-
,  ||| S:16418 E:16420 ||| ,
the  ||| S:16420 E:16424 ||| DT
increased  ||| S:16424 E:16434 ||| JJ
expression  ||| S:16434 E:16455 ||| NN
of  ||| S:16455 E:16458 ||| IN
Chk1 ||| S:16458 E:16462 ||| NNP
,  ||| S:16462 E:16464 ||| ,
Chk2 ||| S:16464 E:16468 ||| NNP
,  ||| S:16468 E:16470 ||| ,
and  ||| S:16470 E:16474 ||| CC
E2F1  ||| S:16474 E:16479 ||| CD
best  ||| S:16479 E:16484 ||| JJS
discriminates  ||| S:16484 E:16498 ||| JJ
control  ||| S:16498 E:16506 ||| NN
from  ||| S:16506 E:16521 ||| IN
SN50-treated  ||| S:16521 E:16534 ||| CD
explants ||| S:16534 E:16542 ||| NNS
.  ||| S:16542 E:16544 ||| .
Of  ||| S:16544 E:16547 ||| IN
particular  ||| S:16547 E:16558 ||| JJ
interest  ||| S:16558 E:16567 ||| NN
is  ||| S:16567 E:16570 ||| VBZ
E2F1 ||| S:16570 E:16574 ||| CD
.  ||| S:16574 E:16586 ||| .
Among  ||| S:16586 E:16592 ||| IN
the  ||| S:16592 E:16596 ||| DT
five  ||| S:16596 E:16601 ||| CD
known  ||| S:16601 E:16607 ||| VBN
mammalian  ||| S:16607 E:16617 ||| JJ
E2Fs ||| S:16617 E:16621 ||| NN
,  ||| S:16621 E:16623 ||| ,
the  ||| S:16623 E:16627 ||| DT
ability  ||| S:16627 E:16635 ||| NN
to  ||| S:16635 E:16648 ||| TO
induce  ||| S:16648 E:16655 ||| VB
apoptosis  ||| S:16655 E:16665 ||| NN
is  ||| S:16665 E:16668 ||| VBZ
unique  ||| S:16668 E:16675 ||| JJ
to  ||| S:16675 E:16678 ||| TO
E2F1  ||| S:16678 E:16683 ||| CD
[  ||| S:16683 E:16685 ||| -LRB-
49  ||| S:16685 E:16688 ||| CD
]  ||| S:16688 E:16690 ||| -RRB-
.  ||| S:16690 E:16702 ||| .
Overexpression  ||| S:16702 E:16717 ||| NNP
of  ||| S:16717 E:16720 ||| IN
E2F1  ||| S:16720 E:16725 ||| CD
in  ||| S:16725 E:16728 ||| IN
several  ||| S:16728 E:16736 ||| JJ
cell  ||| S:16736 E:16741 ||| NN
lines  ||| S:16741 E:16747 ||| NNS
results  ||| S:16747 E:16755 ||| NNS
in  ||| S:16755 E:16758 ||| IN
G  ||| S:16758 E:16781 ||| NNP
2  ||| S:16781 E:16783 ||| CD
arrest ||| S:16783 E:16789 ||| NN
,  ||| S:16789 E:16791 ||| ,
as  ||| S:16791 E:16794 ||| RB
well  ||| S:16794 E:16799 ||| RB
as  ||| S:16799 E:16802 ||| IN
apoptosis  ||| S:16802 E:16812 ||| NN
via  ||| S:16812 E:16826 ||| IN
p53-dependent  ||| S:16826 E:16840 ||| NNP
and  ||| S:16840 E:16844 ||| CC
p53-independent  ||| S:16844 E:16860 ||| CD
pathways  ||| S:16860 E:16869 ||| NNS
[  ||| S:16869 E:16871 ||| -LRB-
50  ||| S:16871 E:16874 ||| CD
51  ||| S:16874 E:16877 ||| CD
52  ||| S:16877 E:16880 ||| CD
]  ||| S:16880 E:16882 ||| -RRB-
.  ||| S:16882 E:16894 ||| .
The  ||| S:16894 E:16898 ||| DT
presence  ||| S:16898 E:16907 ||| NN
of  ||| S:16907 E:16910 ||| IN
a  ||| S:16910 E:16912 ||| DT
dysplastic  ||| S:16912 E:16923 ||| JJ
SMG  ||| S:16923 E:16927 ||| NNP
phenotype  ||| S:16927 E:16937 ||| NN
in  ||| S:16937 E:16951 ||| IN
E2f1  ||| S:16951 E:16956 ||| CD
- ||| S:16956 E:16957 ||| :
/ ||| S:16957 E:16958 ||| NNP
-mice  ||| S:16958 E:16964 ||| NNP
indicates  ||| S:16964 E:16974 ||| VBZ
that  ||| S:16974 E:16979 ||| IN
E2F1  ||| S:16979 E:16994 ||| NNP
plays  ||| S:16994 E:17000 ||| VBZ
an  ||| S:17000 E:17003 ||| DT
important  ||| S:17003 E:17013 ||| JJ
role  ||| S:17013 E:17018 ||| NN
during  ||| S:17018 E:17025 ||| IN
SMG  ||| S:17025 E:17029 ||| NNP
development  ||| S:17029 E:17041 ||| NN
[  ||| S:17041 E:17043 ||| -LRB-
53  ||| S:17043 E:17046 ||| CD
]  ||| S:17046 E:17048 ||| -RRB-
.  ||| S:17048 E:17060 ||| .
Moreover ||| S:17060 E:17068 ||| RB
,  ||| S:17068 E:17070 ||| ,
E2F1  ||| S:17070 E:17075 ||| CD
overexpression  ||| S:17075 E:17090 ||| NN
in  ||| S:17090 E:17093 ||| IN
human  ||| S:17093 E:17099 ||| JJ
salivary  ||| S:17099 E:17108 ||| JJ
gland  ||| S:17108 E:17124 ||| NNS
( ||| S:17124 E:17125 ||| -LRB-
HSG ||| S:17125 E:17128 ||| NNP
)  ||| S:17128 E:17130 ||| -RRB-
cells  ||| S:17130 E:17136 ||| NNS
diverted  ||| S:17136 E:17145 ||| VBN
these  ||| S:17145 E:17151 ||| DT
cells  ||| S:17151 E:17157 ||| NNS
into  ||| S:17157 E:17162 ||| IN
an  ||| S:17162 E:17165 ||| DT
apoptotic  ||| S:17165 E:17185 ||| JJ
pathway  ||| S:17185 E:17193 ||| NNS
[  ||| S:17193 E:17195 ||| -LRB-
54  ||| S:17195 E:17198 ||| CD
]  ||| S:17198 E:17200 ||| -RRB-
.  ||| S:17200 E:17212 ||| .
Among  ||| S:17212 E:17218 ||| IN
apoptosis  ||| S:17218 E:17228 ||| JJ
proteins  ||| S:17228 E:17237 ||| NNS
with  ||| S:17237 E:17242 ||| IN
altered  ||| S:17242 E:17250 ||| JJ
expression  ||| S:17250 E:17261 ||| NN
( ||| S:17261 E:17262 ||| -LRB-
Fig.  ||| S:17262 E:17277 ||| NNP
12B ||| S:17277 E:17280 ||| NNP
) ||| S:17280 E:17281 ||| -RRB-
,  ||| S:17281 E:17283 ||| ,
PNN  ||| S:17283 E:17287 ||| NNP
analysis  ||| S:17287 E:17296 ||| NN
demonstrates  ||| S:17296 E:17309 ||| VBZ
that  ||| S:17309 E:17314 ||| DT
increased  ||| S:17314 E:17324 ||| JJ
expression  ||| S:17324 E:17345 ||| NN
of  ||| S:17345 E:17348 ||| IN
FAF  ||| S:17348 E:17352 ||| NNP
and  ||| S:17352 E:17356 ||| CC
Caspase  ||| S:17356 E:17364 ||| NNP
6  ||| S:17364 E:17366 ||| CD
best  ||| S:17366 E:17371 ||| JJS
discriminates  ||| S:17371 E:17385 ||| JJ
control  ||| S:17385 E:17393 ||| NN
from  ||| S:17393 E:17408 ||| IN
SN50-treated  ||| S:17408 E:17421 ||| CD
explants ||| S:17421 E:17429 ||| NNS
.  ||| S:17429 E:17431 ||| .
Caspase  ||| S:17431 E:17439 ||| NNP
6  ||| S:17439 E:17441 ||| CD
is  ||| S:17441 E:17444 ||| VBZ
activated  ||| S:17444 E:17454 ||| VBN
by  ||| S:17454 E:17457 ||| IN
active  ||| S:17457 E:17474 ||| JJ
Caspase  ||| S:17474 E:17482 ||| NNP
3  ||| S:17482 E:17484 ||| CD
and  ||| S:17484 E:17488 ||| CC
in  ||| S:17488 E:17491 ||| IN
turn  ||| S:17491 E:17496 ||| NN
cleaves  ||| S:17496 E:17504 ||| NN
lamin ||| S:17504 E:17509 ||| NN
,  ||| S:17509 E:17511 ||| ,
resulting  ||| S:17511 E:17521 ||| VBG
in  ||| S:17521 E:17524 ||| IN
nuclear  ||| S:17524 E:17542 ||| JJ
membrane  ||| S:17542 E:17551 ||| JJ
fragmentation  ||| S:17551 E:17565 ||| NNS
[  ||| S:17565 E:17567 ||| -LRB-
55  ||| S:17567 E:17570 ||| CD
]  ||| S:17570 E:17572 ||| -RRB-
.  ||| S:17572 E:17574 ||| .
FAF  ||| S:17574 E:17578 ||| NNP
interacts  ||| S:17578 E:17588 ||| NN
with  ||| S:17588 E:17593 ||| IN
the  ||| S:17593 E:17607 ||| DT
cytoplasmic  ||| S:17607 E:17619 ||| JJ
domain  ||| S:17619 E:17626 ||| NN
of  ||| S:17626 E:17629 ||| IN
the  ||| S:17629 E:17633 ||| DT
Fas  ||| S:17633 E:17637 ||| JJ
receptor  ||| S:17637 E:17646 ||| NN
to  ||| S:17646 E:17649 ||| TO
potentiate  ||| S:17649 E:17670 ||| VB
Fas-mediated  ||| S:17670 E:17683 ||| JJ
apoptosis  ||| S:17683 E:17693 ||| NNS
[  ||| S:17693 E:17695 ||| -LRB-
56  ||| S:17695 E:17698 ||| CD
57  ||| S:17698 E:17701 ||| CD
]  ||| S:17701 E:17703 ||| -RRB-
.  ||| S:17703 E:17705 ||| .
Thus ||| S:17705 E:17709 ||| RB
,  ||| S:17709 E:17711 ||| ,
the  ||| S:17711 E:17715 ||| DT
up-regulated  ||| S:17715 E:17738 ||| JJ
cell  ||| S:17738 E:17743 ||| NN
cycle  ||| S:17743 E:17749 ||| NN
inhibitors  ||| S:17749 E:17760 ||| NNS
and  ||| S:17760 E:17764 ||| CC
apoptotic  ||| S:17764 E:17774 ||| JJ
proteins  ||| S:17774 E:17783 ||| NNS
clearly  ||| S:17783 E:17801 ||| RB
favor  ||| S:17801 E:17807 ||| VB
cell  ||| S:17807 E:17812 ||| NN
cycle  ||| S:17812 E:17818 ||| NN
arrest  ||| S:17818 E:17825 ||| NN
and  ||| S:17825 E:17829 ||| CC
death ||| S:17829 E:17834 ||| NN
.  ||| S:17834 E:17846 ||| .
Among  ||| S:17846 E:17852 ||| IN
signal  ||| S:17852 E:17859 ||| NN
transduction  ||| S:17859 E:17872 ||| NN
proteins  ||| S:17872 E:17881 ||| NNS
with  ||| S:17881 E:17886 ||| IN
altered  ||| S:17886 E:17904 ||| JJ
expression  ||| S:17904 E:17915 ||| NN
( ||| S:17915 E:17916 ||| -LRB-
Fig.  ||| S:17916 E:17921 ||| NNP
12C ||| S:17921 E:17924 ||| NNP
) ||| S:17924 E:17925 ||| -RRB-
,  ||| S:17925 E:17927 ||| ,
PNN  ||| S:17927 E:17931 ||| NNP
analysis  ||| S:17931 E:17940 ||| NN
shows  ||| S:17940 E:17946 ||| NNS
that  ||| S:17946 E:17951 ||| IN
members  ||| S:17951 E:17959 ||| NNS
of  ||| S:17959 E:17972 ||| IN
all  ||| S:17972 E:17976 ||| DT
three  ||| S:17976 E:17982 ||| CD
growth  ||| S:17982 E:17989 ||| NN
factor  ||| S:17989 E:17996 ||| NN
pathways  ||| S:17996 E:18005 ||| NNS
( ||| S:18005 E:18006 ||| -LRB-
Ras ||| S:18006 E:18009 ||| NNP
/ ||| S:18009 E:18010 ||| NNP
Raf ||| S:18010 E:18013 ||| NNP
;  ||| S:18013 E:18015 ||| :
JAK ||| S:18015 E:18018 ||| NNP
/ ||| S:18018 E:18019 ||| NNP
STAT ||| S:18019 E:18023 ||| NNP
;  ||| S:18023 E:18025 ||| :
JNK ||| S:18025 E:18028 ||| NNP
)  ||| S:18028 E:18040 ||| -RRB-
have  ||| S:18040 E:18045 ||| VBP
high  ||| S:18045 E:18050 ||| JJ
relative  ||| S:18050 E:18059 ||| JJ
importance  ||| S:18059 E:18070 ||| NN
in  ||| S:18070 E:18073 ||| IN
discriminating  ||| S:18073 E:18088 ||| VBG
control  ||| S:18088 E:18106 ||| NN
from  ||| S:18106 E:18111 ||| IN
SN50-treated  ||| S:18111 E:18124 ||| CD
explants ||| S:18124 E:18132 ||| NNS
.  ||| S:18132 E:18134 ||| .
Of  ||| S:18134 E:18137 ||| IN
particular  ||| S:18137 E:18148 ||| JJ
note  ||| S:18148 E:18153 ||| NN
are  ||| S:18153 E:18157 ||| VBP
c-Raf ||| S:18157 E:18162 ||| JJ
,  ||| S:18162 E:18174 ||| ,
ERK2 ||| S:18174 E:18178 ||| NNP
,  ||| S:18178 E:18180 ||| ,
and  ||| S:18180 E:18184 ||| CC
JAK1 ||| S:18184 E:18188 ||| NNP
.  ||| S:18188 E:18190 ||| .
Raf  ||| S:18190 E:18194 ||| NNP
plays  ||| S:18194 E:18200 ||| VBZ
a  ||| S:18200 E:18202 ||| DT
key  ||| S:18202 E:18206 ||| JJ
role  ||| S:18206 E:18211 ||| NN
in  ||| S:18211 E:18214 ||| IN
the  ||| S:18214 E:18218 ||| DT
Ras  ||| S:18218 E:18222 ||| NNP
signaling  ||| S:18222 E:18242 ||| FW
pathway  ||| S:18242 E:18250 ||| FW
( ||| S:18250 E:18251 ||| -LRB-
Fig.  ||| S:18251 E:18256 ||| CD
1 ||| S:18256 E:18257 ||| CD
) ||| S:18257 E:18258 ||| -RRB-
.  ||| S:18258 E:18260 ||| .
That  ||| S:18260 E:18265 ||| IN
ERK2  ||| S:18265 E:18270 ||| NNP
is  ||| S:18270 E:18273 ||| VBZ
of  ||| S:18273 E:18276 ||| IN
very  ||| S:18276 E:18281 ||| RB
high  ||| S:18281 E:18286 ||| JJ
relative  ||| S:18286 E:18305 ||| JJ
importance  ||| S:18305 E:18316 ||| NN
is  ||| S:18316 E:18319 ||| VBZ
consistent  ||| S:18319 E:18330 ||| JJ
with  ||| S:18330 E:18335 ||| IN
the  ||| S:18335 E:18339 ||| DT
observation  ||| S:18339 E:18351 ||| NN
that  ||| S:18351 E:18356 ||| IN
the  ||| S:18356 E:18370 ||| DT
MAPK ||| S:18370 E:18374 ||| NNP
/ ||| S:18374 E:18375 ||| NNP
ERK  ||| S:18375 E:18379 ||| NNP
overrides  ||| S:18379 E:18389 ||| NNS
apoptotic  ||| S:18389 E:18399 ||| VBP
signaling  ||| S:18399 E:18409 ||| VBG
from  ||| S:18409 E:18414 ||| IN
Fas ||| S:18414 E:18417 ||| NNP
,  ||| S:18417 E:18419 ||| ,
TNF  ||| S:18419 E:18423 ||| NNP
and  ||| S:18423 E:18437 ||| CC
TRAIL  ||| S:18437 E:18443 ||| NNP
receptors  ||| S:18443 E:18453 ||| NNS
[  ||| S:18453 E:18455 ||| -LRB-
58  ||| S:18455 E:18458 ||| CD
]  ||| S:18458 E:18460 ||| -RRB-
.  ||| S:18460 E:18462 ||| .
It  ||| S:18462 E:18465 ||| PRP
appears  ||| S:18465 E:18473 ||| VBZ
that  ||| S:18473 E:18478 ||| IN
effectors  ||| S:18478 E:18488 ||| VBG
apart  ||| S:18488 E:18504 ||| RP
from  ||| S:18504 E:18509 ||| IN
the  ||| S:18509 E:18513 ||| DT
MAPK ||| S:18513 E:18517 ||| NNP
/ ||| S:18517 E:18518 ||| NNP
ERK  ||| S:18518 E:18522 ||| NNP
pathway  ||| S:18522 E:18530 ||| NN
may  ||| S:18530 E:18534 ||| MD
also  ||| S:18534 E:18539 ||| RB
mediate  ||| S:18539 E:18547 ||| VB
the  ||| S:18547 E:18561 ||| DT
anti-apoptotic  ||| S:18561 E:18576 ||| JJ
function  ||| S:18576 E:18585 ||| NN
of  ||| S:18585 E:18588 ||| IN
c-Raf  ||| S:18588 E:18594 ||| NNP
[ ||| S:18594 E:18595 ||| -LRB-
55a ||| S:18595 E:18598 ||| NNP
] ||| S:18598 E:18599 ||| -RRB-
.  ||| S:18599 E:18601 ||| .
Further ||| S:18601 E:18608 ||| RB
,  ||| S:18608 E:18610 ||| ,
both  ||| S:18610 E:18615 ||| CC
the  ||| S:18615 E:18629 ||| DT
SHP-2 ||| S:18629 E:18634 ||| NNP
/ ||| S:18634 E:18635 ||| NNP
Ras  ||| S:18635 E:18639 ||| NNP
and  ||| S:18639 E:18643 ||| CC
JAK ||| S:18643 E:18646 ||| NNP
/ ||| S:18646 E:18647 ||| CD
STAT3  ||| S:18647 E:18653 ||| CD
pathways  ||| S:18653 E:18662 ||| NNS
are  ||| S:18662 E:18666 ||| VBP
activated  ||| S:18666 E:18676 ||| VBN
by  ||| S:18676 E:18689 ||| IN
IL-6R ||| S:18689 E:18694 ||| CD
/ ||| S:18694 E:18695 ||| CD
gp130  ||| S:18695 E:18701 ||| CD
signaling  ||| S:18701 E:18711 ||| NNS
( ||| S:18711 E:18712 ||| -LRB-
Fig.  ||| S:18712 E:18717 ||| CD
1 ||| S:18717 E:18718 ||| CD
) ||| S:18718 E:18719 ||| -RRB-
.  ||| S:18719 E:18731 ||| .
Moreover ||| S:18731 E:18739 ||| RB
,  ||| S:18739 E:18741 ||| ,
it  ||| S:18741 E:18744 ||| PRP
is  ||| S:18744 E:18747 ||| VBZ
especially  ||| S:18747 E:18758 ||| RB
noteworthy  ||| S:18758 E:18769 ||| VBN
that  ||| S:18769 E:18774 ||| IN
the  ||| S:18774 E:18778 ||| DT
nearly  ||| S:18778 E:18795 ||| RB
2-fold  ||| S:18795 E:18813 ||| CD
decline  ||| S:18813 E:18821 ||| NN
of  ||| S:18821 E:18824 ||| IN
glucocorticoid  ||| S:18824 E:18839 ||| JJ
receptor  ||| S:18839 E:18858 ||| NN
( ||| S:18858 E:18859 ||| -LRB-
GR ||| S:18859 E:18861 ||| NNP
)  ||| S:18861 E:18863 ||| -RRB-
( ||| S:18863 E:18864 ||| -LRB-
Table  ||| S:18864 E:18870 ||| NNP
2 ||| S:18870 E:18871 ||| CD
)  ||| S:18871 E:18873 ||| -RRB-
is  ||| S:18873 E:18876 ||| VBZ
also  ||| S:18876 E:18881 ||| RB
of  ||| S:18881 E:18884 ||| IN
very  ||| S:18884 E:18889 ||| RB
high  ||| S:18889 E:18894 ||| JJ
relative  ||| S:18894 E:18903 ||| JJ
importance  ||| S:18903 E:18924 ||| NN
in  ||| S:18924 E:18927 ||| IN
defining  ||| S:18927 E:18936 ||| JJ
SMGs  ||| S:18936 E:18941 ||| JJ
deprived  ||| S:18941 E:18950 ||| NN
of  ||| S:18950 E:18953 ||| IN
NF-κB  ||| S:18953 E:18959 ||| JJ
nuclear  ||| S:18959 E:18967 ||| JJ
translocation ||| S:18967 E:18980 ||| NN
.  ||| S:18980 E:18992 ||| .
As  ||| S:18992 E:18995 ||| RB
noted  ||| S:18995 E:19001 ||| VBD
above ||| S:19001 E:19006 ||| RB
,  ||| S:19006 E:19008 ||| ,
CORT ||| S:19008 E:19012 ||| NNP
/ ||| S:19012 E:19013 ||| NNP
GR  ||| S:19013 E:19016 ||| NNP
binding  ||| S:19016 E:19024 ||| VBD
both  ||| S:19024 E:19029 ||| DT
activates  ||| S:19029 E:19039 ||| JJ
specific  ||| S:19039 E:19058 ||| JJ
gene  ||| S:19058 E:19063 ||| NN
expression  ||| S:19063 E:19074 ||| NN
and  ||| S:19074 E:19078 ||| CC
transrepresses  ||| S:19078 E:19093 ||| JJ
NF-κB  ||| S:19093 E:19099 ||| NN
[  ||| S:19099 E:19101 ||| -LRB-
47  ||| S:19101 E:19104 ||| CD
]  ||| S:19104 E:19106 ||| -RRB-
.  ||| S:19106 E:19108 ||| .
To  ||| S:19108 E:19121 ||| TO
repress  ||| S:19121 E:19129 ||| VB
NF-κB ||| S:19129 E:19134 ||| JJ
,  ||| S:19134 E:19136 ||| ,
the  ||| S:19136 E:19140 ||| DT
GR  ||| S:19140 E:19143 ||| NNP
associates  ||| S:19143 E:19154 ||| NNS
through  ||| S:19154 E:19162 ||| IN
protein-protein  ||| S:19162 E:19188 ||| JJ
interactions  ||| S:19188 E:19201 ||| NNS
with  ||| S:19201 E:19206 ||| IN
NF-κB  ||| S:19206 E:19212 ||| JJ
bound  ||| S:19212 E:19218 ||| NN
at  ||| S:19218 E:19221 ||| IN
κB  ||| S:19221 E:19224 ||| JJ
response  ||| S:19224 E:19233 ||| NN
elements  ||| S:19233 E:19242 ||| NNS
[  ||| S:19242 E:19254 ||| -LRB-
44  ||| S:19254 E:19257 ||| CD
45  ||| S:19257 E:19260 ||| CD
46  ||| S:19260 E:19263 ||| CD
47  ||| S:19263 E:19266 ||| CD
]  ||| S:19266 E:19268 ||| -RRB-
.  ||| S:19268 E:19270 ||| .
The  ||| S:19270 E:19274 ||| DT
precise  ||| S:19274 E:19282 ||| JJ
relationship  ||| S:19282 E:19295 ||| NN
between  ||| S:19295 E:19313 ||| IN
decreased  ||| S:19313 E:19323 ||| JJ
NF-κB-mediated  ||| S:19323 E:19338 ||| JJ
transcription  ||| S:19338 E:19352 ||| NN
and  ||| S:19352 E:19356 ||| CC
a  ||| S:19356 E:19358 ||| DT
decreased  ||| S:19358 E:19368 ||| JJ
GR  ||| S:19368 E:19381 ||| NNP
protein  ||| S:19381 E:19389 ||| NN
expression  ||| S:19389 E:19400 ||| NN
is  ||| S:19400 E:19403 ||| VBZ
unclear ||| S:19403 E:19410 ||| JJ
.  ||| S:19410 E:19422 ||| .
Nevertheless ||| S:19422 E:19434 ||| RB
,  ||| S:19434 E:19436 ||| ,
CORT ||| S:19436 E:19440 ||| NNP
/ ||| S:19440 E:19441 ||| NNP
GR  ||| S:19441 E:19444 ||| NNP
function  ||| S:19444 E:19453 ||| NN
is  ||| S:19453 E:19456 ||| VBZ
important  ||| S:19456 E:19466 ||| JJ
to  ||| S:19466 E:19479 ||| TO
embryonic  ||| S:19479 E:19489 ||| FW
SMG  ||| S:19489 E:19493 ||| FW
morphogenesis  ||| S:19493 E:19507 ||| FW
[  ||| S:19507 E:19509 ||| -LRB-
60  ||| S:19509 E:19512 ||| CD
]  ||| S:19512 E:19514 ||| -RRB-
.  ||| S:19514 E:19516 ||| .
Radioimmunoassays  ||| S:19516 E:19544 ||| NNP
first  ||| S:19544 E:19550 ||| RB
detect  ||| S:19550 E:19557 ||| VB
SMG  ||| S:19557 E:19561 ||| NNP
CORT  ||| S:19561 E:19566 ||| NNP
in  ||| S:19566 E:19569 ||| IN
amounts  ||| S:19569 E:19577 ||| NNS
> ||| S:19577 E:19578 ||| CD
2  ||| S:19578 E:19580 ||| CD
pg ||| S:19580 E:19582 ||| CD
/ ||| S:19582 E:19583 ||| CD
gland  ||| S:19583 E:19589 ||| NN
on  ||| S:19589 E:19592 ||| IN
E15 ||| S:19592 E:19595 ||| CD
;  ||| S:19595 E:19607 ||| :
Western  ||| S:19607 E:19615 ||| JJ
analysis  ||| S:19615 E:19624 ||| NN
first  ||| S:19624 E:19630 ||| JJ
detects  ||| S:19630 E:19638 ||| JJ
SMG  ||| S:19638 E:19642 ||| NNP
GR  ||| S:19642 E:19645 ||| NNP
on  ||| S:19645 E:19648 ||| IN
E14  ||| S:19648 E:19652 ||| NNP
( ||| S:19652 E:19653 ||| -LRB-
0.14  ||| S:19653 E:19668 ||| FW
fmol ||| S:19668 E:19672 ||| FW
/ ||| S:19672 E:19673 ||| FW
gland ||| S:19673 E:19678 ||| FW
) ||| S:19678 E:19679 ||| -RRB-
.  ||| S:19679 E:19681 ||| .
By  ||| S:19681 E:19684 ||| IN
E18 ||| S:19684 E:19687 ||| NNP
,  ||| S:19687 E:19689 ||| ,
SMG  ||| S:19689 E:19693 ||| NNP
CORT  ||| S:19693 E:19698 ||| NNP
has  ||| S:19698 E:19702 ||| VBZ
increased  ||| S:19702 E:19712 ||| VBN
more  ||| S:19712 E:19717 ||| JJR
than  ||| S:19717 E:19732 ||| IN
50-fold ||| S:19732 E:19739 ||| NNP
,  ||| S:19739 E:19741 ||| ,
and  ||| S:19741 E:19745 ||| CC
SMG  ||| S:19745 E:19749 ||| NNP
GR  ||| S:19749 E:19752 ||| NNP
has  ||| S:19752 E:19756 ||| VBZ
increased  ||| S:19756 E:19766 ||| VBN
nearly  ||| S:19766 E:19773 ||| RB
11-fold ||| S:19773 E:19780 ||| CD
.  ||| S:19780 E:19782 ||| .
The  ||| S:19782 E:19786 ||| DT
SMG  ||| S:19786 E:19800 ||| NNP
GR  ||| S:19800 E:19803 ||| NNP
is  ||| S:19803 E:19806 ||| VBZ
functional ||| S:19806 E:19816 ||| VBN
,  ||| S:19816 E:19818 ||| ,
as  ||| S:19818 E:19821 ||| RB
defined  ||| S:19821 E:19829 ||| VBN
by  ||| S:19829 E:19832 ||| IN
its  ||| S:19832 E:19836 ||| PRP$
ability  ||| S:19836 E:19844 ||| NN
to  ||| S:19844 E:19847 ||| TO
bind  ||| S:19847 E:19852 ||| VB
a  ||| S:19852 E:19854 ||| DT
DNA  ||| S:19854 E:19868 ||| NN
response  ||| S:19868 E:19877 ||| NN
element  ||| S:19877 E:19885 ||| NN
( ||| S:19885 E:19886 ||| -LRB-
GRE ||| S:19886 E:19889 ||| NNP
) ||| S:19889 E:19890 ||| -RRB-
.  ||| S:19890 E:19892 ||| .
Increasing  ||| S:19892 E:19903 ||| VBG
CORT ||| S:19903 E:19907 ||| NNP
/ ||| S:19907 E:19908 ||| NNP
GR  ||| S:19908 E:19911 ||| NNP
function  ||| S:19911 E:19931 ||| NN
in  ||| S:19931 E:19934 ||| IN
vivo  ||| S:19934 E:19939 ||| NN
is  ||| S:19939 E:19942 ||| VBZ
associated  ||| S:19942 E:19953 ||| VBN
with  ||| S:19953 E:19958 ||| IN
a  ||| S:19958 E:19970 ||| DT
significant  ||| S:19970 E:19982 ||| JJ
decline  ||| S:19982 E:19990 ||| NN
in  ||| S:19990 E:19993 ||| IN
TGF-β  ||| S:19993 E:19999 ||| JJ
expression  ||| S:19999 E:20010 ||| NN
and  ||| S:20010 E:20014 ||| CC
a  ||| S:20014 E:20016 ||| DT
significant  ||| S:20016 E:20038 ||| JJ
increase  ||| S:20038 E:20047 ||| NN
in  ||| S:20047 E:20050 ||| IN
cell  ||| S:20050 E:20055 ||| NN
division ||| S:20055 E:20063 ||| NN
.  ||| S:20063 E:20065 ||| .
SMG  ||| S:20065 E:20069 ||| NNP
primordia  ||| S:20069 E:20079 ||| VBD
cultured  ||| S:20079 E:20088 ||| VBN
under  ||| S:20088 E:20104 ||| IN
serumless ||| S:20104 E:20113 ||| NN
,  ||| S:20113 E:20115 ||| ,
chemically  ||| S:20115 E:20126 ||| RB
defined  ||| S:20126 E:20134 ||| VBN
conditions ||| S:20134 E:20144 ||| NNS
,  ||| S:20144 E:20146 ||| ,
and  ||| S:20146 E:20150 ||| CC
deprived  ||| S:20150 E:20159 ||| VBN
of  ||| S:20159 E:20172 ||| IN
CORT ||| S:20172 E:20176 ||| NNP
,  ||| S:20176 E:20178 ||| ,
exhibit  ||| S:20178 E:20186 ||| VBG
a  ||| S:20186 E:20188 ||| DT
dramatic  ||| S:20188 E:20197 ||| JJ
decline  ||| S:20197 E:20205 ||| NN
of  ||| S:20205 E:20208 ||| IN
SMG  ||| S:20208 E:20212 ||| NNP
branching  ||| S:20212 E:20232 ||| FW
morphogenesis ||| S:20232 E:20245 ||| FW
.  ||| S:20245 E:20247 ||| .
It  ||| S:20247 E:20250 ||| PRP
is  ||| S:20250 E:20253 ||| VBZ
reasonable ||| S:20253 E:20263 ||| JJ
,  ||| S:20263 E:20265 ||| ,
then ||| S:20265 E:20269 ||| RB
,  ||| S:20269 E:20271 ||| ,
to  ||| S:20271 E:20274 ||| TO
assume  ||| S:20274 E:20281 ||| VB
that  ||| S:20281 E:20286 ||| IN
the  ||| S:20286 E:20300 ||| DT
high  ||| S:20300 E:20305 ||| JJ
relative  ||| S:20305 E:20314 ||| JJ
importance  ||| S:20314 E:20325 ||| NN
of  ||| S:20325 E:20328 ||| IN
diminished  ||| S:20328 E:20339 ||| JJ
GR  ||| S:20339 E:20342 ||| NNP
protein  ||| S:20342 E:20360 ||| NN
expression  ||| S:20360 E:20371 ||| NN
to  ||| S:20371 E:20374 ||| TO
the  ||| S:20374 E:20378 ||| DT
phenotype  ||| S:20378 E:20388 ||| NN
of  ||| S:20388 E:20391 ||| IN
SN50-treated  ||| S:20391 E:20404 ||| NNP
SMGs  ||| S:20404 E:20409 ||| NNP
is  ||| S:20409 E:20422 ||| VBZ
directly  ||| S:20422 E:20431 ||| RB
related  ||| S:20431 E:20439 ||| VBN
to  ||| S:20439 E:20442 ||| TO
the  ||| S:20442 E:20446 ||| DT
significant  ||| S:20446 E:20458 ||| JJ
( ||| S:20458 E:20459 ||| -LRB-
p  ||| S:20459 E:20461 ||| FW
< ||| S:20461 E:20463 ||| SYM
0.001 ||| S:20463 E:20468 ||| FW
)  ||| S:20468 E:20480 ||| -RRB-
decline  ||| S:20480 E:20488 ||| NN
in  ||| S:20488 E:20491 ||| IN
cell  ||| S:20491 E:20496 ||| NN
proliferation  ||| S:20496 E:20510 ||| NN
and  ||| S:20510 E:20514 ||| CC
branching  ||| S:20514 E:20524 ||| NNS
( ||| S:20524 E:20525 ||| -LRB-
Fig.  ||| S:20525 E:20530 ||| NNP
3A ||| S:20530 E:20532 ||| NNP
,  ||| S:20532 E:20534 ||| ,
B ||| S:20534 E:20535 ||| NNP
;  ||| S:20535 E:20547 ||| :
Fig.  ||| S:20547 E:20552 ||| CD
4A ||| S:20552 E:20554 ||| CD
) ||| S:20554 E:20555 ||| -RRB-
.  ||| S:20555 E:20567 ||| .
The  ||| S:20567 E:20571 ||| DT
iterated  ||| S:20571 E:20580 ||| JJ
composite  ||| S:20580 E:20590 ||| JJ
relative  ||| S:20590 E:20599 ||| JJ
importance  ||| S:20599 E:20610 ||| NN
of  ||| S:20610 E:20613 ||| IN
all  ||| S:20613 E:20628 ||| DT
Connections  ||| S:20628 E:20640 ||| NNP
Map  ||| S:20640 E:20644 ||| NNP
proteins  ||| S:20644 E:20653 ||| NNS
with  ||| S:20653 E:20668 ||| IN
altered  ||| S:20668 E:20676 ||| JJ
expression  ||| S:20676 E:20687 ||| NN
as  ||| S:20687 E:20690 ||| IN
a  ||| S:20690 E:20692 ||| DT
consequence  ||| S:20692 E:20704 ||| NN
of  ||| S:20704 E:20707 ||| IN
NF-κB  ||| S:20707 E:20713 ||| JJ
inhibition  ||| S:20713 E:20734 ||| NN
was  ||| S:20734 E:20738 ||| VBD
then  ||| S:20738 E:20743 ||| RB
determined  ||| S:20743 E:20754 ||| VBN
( ||| S:20754 E:20755 ||| -LRB-
Fig.  ||| S:20755 E:20760 ||| CD
13 ||| S:20760 E:20762 ||| CD
) ||| S:20762 E:20763 ||| -RRB-
.  ||| S:20763 E:20765 ||| .
This  ||| S:20765 E:20770 ||| DT
proteomic  ||| S:20770 E:20780 ||| JJ
analysis  ||| S:20780 E:20789 ||| NN
is  ||| S:20789 E:20802 ||| VBZ
a  ||| S:20802 E:20804 ||| DT
time-based  ||| S:20804 E:20815 ||| JJ
"snapshot ||| S:20815 E:20824 ||| NN
"  ||| S:20824 E:20826 ||| ''
of  ||| S:20826 E:20829 ||| IN
proteins  ||| S:20829 E:20838 ||| NNS
assumed  ||| S:20838 E:20846 ||| VBD
to  ||| S:20846 E:20849 ||| TO
be  ||| S:20849 E:20862 ||| VB
associated  ||| S:20862 E:20873 ||| VBN
with  ||| S:20873 E:20878 ||| IN
physiologic  ||| S:20878 E:20890 ||| JJ
function  ||| S:20890 E:20899 ||| NN
at  ||| S:20899 E:20902 ||| IN
the  ||| S:20902 E:20906 ||| DT
moment  ||| S:20906 E:20913 ||| NN
of  ||| S:20913 E:20916 ||| IN
SMG  ||| S:20916 E:20930 ||| NNP
harvesting ||| S:20930 E:20940 ||| NN
.  ||| S:20940 E:20942 ||| .
Viewing  ||| S:20942 E:20950 ||| VBG
the  ||| S:20950 E:20954 ||| DT
most  ||| S:20954 E:20959 ||| RBS
defining  ||| S:20959 E:20968 ||| JJ
proteins  ||| S:20968 E:20977 ||| NNS
with  ||| S:20977 E:20992 ||| IN
altered  ||| S:20992 E:21000 ||| JJ
expression ||| S:21000 E:21010 ||| NN
,  ||| S:21010 E:21012 ||| ,
it  ||| S:21012 E:21015 ||| PRP
is  ||| S:21015 E:21018 ||| VBZ
clearly  ||| S:21018 E:21026 ||| RB
reflective  ||| S:21026 E:21037 ||| VBN
of  ||| S:21037 E:21040 ||| IN
increased  ||| S:21040 E:21060 ||| JJ
apoptosis  ||| S:21060 E:21070 ||| NNS
( ||| S:21070 E:21071 ||| -LRB-
increased  ||| S:21071 E:21081 ||| VBN
Chk1 ||| S:21081 E:21085 ||| NNP
,  ||| S:21085 E:21087 ||| ,
Caspase  ||| S:21087 E:21095 ||| NNP
6 ||| S:21095 E:21096 ||| CD
,  ||| S:21096 E:21098 ||| ,
E2F1 ||| S:21098 E:21102 ||| CD
) ||| S:21102 E:21103 ||| -RRB-
,  ||| S:21103 E:21105 ||| ,
decreased  ||| S:21105 E:21125 ||| VBD
cell  ||| S:21125 E:21130 ||| NN
proliferation  ||| S:21130 E:21144 ||| NN
and  ||| S:21144 E:21148 ||| CC
branching  ||| S:21148 E:21158 ||| NNS
( ||| S:21158 E:21159 ||| -LRB-
decreased  ||| S:21159 E:21169 ||| UH
GR ||| S:21169 E:21171 ||| UH
) ||| S:21171 E:21172 ||| -RRB-
,  ||| S:21172 E:21174 ||| ,
and ||| S:21174 E:21177 ||| CC
,  ||| S:21177 E:21189 ||| ,
interestingly ||| S:21189 E:21202 ||| RB
,  ||| S:21202 E:21204 ||| ,
increased  ||| S:21204 E:21214 ||| VBN
expression  ||| S:21214 E:21225 ||| NN
of  ||| S:21225 E:21228 ||| IN
diverse  ||| S:21228 E:21236 ||| JJ
signal  ||| S:21236 E:21253 ||| NN
transduction  ||| S:21253 E:21266 ||| NN
pathways  ||| S:21266 E:21275 ||| NNS
( ||| S:21275 E:21276 ||| -LRB-
Ras ||| S:21276 E:21279 ||| NNP
/ ||| S:21279 E:21280 ||| NNP
Raf ||| S:21280 E:21283 ||| NNP
/ ||| S:21283 E:21284 ||| NNP
ERK ||| S:21284 E:21287 ||| NNP
,  ||| S:21287 E:21289 ||| ,
JNK ||| S:21289 E:21292 ||| NNP
)  ||| S:21292 E:21294 ||| -RRB-
to  ||| S:21294 E:21297 ||| TO
compensate  ||| S:21297 E:21318 ||| VB
for  ||| S:21318 E:21322 ||| IN
the  ||| S:21322 E:21326 ||| DT
proapoptotic  ||| S:21326 E:21339 ||| JJ
signal ||| S:21339 E:21345 ||| NN
.  ||| S:21345 E:21375 ||| .
Analysis  ||| S:21375 E:21384 ||| NN
of  ||| S:21384 E:21387 ||| IN
activated  ||| S:21387 E:21397 ||| JJ
pathway  ||| S:21397 E:21405 ||| JJ
components  ||| S:21405 E:21426 ||| NNS
We  ||| S:21426 E:21429 ||| PRP
then  ||| S:21429 E:21434 ||| RB
focused  ||| S:21434 E:21442 ||| VBN
our  ||| S:21442 E:21446 ||| PRP$
attention  ||| S:21446 E:21456 ||| NN
on  ||| S:21456 E:21459 ||| IN
two  ||| S:21459 E:21463 ||| CD
particularly  ||| S:21463 E:21486 ||| RB
important  ||| S:21486 E:21496 ||| JJ
pathways  ||| S:21496 E:21505 ||| JJ
relative  ||| S:21505 E:21514 ||| JJ
to  ||| S:21514 E:21517 ||| TO
cell  ||| S:21517 E:21522 ||| NN
proliferation  ||| S:21522 E:21536 ||| NN
and  ||| S:21536 E:21550 ||| CC
apoptosis ||| S:21550 E:21559 ||| NN
,  ||| S:21559 E:21561 ||| ,
ERK  ||| S:21561 E:21565 ||| NNP
1 ||| S:21565 E:21566 ||| CD
/ ||| S:21566 E:21567 ||| CD
2  ||| S:21567 E:21569 ||| CD
and  ||| S:21569 E:21573 ||| CC
Caspase  ||| S:21573 E:21581 ||| NNP
3 ||| S:21581 E:21582 ||| CD
.  ||| S:21582 E:21584 ||| .
Downstream  ||| S:21584 E:21595 ||| NNP
of  ||| S:21595 E:21609 ||| IN
activated  ||| S:21609 E:21619 ||| JJ
ERK  ||| S:21619 E:21623 ||| NNP
1 ||| S:21623 E:21624 ||| CD
/ ||| S:21624 E:21625 ||| CD
2  ||| S:21625 E:21627 ||| CD
is  ||| S:21627 E:21630 ||| VBZ
an  ||| S:21630 E:21643 ||| DT
upregulation  ||| S:21643 E:21656 ||| NN
of  ||| S:21656 E:21659 ||| IN
cell  ||| S:21659 E:21664 ||| NN
proliferation  ||| S:21664 E:21678 ||| NN
proteins  ||| S:21678 E:21687 ||| NNS
and  ||| S:21687 E:21701 ||| CC
potentially  ||| S:21701 E:21713 ||| RB
enhanced  ||| S:21713 E:21722 ||| JJ
cell  ||| S:21722 E:21727 ||| NN
division ||| S:21727 E:21735 ||| NN
,  ||| S:21735 E:21737 ||| ,
as  ||| S:21737 E:21740 ||| RB
well  ||| S:21740 E:21745 ||| RB
as  ||| S:21745 E:21748 ||| IN
a  ||| S:21748 E:21760 ||| DT
protective  ||| S:21760 E:21771 ||| JJ
effect  ||| S:21771 E:21778 ||| NN
over  ||| S:21778 E:21783 ||| IN
apoptotic  ||| S:21783 E:21793 ||| JJ
signaling  ||| S:21793 E:21803 ||| NN
via  ||| S:21803 E:21807 ||| IN
suppressed  ||| S:21807 E:21828 ||| JJ
activation  ||| S:21828 E:21839 ||| NN
of  ||| S:21839 E:21842 ||| IN
caspase  ||| S:21842 E:21850 ||| JJ
effectors ||| S:21850 E:21859 ||| NN
.  ||| S:21859 E:21861 ||| .
Downstream  ||| S:21861 E:21872 ||| NNP
of  ||| S:21872 E:21886 ||| IN
activated  ||| S:21886 E:21896 ||| JJ
Caspase  ||| S:21896 E:21904 ||| NNP
3  ||| S:21904 E:21906 ||| CD
are  ||| S:21906 E:21910 ||| VBP
the  ||| S:21910 E:21924 ||| DT
sequellae  ||| S:21924 E:21934 ||| NN
of  ||| S:21934 E:21937 ||| IN
apoptosis ||| S:21937 E:21946 ||| NN
,  ||| S:21946 E:21948 ||| ,
including  ||| S:21948 E:21958 ||| VBG
PARP  ||| S:21958 E:21963 ||| NNP
cleavage  ||| S:21963 E:21972 ||| NN
and  ||| S:21972 E:21986 ||| CC
inhibition  ||| S:21986 E:21997 ||| NN
of  ||| S:21997 E:22000 ||| IN
DNA  ||| S:22000 E:22004 ||| NNP
repair ||| S:22004 E:22010 ||| NN
,  ||| S:22010 E:22012 ||| ,
DNA  ||| S:22012 E:22016 ||| NNP
fragmentation ||| S:22016 E:22029 ||| NN
,  ||| S:22029 E:22031 ||| ,
and  ||| S:22031 E:22035 ||| CC
nuclear  ||| S:22035 E:22053 ||| JJ
membrane  ||| S:22053 E:22062 ||| JJ
fragmentation ||| S:22062 E:22075 ||| NN
.  ||| S:22075 E:22077 ||| .
The  ||| S:22077 E:22081 ||| DT
increase  ||| S:22081 E:22090 ||| NN
or  ||| S:22090 E:22093 ||| CC
decrease  ||| S:22093 E:22102 ||| NN
in  ||| S:22102 E:22115 ||| IN
expression  ||| S:22115 E:22126 ||| NN
of  ||| S:22126 E:22129 ||| IN
the  ||| S:22129 E:22133 ||| DT
components  ||| S:22133 E:22144 ||| NNS
of  ||| S:22144 E:22147 ||| IN
any  ||| S:22147 E:22151 ||| DT
signaling  ||| S:22151 E:22161 ||| JJ
pathway  ||| S:22161 E:22169 ||| NN
is  ||| S:22169 E:22182 ||| VBZ
not  ||| S:22182 E:22186 ||| RB
necessarily  ||| S:22186 E:22198 ||| RB
probative  ||| S:22198 E:22208 ||| VBN
of  ||| S:22208 E:22211 ||| IN
pathway  ||| S:22211 E:22219 ||| JJ
activity ||| S:22219 E:22227 ||| NN
.  ||| S:22227 E:22229 ||| .
Rather ||| S:22229 E:22235 ||| RB
,  ||| S:22235 E:22237 ||| ,
it  ||| S:22237 E:22250 ||| PRP
is  ||| S:22250 E:22253 ||| VBZ
the  ||| S:22253 E:22257 ||| DT
change  ||| S:22257 E:22264 ||| NN
in  ||| S:22264 E:22267 ||| IN
the  ||| S:22267 E:22271 ||| DT
level  ||| S:22271 E:22277 ||| NN
of  ||| S:22277 E:22280 ||| IN
activated  ||| S:22280 E:22290 ||| JJ
protein  ||| S:22290 E:22298 ||| NN
that  ||| S:22298 E:22303 ||| WDT
is  ||| S:22303 E:22317 ||| VBZ
physiologically  ||| S:22317 E:22333 ||| JJ
important ||| S:22333 E:22342 ||| JJ
.  ||| S:22342 E:22344 ||| .
Thus ||| S:22344 E:22348 ||| RB
,  ||| S:22348 E:22350 ||| ,
we  ||| S:22350 E:22363 ||| PRP
determined  ||| S:22363 E:22374 ||| VBD
if  ||| S:22374 E:22377 ||| IN
SN50  ||| S:22377 E:22382 ||| CD
treatment  ||| S:22382 E:22392 ||| NN
was  ||| S:22392 E:22396 ||| VBD
associated  ||| S:22396 E:22407 ||| VBN
with  ||| S:22407 E:22422 ||| IN
activation  ||| S:22422 E:22433 ||| NN
of  ||| S:22433 E:22436 ||| IN
the  ||| S:22436 E:22440 ||| DT
ERK1 ||| S:22440 E:22444 ||| CD
/ ||| S:22444 E:22445 ||| CD
2  ||| S:22445 E:22447 ||| CD
and  ||| S:22447 E:22451 ||| CC
Caspase  ||| S:22451 E:22459 ||| NNP
3  ||| S:22459 E:22461 ||| CD
pathways ||| S:22461 E:22469 ||| NN
,  ||| S:22469 E:22471 ||| ,
using  ||| S:22471 E:22487 ||| VBG
E15  ||| S:22487 E:22491 ||| CD
+  ||| S:22491 E:22493 ||| CD
2  ||| S:22493 E:22495 ||| CD
control  ||| S:22495 E:22503 ||| NN
and  ||| S:22503 E:22507 ||| CC
SN50-treated  ||| S:22507 E:22520 ||| CD
explants ||| S:22520 E:22528 ||| NN
,  ||| S:22528 E:22530 ||| ,
1-D  ||| S:22530 E:22534 ||| NNP
Western  ||| S:22534 E:22552 ||| NNP
blot  ||| S:22552 E:22557 ||| JJ
analysis ||| S:22557 E:22565 ||| NN
,  ||| S:22565 E:22567 ||| ,
and  ||| S:22567 E:22571 ||| CC
antibodies  ||| S:22571 E:22582 ||| JJ
specific  ||| S:22582 E:22591 ||| JJ
to  ||| S:22591 E:22605 ||| TO
activated  ||| S:22605 E:22615 ||| VB
( ||| S:22615 E:22616 ||| -LRB-
phosphorylated ||| S:22616 E:22630 ||| FW
/ ||| S:22630 E:22631 ||| FW
cleaved ||| S:22631 E:22638 ||| FW
)  ||| S:22638 E:22650 ||| -RRB-
proteins ||| S:22650 E:22658 ||| NNS
.  ||| S:22658 E:22660 ||| .
Specifically ||| S:22660 E:22672 ||| RB
,  ||| S:22672 E:22674 ||| ,
we  ||| S:22674 E:22677 ||| PRP
evaluated  ||| S:22677 E:22687 ||| VBD
the  ||| S:22687 E:22691 ||| DT
levels  ||| S:22691 E:22698 ||| NNS
of  ||| S:22698 E:22711 ||| IN
activated  ||| S:22711 E:22721 ||| JJ
c-Raf ||| S:22721 E:22726 ||| NN
,  ||| S:22726 E:22728 ||| ,
ERK1 ||| S:22728 E:22732 ||| CD
/ ||| S:22732 E:22733 ||| CD
2 ||| S:22733 E:22734 ||| CD
,  ||| S:22734 E:22736 ||| ,
Caspase  ||| S:22736 E:22744 ||| NNP
3 ||| S:22744 E:22745 ||| CD
,  ||| S:22745 E:22747 ||| ,
and  ||| S:22747 E:22751 ||| CC
PARP  ||| S:22751 E:22756 ||| NNP
using  ||| S:22756 E:22772 ||| VBG
antibodies  ||| S:22772 E:22783 ||| NNS
which  ||| S:22783 E:22789 ||| WDT
identify  ||| S:22789 E:22798 ||| VBP
only  ||| S:22798 E:22803 ||| RB
the  ||| S:22803 E:22807 ||| DT
phosphorylated  ||| S:22807 E:22822 ||| NN
or  ||| S:22822 E:22835 ||| CC
cleaved  ||| S:22835 E:22843 ||| JJ
proteins  ||| S:22843 E:22852 ||| NNS
and  ||| S:22852 E:22856 ||| CC
do  ||| S:22856 E:22859 ||| VBP
not  ||| S:22859 E:22863 ||| RB
cross  ||| S:22863 E:22869 ||| VB
react  ||| S:22869 E:22875 ||| VBN
with  ||| S:22875 E:22880 ||| IN
the  ||| S:22880 E:22884 ||| DT
inactive  ||| S:22884 E:22903 ||| JJ
protein ||| S:22903 E:22910 ||| NN
.  ||| S:22910 E:22912 ||| .
We  ||| S:22912 E:22915 ||| PRP
found  ||| S:22915 E:22921 ||| VBD
a  ||| S:22921 E:22923 ||| DT
significant  ||| S:22923 E:22935 ||| JJ
increase  ||| S:22935 E:22944 ||| NN
( ||| S:22944 E:22945 ||| -LRB-
p  ||| S:22945 E:22947 ||| CD
< ||| S:22947 E:22949 ||| SYM
0.05 ||| S:22949 E:22953 ||| CD
)  ||| S:22953 E:22955 ||| -RRB-
in  ||| S:22955 E:22979 ||| IN
activated  ||| S:22979 E:22989 ||| CD
ERK1 ||| S:22989 E:22993 ||| CD
/ ||| S:22993 E:22994 ||| CD
2 ||| S:22994 E:22995 ||| CD
,  ||| S:22995 E:22997 ||| ,
Caspase  ||| S:22997 E:23005 ||| NNP
3 ||| S:23005 E:23006 ||| CD
,  ||| S:23006 E:23008 ||| ,
and  ||| S:23008 E:23022 ||| CC
PARP  ||| S:23022 E:23027 ||| NNP
in  ||| S:23027 E:23030 ||| IN
SN50-treated  ||| S:23030 E:23043 ||| CD
explants  ||| S:23043 E:23052 ||| NNS
( ||| S:23052 E:23053 ||| -LRB-
Fig.  ||| S:23053 E:23058 ||| CD
14 ||| S:23058 E:23060 ||| CD
) ||| S:23060 E:23061 ||| -RRB-
;  ||| S:23061 E:23063 ||| :
no  ||| S:23063 E:23066 ||| DT
change  ||| S:23066 E:23073 ||| NN
was  ||| S:23073 E:23087 ||| VBD
seen  ||| S:23087 E:23092 ||| VBN
in  ||| S:23092 E:23106 ||| IN
activated  ||| S:23106 E:23116 ||| JJ
c-Raf  ||| S:23116 E:23122 ||| JJ
levels  ||| S:23122 E:23129 ||| NNS
between  ||| S:23129 E:23147 ||| IN
control  ||| S:23147 E:23155 ||| NN
and  ||| S:23155 E:23159 ||| CC
SN50-treated  ||| S:23159 E:23172 ||| CD
explants ||| S:23172 E:23180 ||| NNS
.  ||| S:23180 E:23182 ||| .
The  ||| S:23182 E:23186 ||| DT
greater  ||| S:23186 E:23194 ||| JJR
than  ||| S:23194 E:23209 ||| IN
2-fold  ||| S:23209 E:23216 ||| CD
increase  ||| S:23216 E:23225 ||| NN
in  ||| S:23225 E:23228 ||| IN
Caspase  ||| S:23228 E:23236 ||| NNP
3  ||| S:23236 E:23238 ||| CD
activation  ||| S:23238 E:23249 ||| NN
is  ||| S:23249 E:23252 ||| VBZ
associated  ||| S:23252 E:23273 ||| VBN
with  ||| S:23273 E:23278 ||| IN
a  ||| S:23278 E:23280 ||| DT
1.8-fold  ||| S:23280 E:23289 ||| JJ
increase  ||| S:23289 E:23298 ||| NN
in  ||| S:23298 E:23301 ||| IN
PARP  ||| S:23301 E:23306 ||| NNP
cleavage  ||| S:23306 E:23315 ||| NNS
( ||| S:23315 E:23316 ||| -LRB-
Fig.  ||| S:23316 E:23321 ||| CD
14 ||| S:23321 E:23323 ||| CD
)  ||| S:23323 E:23325 ||| -RRB-
and  ||| S:23325 E:23329 ||| CC
a  ||| S:23329 E:23341 ||| DT
10-fold  ||| S:23341 E:23349 ||| JJ
increase  ||| S:23349 E:23358 ||| NN
in  ||| S:23358 E:23361 ||| IN
apoptosis  ||| S:23361 E:23371 ||| NNS
( ||| S:23371 E:23372 ||| -LRB-
Fig.  ||| S:23372 E:23377 ||| NNP
4B ||| S:23377 E:23379 ||| NNP
) ||| S:23379 E:23380 ||| -RRB-
.  ||| S:23380 E:23382 ||| .
Since  ||| S:23382 E:23388 ||| IN
Caspase  ||| S:23388 E:23396 ||| NNP
3  ||| S:23396 E:23408 ||| CD
is  ||| S:23408 E:23411 ||| VBZ
nodal  ||| S:23411 E:23417 ||| VBN
to  ||| S:23417 E:23420 ||| TO
E2F1  ||| S:23420 E:23425 ||| CD
( ||| S:23425 E:23426 ||| -LRB-
via  ||| S:23426 E:23430 ||| IN
p53 ||| S:23430 E:23433 ||| NN
) ||| S:23433 E:23434 ||| -RRB-
,  ||| S:23434 E:23436 ||| ,
FAF  ||| S:23436 E:23440 ||| NNP
( ||| S:23440 E:23441 ||| -LRB-
via  ||| S:23441 E:23445 ||| IN
Fas ||| S:23445 E:23448 ||| NNP
/ ||| S:23448 E:23449 ||| NNP
Caspase  ||| S:23449 E:23457 ||| NNP
8 ||| S:23457 E:23458 ||| CD
) ||| S:23458 E:23459 ||| -RRB-
,  ||| S:23459 E:23461 ||| ,
and  ||| S:23461 E:23475 ||| CC
Caspase  ||| S:23475 E:23483 ||| NNP
6  ||| S:23483 E:23485 ||| CD
[  ||| S:23485 E:23487 ||| -LRB-
33  ||| S:23487 E:23490 ||| CD
36  ||| S:23490 E:23493 ||| CD
37  ||| S:23493 E:23496 ||| CD
39  ||| S:23496 E:23499 ||| CD
]  ||| S:23499 E:23501 ||| -RRB-
,  ||| S:23501 E:23503 ||| ,
our  ||| S:23503 E:23507 ||| PRP$
observation  ||| S:23507 E:23519 ||| NN
of  ||| S:23519 E:23522 ||| IN
increased  ||| S:23522 E:23543 ||| VBN
activated  ||| S:23543 E:23553 ||| VBN
Caspase  ||| S:23553 E:23561 ||| NNP
3  ||| S:23561 E:23563 ||| CD
is  ||| S:23563 E:23566 ||| VBZ
consistent  ||| S:23566 E:23587 ||| JJ
with  ||| S:23587 E:23592 ||| IN
the  ||| S:23592 E:23596 ||| DT
increased  ||| S:23596 E:23606 ||| JJ
levels  ||| S:23606 E:23613 ||| NNS
of  ||| S:23613 E:23616 ||| IN
E2F1 ||| S:23616 E:23620 ||| NNP
,  ||| S:23620 E:23622 ||| ,
FAF ||| S:23622 E:23625 ||| NNP
,  ||| S:23625 E:23627 ||| ,
and  ||| S:23627 E:23631 ||| CC
Caspase  ||| S:23631 E:23639 ||| NNP
6  ||| S:23639 E:23651 ||| CD
proteins  ||| S:23651 E:23660 ||| NNS
( ||| S:23660 E:23661 ||| -LRB-
Table  ||| S:23661 E:23667 ||| NNP
2 ||| S:23667 E:23668 ||| CD
) ||| S:23668 E:23669 ||| -RRB-
.  ||| S:23669 E:23671 ||| .
Regarding  ||| S:23671 E:23681 ||| VBG
the  ||| S:23681 E:23685 ||| DT
ERK1 ||| S:23685 E:23689 ||| CD
/ ||| S:23689 E:23690 ||| CD
2  ||| S:23690 E:23692 ||| CD
pathway ||| S:23692 E:23699 ||| NN
,  ||| S:23699 E:23701 ||| ,
we  ||| S:23701 E:23714 ||| PRP
found  ||| S:23714 E:23720 ||| VBD
a  ||| S:23720 E:23722 ||| DT
greater  ||| S:23722 E:23730 ||| JJR
than  ||| S:23730 E:23735 ||| IN
2-fold  ||| S:23735 E:23742 ||| CD
increase  ||| S:23742 E:23751 ||| NN
of  ||| S:23751 E:23754 ||| IN
activated  ||| S:23754 E:23764 ||| FW
ERK2  ||| S:23764 E:23769 ||| FW
in  ||| S:23769 E:23782 ||| FW
SN50-treated  ||| S:23782 E:23795 ||| FW
glands  ||| S:23795 E:23802 ||| FW
( ||| S:23802 E:23803 ||| -LRB-
Fig.  ||| S:23803 E:23808 ||| CD
13 ||| S:23808 E:23810 ||| CD
)  ||| S:23810 E:23812 ||| -RRB-
associated  ||| S:23812 E:23823 ||| VBN
with  ||| S:23823 E:23828 ||| IN
a  ||| S:23828 E:23830 ||| DT
1.5-fold  ||| S:23830 E:23849 ||| JJ
increase  ||| S:23849 E:23858 ||| NN
in  ||| S:23858 E:23861 ||| IN
total  ||| S:23861 E:23867 ||| JJ
ERK2  ||| S:23867 E:23872 ||| CD
protein  ||| S:23872 E:23880 ||| NN
( ||| S:23880 E:23881 ||| -LRB-
Table  ||| S:23881 E:23887 ||| NNP
2 ||| S:23887 E:23888 ||| CD
) ||| S:23888 E:23889 ||| -RRB-
.  ||| S:23889 E:23891 ||| .
This  ||| S:23891 E:23896 ||| DT
increased  ||| S:23896 E:23916 ||| JJ
activity  ||| S:23916 E:23925 ||| NN
of  ||| S:23925 E:23928 ||| IN
proapoptotic  ||| S:23928 E:23941 ||| NNS
( ||| S:23941 E:23942 ||| -LRB-
caspase3 ||| S:23942 E:23950 ||| NNP
/ ||| S:23950 E:23951 ||| NNP
PARP ||| S:23951 E:23955 ||| NNP
)  ||| S:23955 E:23957 ||| -RRB-
and  ||| S:23957 E:23961 ||| CC
compensatory  ||| S:23961 E:23984 ||| JJ
antiapoptotic  ||| S:23984 E:23998 ||| NNS
( ||| S:23998 E:23999 ||| -LRB-
ERK1 ||| S:23999 E:24003 ||| CD
/ ||| S:24003 E:24004 ||| CD
2 ||| S:24004 E:24005 ||| CD
)  ||| S:24005 E:24007 ||| -RRB-
pathways  ||| S:24007 E:24016 ||| NN
is  ||| S:24016 E:24019 ||| VBZ
consistent  ||| S:24019 E:24030 ||| JJ
with  ||| S:24030 E:24035 ||| IN
the  ||| S:24035 E:24049 ||| DT
dramatic  ||| S:24049 E:24058 ||| JJ
cell  ||| S:24058 E:24063 ||| NN
death  ||| S:24063 E:24069 ||| NN
seen  ||| S:24069 E:24074 ||| VBN
in  ||| S:24074 E:24077 ||| IN
SN50-treated  ||| S:24077 E:24090 ||| NNP
SMGs ||| S:24090 E:24094 ||| NNP
.  ||| S:24094 E:24106 ||| .
Paradoxically ||| S:24106 E:24119 ||| NNP
,  ||| S:24119 E:24121 ||| ,
increased  ||| S:24121 E:24131 ||| VBD
ERK1  ||| S:24131 E:24136 ||| CD
activation  ||| S:24136 E:24147 ||| NN
is  ||| S:24147 E:24150 ||| VBZ
seen  ||| S:24150 E:24155 ||| VBN
despite  ||| S:24155 E:24173 ||| IN
a  ||| S:24173 E:24175 ||| DT
1.6-fold  ||| S:24175 E:24184 ||| JJ
decrease  ||| S:24184 E:24193 ||| NN
in  ||| S:24193 E:24196 ||| IN
total  ||| S:24196 E:24202 ||| JJ
ERK1  ||| S:24202 E:24207 ||| CD
protein  ||| S:24207 E:24215 ||| NN
( ||| S:24215 E:24216 ||| -LRB-
Table  ||| S:24216 E:24222 ||| NNP
2 ||| S:24222 E:24223 ||| CD
)  ||| S:24223 E:24225 ||| -RRB-
and  ||| S:24225 E:24239 ||| CC
increased  ||| S:24239 E:24249 ||| VBD
ERK  ||| S:24249 E:24253 ||| NNP
1 ||| S:24253 E:24254 ||| CD
/ ||| S:24254 E:24255 ||| CD
2  ||| S:24255 E:24257 ||| CD
activation  ||| S:24257 E:24268 ||| NN
is  ||| S:24268 E:24271 ||| VBZ
associated  ||| S:24271 E:24282 ||| VBN
with  ||| S:24282 E:24287 ||| IN
virtually  ||| S:24287 E:24307 ||| RB
no  ||| S:24307 E:24310 ||| DT
change  ||| S:24310 E:24317 ||| NN
in  ||| S:24317 E:24320 ||| IN
the  ||| S:24320 E:24324 ||| DT
antecedent  ||| S:24324 E:24335 ||| JJ
activation  ||| S:24335 E:24346 ||| NN
of  ||| S:24346 E:24349 ||| IN
c-Raf ||| S:24349 E:24354 ||| JJ
.  ||| S:24354 E:24356 ||| .
The  ||| S:24356 E:24370 ||| DT
latter  ||| S:24370 E:24377 ||| NN
is  ||| S:24377 E:24380 ||| VBZ
consistent  ||| S:24380 E:24391 ||| JJ
with  ||| S:24391 E:24396 ||| IN
the  ||| S:24396 E:24400 ||| DT
demonstration  ||| S:24400 E:24414 ||| NN
that  ||| S:24414 E:24419 ||| IN
c-Raf  ||| S:24419 E:24435 ||| JJ
function  ||| S:24435 E:24444 ||| NN
is  ||| S:24444 E:24447 ||| VBZ
not  ||| S:24447 E:24451 ||| RB
mediated  ||| S:24451 E:24460 ||| VBN
by  ||| S:24460 E:24463 ||| IN
the  ||| S:24463 E:24467 ||| DT
MAPK ||| S:24467 E:24471 ||| NNP
/ ||| S:24471 E:24472 ||| NNP
ERK  ||| S:24472 E:24476 ||| NNP
cascade  ||| S:24476 E:24484 ||| NN
[  ||| S:24484 E:24486 ||| -LRB-
59  ||| S:24486 E:24489 ||| CD
]  ||| S:24489 E:24491 ||| -RRB-
.  ||| S:24491 E:24503 ||| .
Moreover ||| S:24503 E:24511 ||| RB
,  ||| S:24511 E:24513 ||| ,
although  ||| S:24513 E:24522 ||| IN
we  ||| S:24522 E:24525 ||| PRP
find  ||| S:24525 E:24530 ||| VBP
an  ||| S:24530 E:24533 ||| DT
increase  ||| S:24533 E:24542 ||| NN
in  ||| S:24542 E:24545 ||| IN
total  ||| S:24545 E:24551 ||| JJ
Raf  ||| S:24551 E:24565 ||| JJ
protein  ||| S:24565 E:24573 ||| NN
( ||| S:24573 E:24574 ||| -LRB-
Table  ||| S:24574 E:24580 ||| NNP
2 ||| S:24580 E:24581 ||| CD
) ||| S:24581 E:24582 ||| -RRB-
,  ||| S:24582 E:24584 ||| ,
no  ||| S:24584 E:24587 ||| DT
increase  ||| S:24587 E:24596 ||| NN
in  ||| S:24596 E:24599 ||| IN
activated  ||| S:24599 E:24609 ||| JJ
c-Raf  ||| S:24609 E:24615 ||| NN
is  ||| S:24615 E:24628 ||| VBZ
found ||| S:24628 E:24633 ||| VBN
;  ||| S:24633 E:24635 ||| :
we  ||| S:24635 E:24638 ||| PRP
also  ||| S:24638 E:24643 ||| RB
see  ||| S:24643 E:24647 ||| VB
a  ||| S:24647 E:24649 ||| DT
2-fold  ||| S:24649 E:24656 ||| JJ
increase  ||| S:24656 E:24665 ||| NN
in  ||| S:24665 E:24668 ||| IN
activated  ||| S:24668 E:24678 ||| JJ
Caspase  ||| S:24678 E:24696 ||| NNP
3  ||| S:24696 E:24698 ||| CD
but  ||| S:24698 E:24702 ||| CC
no  ||| S:24702 E:24705 ||| DT
change  ||| S:24705 E:24712 ||| NN
in  ||| S:24712 E:24715 ||| IN
total  ||| S:24715 E:24721 ||| JJ
Caspase  ||| S:24721 E:24729 ||| NNP
3  ||| S:24729 E:24731 ||| CD
protein ||| S:24731 E:24738 ||| NN
.  ||| S:24738 E:24740 ||| .
These  ||| S:24740 E:24746 ||| DT
results  ||| S:24746 E:24764 ||| NNS
clearly  ||| S:24764 E:24772 ||| RB
illustrate  ||| S:24772 E:24783 ||| VB
that  ||| S:24783 E:24788 ||| IN
changes  ||| S:24788 E:24796 ||| NNS
in  ||| S:24796 E:24810 ||| IN
total  ||| S:24810 E:24816 ||| JJ
protein  ||| S:24816 E:24824 ||| NN
level  ||| S:24824 E:24830 ||| NN
are  ||| S:24830 E:24834 ||| VBP
not  ||| S:24834 E:24838 ||| RB
always  ||| S:24838 E:24855 ||| RB
indicative  ||| S:24855 E:24866 ||| JJ
of  ||| S:24866 E:24869 ||| IN
altered  ||| S:24869 E:24877 ||| JJ
protein  ||| S:24877 E:24896 ||| NN
activity ||| S:24896 E:24904 ||| NN
.  ||| S:24904 E:24917 ||| .
Finally ||| S:24917 E:24924 ||| RB
,  ||| S:24924 E:24926 ||| ,
it  ||| S:24926 E:24929 ||| PRP
should  ||| S:24929 E:24936 ||| MD
be  ||| S:24936 E:24939 ||| VB
noted  ||| S:24939 E:24945 ||| VBN
that  ||| S:24945 E:24950 ||| IN
a  ||| S:24950 E:24952 ||| DT
recent  ||| S:24952 E:24959 ||| JJ
study  ||| S:24959 E:24965 ||| NN
using  ||| S:24965 E:24981 ||| VBG
cell  ||| S:24981 E:24986 ||| NN
lines  ||| S:24986 E:24992 ||| NNS
raised  ||| S:24992 E:24999 ||| VBD
the  ||| S:24999 E:25003 ||| DT
possibility  ||| S:25003 E:25015 ||| NN
that  ||| S:25015 E:25020 ||| IN
SN50 ||| S:25020 E:25024 ||| NNP
's  ||| S:25024 E:25027 ||| POS
action  ||| S:25027 E:25034 ||| NN
is  ||| S:25034 E:25047 ||| VBZ
not  ||| S:25047 E:25051 ||| RB
specific  ||| S:25051 E:25060 ||| JJ
to  ||| S:25060 E:25063 ||| TO
NF-κB  ||| S:25063 E:25069 ||| NNP
[  ||| S:25069 E:25071 ||| -LRB-
61  ||| S:25071 E:25074 ||| CD
62  ||| S:25074 E:25077 ||| CD
]  ||| S:25077 E:25079 ||| -RRB-
.  ||| S:25079 E:25081 ||| .
SN50  ||| S:25081 E:25086 ||| NNP
is  ||| S:25086 E:25089 ||| VBZ
composed  ||| S:25089 E:25098 ||| VBN
of  ||| S:25098 E:25101 ||| IN
the  ||| S:25101 E:25115 ||| DT
NLS  ||| S:25115 E:25119 ||| NNP
for  ||| S:25119 E:25123 ||| IN
NF-κB  ||| S:25123 E:25129 ||| NNP
p50  ||| S:25129 E:25133 ||| NNP
and  ||| S:25133 E:25137 ||| CC
was  ||| S:25137 E:25141 ||| VBD
believed  ||| S:25141 E:25150 ||| VBN
to  ||| S:25150 E:25153 ||| TO
specifically  ||| S:25153 E:25166 ||| RB
block  ||| S:25166 E:25182 ||| VB
NF-κB  ||| S:25182 E:25188 ||| JJ
p50 ||| S:25188 E:25191 ||| CD
/ ||| S:25191 E:25192 ||| CD
p65  ||| S:25192 E:25196 ||| CD
nuclear  ||| S:25196 E:25204 ||| JJ
translocation  ||| S:25204 E:25218 ||| NN
by  ||| S:25218 E:25221 ||| IN
binding  ||| S:25221 E:25229 ||| VBG
the  ||| S:25229 E:25233 ||| DT
NLS  ||| S:25233 E:25247 ||| NNP
receptor  ||| S:25247 E:25256 ||| NN
complex  ||| S:25256 E:25264 ||| NN
and  ||| S:25264 E:25268 ||| CC
preventing  ||| S:25268 E:25279 ||| VBG
transport  ||| S:25279 E:25289 ||| NN
through  ||| S:25289 E:25297 ||| IN
the  ||| S:25297 E:25311 ||| DT
nuclear  ||| S:25311 E:25319 ||| JJ
pore  ||| S:25319 E:25324 ||| NNS
[  ||| S:25324 E:25326 ||| -LRB-
33  ||| S:25326 E:25329 ||| CD
34  ||| S:25329 E:25332 ||| CD
35  ||| S:25332 E:25335 ||| CD
]  ||| S:25335 E:25337 ||| -RRB-
.  ||| S:25337 E:25339 ||| .
However ||| S:25339 E:25346 ||| RB
,  ||| S:25346 E:25348 ||| ,
Torgerson  ||| S:25348 E:25358 ||| NNP
and  ||| S:25358 E:25372 ||| CC
coworkers  ||| S:25372 E:25382 ||| NNS
[  ||| S:25382 E:25384 ||| -LRB-
61  ||| S:25384 E:25387 ||| CD
]  ||| S:25387 E:25389 ||| -RRB-
have  ||| S:25389 E:25394 ||| VBP
shown  ||| S:25394 E:25400 ||| VBN
that  ||| S:25400 E:25405 ||| IN
SN50  ||| S:25405 E:25410 ||| CD
treatment  ||| S:25410 E:25420 ||| NN
inhibited  ||| S:25420 E:25440 ||| VBD
nuclear  ||| S:25440 E:25448 ||| JJ
transport  ||| S:25448 E:25458 ||| NN
of  ||| S:25458 E:25461 ||| IN
transcription  ||| S:25461 E:25475 ||| JJ
factors  ||| S:25475 E:25483 ||| NNS
NFAT ||| S:25483 E:25487 ||| NNP
,  ||| S:25487 E:25489 ||| ,
AP-1 ||| S:25489 E:25493 ||| NNP
,  ||| S:25493 E:25505 ||| ,
STAT1 ||| S:25505 E:25510 ||| NNP
,  ||| S:25510 E:25512 ||| ,
and  ||| S:25512 E:25516 ||| CC
NF-κB  ||| S:25516 E:25522 ||| JJ
at  ||| S:25522 E:25525 ||| IN
a  ||| S:25525 E:25527 ||| DT
high  ||| S:25527 E:25532 ||| JJ
dose  ||| S:25532 E:25537 ||| NN
of  ||| S:25537 E:25540 ||| IN
210  ||| S:25540 E:25544 ||| CD
μg ||| S:25544 E:25546 ||| CD
/ ||| S:25546 E:25547 ||| CD
ml  ||| S:25547 E:25550 ||| NN
in  ||| S:25550 E:25553 ||| IN
Junkrat  ||| S:25553 E:25571 ||| NNP
cells ||| S:25571 E:25576 ||| NNS
.  ||| S:25576 E:25578 ||| .
However ||| S:25578 E:25585 ||| RB
,  ||| S:25585 E:25587 ||| ,
others  ||| S:25587 E:25594 ||| NNS
have  ||| S:25594 E:25599 ||| VBP
shown  ||| S:25599 E:25605 ||| VBN
that  ||| S:25605 E:25610 ||| IN
lower  ||| S:25610 E:25616 ||| JJR
doses  ||| S:25616 E:25622 ||| JJ
≤  ||| S:25622 E:25624 ||| CD
100  ||| S:25624 E:25638 ||| CD
μg ||| S:25638 E:25640 ||| CD
/ ||| S:25640 E:25641 ||| CD
ml  ||| S:25641 E:25644 ||| NN
of  ||| S:25644 E:25647 ||| IN
SN50  ||| S:25647 E:25652 ||| NNP
specifically  ||| S:25652 E:25665 ||| RB
inhibited  ||| S:25665 E:25675 ||| VBD
NF-κB  ||| S:25675 E:25681 ||| JJ
nuclear  ||| S:25681 E:25699 ||| JJ
translocation  ||| S:25699 E:25713 ||| NN
in  ||| S:25713 E:25716 ||| IN
human  ||| S:25716 E:25722 ||| JJ
peripheral  ||| S:25722 E:25733 ||| JJ
blood  ||| S:25733 E:25739 ||| NN
lymphocytes  ||| S:25739 E:25751 ||| NNS
and  ||| S:25751 E:25765 ||| CC
murine  ||| S:25765 E:25772 ||| JJ
T  ||| S:25772 E:25774 ||| NN
cells  ||| S:25774 E:25780 ||| NNS
[  ||| S:25780 E:25782 ||| -LRB-
33  ||| S:25782 E:25785 ||| CD
63  ||| S:25785 E:25788 ||| CD
]  ||| S:25788 E:25790 ||| -RRB-
.  ||| S:25790 E:25792 ||| .
These  ||| S:25792 E:25798 ||| DT
reported  ||| S:25798 E:25807 ||| JJ
differences  ||| S:25807 E:25819 ||| NNS
are  ||| S:25819 E:25833 ||| VBP
likely  ||| S:25833 E:25840 ||| RB
due  ||| S:25840 E:25844 ||| JJ
to  ||| S:25844 E:25847 ||| TO
dose-dependent  ||| S:25847 E:25862 ||| JJ
or  ||| S:25862 E:25865 ||| CC
cell-specific  ||| S:25865 E:25879 ||| JJ
differences  ||| S:25879 E:25901 ||| NNS
in  ||| S:25901 E:25904 ||| IN
the  ||| S:25904 E:25908 ||| DT
effect  ||| S:25908 E:25915 ||| NN
of  ||| S:25915 E:25918 ||| IN
SN50  ||| S:25918 E:25923 ||| NNP
[  ||| S:25923 E:25925 ||| -LRB-
64  ||| S:25925 E:25928 ||| CD
]  ||| S:25928 E:25930 ||| -RRB-
.  ||| S:25930 E:25932 ||| .
Given  ||| S:25932 E:25938 ||| VBN
that ||| S:25938 E:25942 ||| IN
:  ||| S:25942 E:25944 ||| :
( ||| S:25944 E:25945 ||| -LRB-
1 ||| S:25945 E:25946 ||| LS
)  ||| S:25946 E:25948 ||| -RRB-
embryonic  ||| S:25948 E:25968 ||| JJ
SMGs  ||| S:25968 E:25973 ||| NN
were  ||| S:25973 E:25978 ||| VBD
cultured  ||| S:25978 E:25987 ||| VBN
in  ||| S:25987 E:25990 ||| IN
the  ||| S:25990 E:25994 ||| DT
presence  ||| S:25994 E:26003 ||| NN
of  ||| S:26003 E:26006 ||| IN
100  ||| S:26006 E:26010 ||| CD
μg ||| S:26010 E:26012 ||| CD
/ ||| S:26012 E:26013 ||| CD
ml  ||| S:26013 E:26016 ||| CD
SN50 ||| S:26016 E:26020 ||| CD
,  ||| S:26020 E:26022 ||| ,
( ||| S:26022 E:26023 ||| -LRB-
2 ||| S:26023 E:26024 ||| LS
)  ||| S:26024 E:26036 ||| -RRB-
immunodetectable  ||| S:26036 E:26053 ||| JJ
NF-κB  ||| S:26053 E:26059 ||| NN
was  ||| S:26059 E:26063 ||| VBD
absent  ||| S:26063 E:26070 ||| VBN
from  ||| S:26070 E:26075 ||| IN
SMG  ||| S:26075 E:26079 ||| NNP
epithelia  ||| S:26079 E:26099 ||| FW
nuclei  ||| S:26099 E:26106 ||| FW
in  ||| S:26106 E:26109 ||| FW
TNF  ||| S:26109 E:26113 ||| FW
+  ||| S:26113 E:26115 ||| FW
SN50-treated  ||| S:26115 E:26128 ||| FW
explants ||| S:26128 E:26136 ||| FW
,  ||| S:26136 E:26138 ||| ,
and  ||| S:26138 E:26142 ||| CC
( ||| S:26142 E:26143 ||| -LRB-
3 ||| S:26143 E:26144 ||| LS
)  ||| S:26144 E:26146 ||| -RRB-
one  ||| S:26146 E:26150 ||| CD
cannot  ||| S:26150 E:26167 ||| CD
extrapolate  ||| S:26167 E:26179 ||| CD
observations  ||| S:26179 E:26192 ||| NNS
in  ||| S:26192 E:26195 ||| IN
Jurkat  ||| S:26195 E:26202 ||| NNP
cells  ||| S:26202 E:26208 ||| NNS
to  ||| S:26208 E:26211 ||| TO
those  ||| S:26211 E:26217 ||| DT
in  ||| S:26217 E:26230 ||| IN
primary  ||| S:26230 E:26238 ||| JJ
cells  ||| S:26238 E:26244 ||| NNS
[  ||| S:26244 E:26246 ||| -LRB-
64  ||| S:26246 E:26249 ||| CD
]  ||| S:26249 E:26251 ||| -RRB-
or  ||| S:26251 E:26254 ||| CC
organ  ||| S:26254 E:26260 ||| JJ
cultures ||| S:26260 E:26268 ||| NNS
,  ||| S:26268 E:26270 ||| ,
it  ||| S:26270 E:26273 ||| PRP
is  ||| S:26273 E:26276 ||| VBZ
most  ||| S:26276 E:26291 ||| RBS
probable  ||| S:26291 E:26300 ||| JJ
that  ||| S:26300 E:26305 ||| IN
our  ||| S:26305 E:26309 ||| PRP$
observed  ||| S:26309 E:26318 ||| JJ
interruption  ||| S:26318 E:26331 ||| NN
of  ||| S:26331 E:26334 ||| IN
SMG  ||| S:26334 E:26348 ||| NNP
development  ||| S:26348 E:26360 ||| NN
is  ||| S:26360 E:26363 ||| VBZ
proximately  ||| S:26363 E:26375 ||| JJ
due  ||| S:26375 E:26379 ||| JJ
exclusively  ||| S:26379 E:26391 ||| NN
to  ||| S:26391 E:26394 ||| TO
the  ||| S:26394 E:26408 ||| DT
inhibition  ||| S:26408 E:26419 ||| NN
of  ||| S:26419 E:26422 ||| IN
NF-κB  ||| S:26422 E:26428 ||| JJ
nuclear  ||| S:26428 E:26436 ||| JJ
translocation ||| S:26436 E:26449 ||| NN
.  ||| S:26449 E:26451 ||| .
Indeed ||| S:26451 E:26457 ||| RB
,  ||| S:26457 E:26459 ||| ,
for  ||| S:26459 E:26473 ||| IN
low  ||| S:26473 E:26477 ||| JJ
doses  ||| S:26477 E:26483 ||| NNS
of  ||| S:26483 E:26486 ||| IN
SN50 ||| S:26486 E:26490 ||| NNP
,  ||| S:26490 E:26492 ||| ,
there  ||| S:26492 E:26498 ||| EX
is  ||| S:26498 E:26501 ||| VBZ
no  ||| S:26501 E:26504 ||| DT
evidence  ||| S:26504 E:26513 ||| NN
in  ||| S:26513 E:26516 ||| IN
the  ||| S:26516 E:26520 ||| DT
literature  ||| S:26520 E:26541 ||| NN
to  ||| S:26541 E:26544 ||| TO
the  ||| S:26544 E:26548 ||| DT
contrary ||| S:26548 E:26556 ||| NN
.  ||| S:26556 E:26558 ||| .
Nonetheless ||| S:26558 E:26569 ||| RB
,  ||| S:26569 E:26571 ||| ,
we  ||| S:26571 E:26574 ||| PRP
do  ||| S:26574 E:26577 ||| VBP
recognize  ||| S:26577 E:26587 ||| VBN
that  ||| S:26587 E:26602 ||| IN
absence  ||| S:26602 E:26610 ||| NN
of  ||| S:26610 E:26613 ||| IN
evidence  ||| S:26613 E:26622 ||| NN
is  ||| S:26622 E:26625 ||| VBZ
not  ||| S:26625 E:26629 ||| RB
necessarily  ||| S:26629 E:26641 ||| RB
evidence  ||| S:26641 E:26650 ||| NN
of  ||| S:26650 E:26663 ||| IN
absence ||| S:26663 E:26670 ||| NN
.  ||| S:26670 E:26703 ||| .
Conclusions  ||| S:26703 E:26723 ||| VBG
Our  ||| S:26723 E:26727 ||| PRP$
results  ||| S:26727 E:26735 ||| NNS
indicate  ||| S:26735 E:26744 ||| VBP
that  ||| S:26744 E:26749 ||| IN
NF-κB-mediated  ||| S:26749 E:26764 ||| JJ
transcription  ||| S:26764 E:26786 ||| NN
is  ||| S:26786 E:26789 ||| VBZ
directly  ||| S:26789 E:26798 ||| RB
or  ||| S:26798 E:26801 ||| CC
indirectly  ||| S:26801 E:26812 ||| RB
critical  ||| S:26812 E:26821 ||| JJ
to  ||| S:26821 E:26824 ||| TO
embryonic  ||| S:26824 E:26834 ||| FW
SMG  ||| S:26834 E:26846 ||| FW
developmental  ||| S:26846 E:26860 ||| FW
homeostasis ||| S:26860 E:26871 ||| FW
.  ||| S:26871 E:26873 ||| .
We  ||| S:26873 E:26876 ||| PRP
demonstrate  ||| S:26876 E:26888 ||| VBP
the  ||| S:26888 E:26892 ||| DT
interplay  ||| S:26892 E:26910 ||| NN
between  ||| S:26910 E:26918 ||| IN
gene  ||| S:26918 E:26923 ||| NN
expression ||| S:26923 E:26933 ||| NN
,  ||| S:26933 E:26935 ||| ,
protein  ||| S:26935 E:26943 ||| NN
expression ||| S:26943 E:26953 ||| NN
,  ||| S:26953 E:26955 ||| ,
protein  ||| S:26955 E:26971 ||| NN
activity ||| S:26971 E:26979 ||| NN
,  ||| S:26979 E:26981 ||| ,
and  ||| S:26981 E:26985 ||| CC
morphology  ||| S:26985 E:26996 ||| NN
in  ||| S:26996 E:26999 ||| IN
response  ||| S:26999 E:27008 ||| NN
to  ||| S:27008 E:27011 ||| TO
NF-κB  ||| S:27011 E:27017 ||| JJ
inhibition ||| S:27017 E:27027 ||| NN
.  ||| S:27027 E:27037 ||| .
Gene ||| S:27037 E:27041 ||| NNP
/ ||| S:27041 E:27042 ||| NNP
protein  ||| S:27042 E:27050 ||| NN
differences  ||| S:27050 E:27062 ||| NNS
between  ||| S:27062 E:27070 ||| IN
control  ||| S:27070 E:27078 ||| NN
and  ||| S:27078 E:27090 ||| CC
NF-κB-inhibited  ||| S:27090 E:27106 ||| JJ
phenotypes  ||| S:27106 E:27117 ||| NNS
are  ||| S:27117 E:27121 ||| VBP
not  ||| S:27121 E:27125 ||| RB
linearly  ||| S:27125 E:27134 ||| JJ
causal  ||| S:27134 E:27141 ||| NN
of  ||| S:27141 E:27144 ||| IN
SMG  ||| S:27144 E:27156 ||| NNP
dysplasia ||| S:27156 E:27165 ||| NN
.  ||| S:27165 E:27167 ||| .
In  ||| S:27167 E:27170 ||| IN
fact ||| S:27170 E:27174 ||| NN
,  ||| S:27174 E:27176 ||| ,
these  ||| S:27176 E:27182 ||| DT
differences  ||| S:27182 E:27194 ||| NNS
are  ||| S:27194 E:27198 ||| VBP
discovered  ||| S:27198 E:27217 ||| VBN
correlations  ||| S:27217 E:27230 ||| VBN
between  ||| S:27230 E:27238 ||| IN
network  ||| S:27238 E:27246 ||| NN
components  ||| S:27246 E:27257 ||| NNS
and  ||| S:27257 E:27261 ||| CC
an  ||| S:27261 E:27264 ||| DT
emerging  ||| S:27264 E:27273 ||| VBG
SMG  ||| S:27273 E:27285 ||| NNP
phenotype ||| S:27285 E:27294 ||| NN
,  ||| S:27294 E:27296 ||| ,
a  ||| S:27296 E:27298 ||| DT
glimpse  ||| S:27298 E:27306 ||| NN
of  ||| S:27306 E:27309 ||| IN
nonlinear  ||| S:27309 E:27319 ||| JJ
organogenesis  ||| S:27319 E:27333 ||| NNS
[  ||| S:27333 E:27335 ||| -LRB-
65  ||| S:27335 E:27338 ||| CD
]  ||| S:27338 E:27348 ||| -RRB-
.  ||| S:27348 E:27358 ||| .
Considering  ||| S:27358 E:27370 ||| VBG
the  ||| S:27370 E:27374 ||| DT
outcome  ||| S:27374 E:27382 ||| NN
of  ||| S:27382 E:27385 ||| IN
this  ||| S:27385 E:27390 ||| DT
study  ||| S:27390 E:27396 ||| NN
relative  ||| S:27396 E:27405 ||| JJ
to  ||| S:27405 E:27408 ||| TO
the  ||| S:27408 E:27421 ||| DT
Connections  ||| S:27421 E:27433 ||| NNP
Map  ||| S:27433 E:27437 ||| NNP
( ||| S:27437 E:27438 ||| -LRB-
Fig.  ||| S:27438 E:27443 ||| CD
1 ||| S:27443 E:27444 ||| CD
) ||| S:27444 E:27445 ||| -RRB-
,  ||| S:27445 E:27447 ||| ,
it  ||| S:27447 E:27450 ||| PRP
is  ||| S:27450 E:27461 ||| VBZ
apparent  ||| S:27461 E:27470 ||| JJ
that  ||| S:27470 E:27475 ||| IN
NF-κB  ||| S:27475 E:27481 ||| JJ
nuclear  ||| S:27481 E:27489 ||| JJ
translocation  ||| S:27489 E:27503 ||| NN
is  ||| S:27503 E:27506 ||| VBZ
functionally  ||| S:27506 E:27527 ||| JJ
integral  ||| S:27527 E:27536 ||| NN
to  ||| S:27536 E:27539 ||| TO
a  ||| S:27539 E:27541 ||| DT
genetic  ||| S:27541 E:27549 ||| JJ
network  ||| S:27549 E:27557 ||| NN
with  ||| S:27557 E:27562 ||| IN
broadly  ||| S:27562 E:27570 ||| RB
related ||| S:27570 E:27577 ||| VBN
,  ||| S:27577 E:27579 ||| ,
rather  ||| S:27579 E:27594 ||| RB
than  ||| S:27594 E:27599 ||| IN
independent ||| S:27599 E:27610 ||| JJ
,  ||| S:27610 E:27612 ||| ,
components ||| S:27612 E:27622 ||| NNS
.  ||| S:27622 E:27624 ||| .
It  ||| S:27624 E:27627 ||| PRP
may  ||| S:27627 E:27631 ||| MD
be  ||| S:27631 E:27634 ||| VB
said  ||| S:27634 E:27639 ||| VBN
to  ||| S:27639 E:27642 ||| TO
represent  ||| S:27642 E:27660 ||| VB
the  ||| S:27660 E:27664 ||| DT
collective  ||| S:27664 E:27675 ||| JJ
dynamics  ||| S:27675 E:27684 ||| NNS
of  ||| S:27684 E:27687 ||| IN
a  ||| S:27687 E:27689 ||| DT
"small-world ||| S:27689 E:27701 ||| NN
"  ||| S:27701 E:27703 ||| ''
network  ||| S:27703 E:27711 ||| NN
such  ||| S:27711 E:27724 ||| JJ
that  ||| S:27724 E:27729 ||| IN
the  ||| S:27729 E:27733 ||| DT
average  ||| S:27733 E:27741 ||| JJ
number  ||| S:27741 E:27748 ||| NN
of  ||| S:27748 E:27751 ||| IN
factors  ||| S:27751 E:27759 ||| NNS
in  ||| S:27759 E:27762 ||| IN
the  ||| S:27762 E:27766 ||| DT
shortest  ||| S:27766 E:27775 ||| JJS
chain  ||| S:27775 E:27789 ||| NN
connecting  ||| S:27789 E:27800 ||| VBG
any  ||| S:27800 E:27804 ||| DT
two  ||| S:27804 E:27808 ||| CD
factors  ||| S:27808 E:27816 ||| NNS
is  ||| S:27816 E:27819 ||| VBZ
small  ||| S:27819 E:27825 ||| JJ
[  ||| S:27825 E:27827 ||| -LRB-
66  ||| S:27827 E:27830 ||| CD
]  ||| S:27830 E:27832 ||| -RRB-
.  ||| S:27832 E:27834 ||| .
Such  ||| S:27834 E:27839 ||| JJ
dynamical  ||| S:27839 E:27857 ||| JJ
systems  ||| S:27857 E:27865 ||| NNS
with  ||| S:27865 E:27870 ||| IN
small-world  ||| S:27870 E:27882 ||| JJ
coupling  ||| S:27882 E:27891 ||| NNS
display  ||| S:27891 E:27899 ||| VBP
enhanced  ||| S:27899 E:27916 ||| VBN
signal-propagation  ||| S:27916 E:27935 ||| JJ
speed  ||| S:27935 E:27941 ||| NN
and  ||| S:27941 E:27945 ||| CC
synchronizability ||| S:27945 E:27962 ||| NN
.  ||| S:27962 E:27964 ||| .
Thus ||| S:27964 E:27968 ||| RB
,  ||| S:27968 E:27970 ||| ,
if  ||| S:27970 E:27981 ||| IN
one  ||| S:27981 E:27985 ||| CD
focuses  ||| S:27985 E:27993 ||| NN
on  ||| S:27993 E:27996 ||| IN
the  ||| S:27996 E:28000 ||| DT
superimposition  ||| S:28000 E:28016 ||| NN
of  ||| S:28016 E:28019 ||| IN
the  ||| S:28019 E:28023 ||| DT
various  ||| S:28023 E:28031 ||| JJ
layers  ||| S:28031 E:28038 ||| NNS
of  ||| S:28038 E:28049 ||| IN
information ||| S:28049 E:28060 ||| NN
,  ||| S:28060 E:28062 ||| ,
namely  ||| S:28062 E:28069 ||| RB
morphology ||| S:28069 E:28079 ||| JJ
,  ||| S:28079 E:28081 ||| ,
gene  ||| S:28081 E:28086 ||| NN
expression ||| S:28086 E:28096 ||| NN
,  ||| S:28096 E:28098 ||| ,
protein  ||| S:28098 E:28114 ||| NN
expression ||| S:28114 E:28124 ||| NN
,  ||| S:28124 E:28126 ||| ,
and  ||| S:28126 E:28130 ||| CC
protein  ||| S:28130 E:28138 ||| NN
activity  ||| S:28138 E:28147 ||| NN
( ||| S:28147 E:28148 ||| -LRB-
Figs.  ||| S:28148 E:28154 ||| CD
3 ||| S:28154 E:28155 ||| CD
,  ||| S:28155 E:28157 ||| ,
4 ||| S:28157 E:28158 ||| CD
,  ||| S:28158 E:28160 ||| ,
5 ||| S:28160 E:28161 ||| CD
,  ||| S:28161 E:28163 ||| ,
6 ||| S:28163 E:28164 ||| CD
,  ||| S:28164 E:28166 ||| ,
7 ||| S:28166 E:28167 ||| CD
,  ||| S:28167 E:28169 ||| ,
8 ||| S:28169 E:28170 ||| CD
,  ||| S:28170 E:28180 ||| ,
9 ||| S:28180 E:28181 ||| CD
,  ||| S:28181 E:28183 ||| ,
10 ||| S:28183 E:28185 ||| CD
,  ||| S:28185 E:28187 ||| ,
11 ||| S:28187 E:28189 ||| CD
,  ||| S:28189 E:28191 ||| ,
12 ||| S:28191 E:28193 ||| CD
,  ||| S:28193 E:28195 ||| ,
13 ||| S:28195 E:28197 ||| CD
,  ||| S:28197 E:28199 ||| ,
14 ||| S:28199 E:28201 ||| CD
) ||| S:28201 E:28202 ||| -RRB-
,  ||| S:28202 E:28204 ||| ,
one  ||| S:28204 E:28208 ||| PRP
can  ||| S:28208 E:28212 ||| MD
visualize  ||| S:28212 E:28222 ||| VB
a  ||| S:28222 E:28224 ||| DT
coordinated ||| S:28224 E:28235 ||| NN
,  ||| S:28235 E:28245 ||| ,
multidimensional  ||| S:28245 E:28262 ||| JJ
response  ||| S:28262 E:28271 ||| NN
to  ||| S:28271 E:28274 ||| TO
inhibited  ||| S:28274 E:28284 ||| VB
NF-κB  ||| S:28284 E:28290 ||| JJ
nuclear  ||| S:28290 E:28306 ||| JJ
translocation ||| S:28306 E:28319 ||| NN
.  ||| S:28319 E:28321 ||| .
This  ||| S:28321 E:28326 ||| DT
visualization ||| S:28326 E:28339 ||| NN
,  ||| S:28339 E:28341 ||| ,
however ||| S:28341 E:28348 ||| RB
,  ||| S:28348 E:28350 ||| ,
is  ||| S:28350 E:28353 ||| VBZ
necessarily  ||| S:28353 E:28373 ||| RB
impressionistic  ||| S:28373 E:28389 ||| VBN
even  ||| S:28389 E:28394 ||| RB
though  ||| S:28394 E:28401 ||| IN
our  ||| S:28401 E:28405 ||| PRP$
assays  ||| S:28405 E:28412 ||| NNS
have  ||| S:28412 E:28417 ||| VBP
some  ||| S:28417 E:28422 ||| DT
precision ||| S:28422 E:28431 ||| NN
.  ||| S:28431 E:28441 ||| .
This  ||| S:28441 E:28446 ||| DT
is  ||| S:28446 E:28449 ||| VBZ
so  ||| S:28449 E:28452 ||| RB
because  ||| S:28452 E:28460 ||| IN
we  ||| S:28460 E:28463 ||| PRP
cannot  ||| S:28463 E:28470 ||| VBP
extrapolate  ||| S:28470 E:28482 ||| VBN
from  ||| S:28482 E:28487 ||| IN
transcriptome  ||| S:28487 E:28509 ||| VBG
to  ||| S:28509 E:28512 ||| TO
proteome  ||| S:28512 E:28521 ||| VB
to  ||| S:28521 E:28524 ||| TO
activated  ||| S:28524 E:28534 ||| VB
proteins  ||| S:28534 E:28543 ||| NNS
with  ||| S:28543 E:28548 ||| IN
any  ||| S:28548 E:28552 ||| DT
accuracy  ||| S:28552 E:28561 ||| NN
( ||| S:28561 E:28562 ||| -LRB-
in  ||| S:28562 E:28565 ||| IN
the  ||| S:28565 E:28577 ||| DT
absence  ||| S:28577 E:28585 ||| NN
of  ||| S:28585 E:28588 ||| IN
actual  ||| S:28588 E:28595 ||| JJ
steady-state  ||| S:28595 E:28608 ||| JJ
measures ||| S:28608 E:28616 ||| NNS
) ||| S:28616 E:28617 ||| -RRB-
,  ||| S:28617 E:28628 ||| ,
and  ||| S:28628 E:28632 ||| CC
because  ||| S:28632 E:28640 ||| RB
in  ||| S:28640 E:28643 ||| IN
these  ||| S:28643 E:28649 ||| DT
experiments  ||| S:28649 E:28661 ||| JJ
time  ||| S:28661 E:28674 ||| NN
is  ||| S:28674 E:28677 ||| VBZ
necessarily  ||| S:28677 E:28689 ||| RB
cross-sectional ||| S:28689 E:28704 ||| JJ
,  ||| S:28704 E:28706 ||| ,
not  ||| S:28706 E:28710 ||| RB
longitudinal ||| S:28710 E:28722 ||| VBN
.  ||| S:28722 E:28732 ||| .
Nevertheless ||| S:28732 E:28744 ||| RB
,  ||| S:28744 E:28746 ||| ,
relative  ||| S:28746 E:28755 ||| JJ
to  ||| S:28755 E:28758 ||| TO
understanding  ||| S:28758 E:28772 ||| VB
a  ||| S:28772 E:28774 ||| DT
complex  ||| S:28774 E:28782 ||| JJ
genetic  ||| S:28782 E:28798 ||| JJ
network  ||| S:28798 E:28806 ||| NN
and  ||| S:28806 E:28810 ||| CC
organogenesis ||| S:28810 E:28823 ||| NN
,  ||| S:28823 E:28825 ||| ,
our  ||| S:28825 E:28829 ||| PRP$
results  ||| S:28829 E:28837 ||| NNS
demonstrate  ||| S:28837 E:28849 ||| VBP
the  ||| S:28849 E:28861 ||| DT
importance  ||| S:28861 E:28872 ||| NN
of  ||| S:28872 E:28875 ||| IN
contemporaneously  ||| S:28875 E:28893 ||| NNS
evaluating  ||| S:28893 E:28904 ||| VBG
the  ||| S:28904 E:28908 ||| DT
gene ||| S:28908 E:28912 ||| NN
,  ||| S:28912 E:28922 ||| ,
protein ||| S:28922 E:28929 ||| NN
,  ||| S:28929 E:28940 ||| ,
and  ||| S:28940 E:28944 ||| CC
activated  ||| S:28944 E:28954 ||| JJ
protein  ||| S:28954 E:28962 ||| NN
expression  ||| S:28962 E:28973 ||| NN
of  ||| S:28973 E:28984 ||| IN
multiple  ||| S:28984 E:28993 ||| JJ
components  ||| S:28993 E:29004 ||| NNS
from  ||| S:29004 E:29009 ||| IN
multiple  ||| S:29009 E:29018 ||| JJ
pathways  ||| S:29018 E:29027 ||| NN
within  ||| S:29027 E:29034 ||| IN
broad  ||| S:29034 E:29048 ||| JJ
functional  ||| S:29048 E:29059 ||| JJ
categories ||| S:29059 E:29069 ||| NNS
.  ||| S:29069 E:29071 ||| .
Understanding  ||| S:29071 E:29085 ||| VBG
the  ||| S:29085 E:29089 ||| DT
signal  ||| S:29089 E:29096 ||| NN
dynamics  ||| S:29096 E:29105 ||| NNS
of  ||| S:29105 E:29116 ||| IN
these  ||| S:29116 E:29122 ||| DT
pathways  ||| S:29122 E:29131 ||| NN
will  ||| S:29131 E:29136 ||| MD
require  ||| S:29136 E:29144 ||| VB
expanded  ||| S:29144 E:29153 ||| VBN
models  ||| S:29153 E:29160 ||| NNS
that  ||| S:29160 E:29165 ||| WDT
encompass  ||| S:29165 E:29183 ||| VBZ
more  ||| S:29183 E:29188 ||| JJR
aspects  ||| S:29188 E:29196 ||| NNS
of  ||| S:29196 E:29199 ||| IN
regulation  ||| S:29199 E:29210 ||| NN
[ ||| S:29210 E:29211 ||| -LRB-
e.g.  ||| S:29211 E:29216 ||| NNP
[  ||| S:29216 E:29218 ||| -LRB-
67  ||| S:29218 E:29221 ||| CD
]  ||| S:29221 E:29223 ||| CD
] ||| S:29223 E:29224 ||| -RRB-
.  ||| S:29224 E:29226 ||| .
Still ||| S:29226 E:29231 ||| RB
,  ||| S:29231 E:29233 ||| ,
we  ||| S:29233 E:29236 ||| PRP
will  ||| S:29236 E:29249 ||| MD
always  ||| S:29249 E:29256 ||| RB
be  ||| S:29256 E:29259 ||| VB
limited  ||| S:29259 E:29267 ||| VBN
by  ||| S:29267 E:29270 ||| IN
the  ||| S:29270 E:29274 ||| DT
fact  ||| S:29274 E:29279 ||| NN
that  ||| S:29279 E:29284 ||| IN
phenotypes  ||| S:29284 E:29295 ||| NNS
are  ||| S:29295 E:29299 ||| VBP
complex ||| S:29299 E:29306 ||| JJ
,  ||| S:29306 E:29316 ||| ,
emergent  ||| S:29316 E:29325 ||| JJ
phenomena  ||| S:29325 E:29335 ||| NNS
[  ||| S:29335 E:29337 ||| -LRB-
16  ||| S:29337 E:29340 ||| CD
]  ||| S:29340 E:29342 ||| -RRB-
.  ||| S:29342 E:29366 ||| .
Materials  ||| S:29366 E:29376 ||| NNS
and  ||| S:29376 E:29380 ||| CC
Methods  ||| S:29380 E:29407 ||| NNP
Tissue  ||| S:29407 E:29414 ||| NNP
collection  ||| S:29414 E:29435 ||| NN
Female  ||| S:29435 E:29442 ||| NNP
B10A ||| S:29442 E:29446 ||| NNP
/ ||| S:29446 E:29447 ||| NNP
SnSg  ||| S:29447 E:29452 ||| JJ
mice ||| S:29452 E:29456 ||| NNS
,  ||| S:29456 E:29458 ||| ,
obtained  ||| S:29458 E:29467 ||| VBN
from  ||| S:29467 E:29472 ||| IN
Jackson  ||| S:29472 E:29490 ||| NNP
Laboratories  ||| S:29490 E:29503 ||| NNPS
( ||| S:29503 E:29504 ||| -LRB-
Bar  ||| S:29504 E:29508 ||| NNP
Harbor ||| S:29508 E:29514 ||| NNP
,  ||| S:29514 E:29516 ||| ,
ME ||| S:29516 E:29518 ||| NNP
) ||| S:29518 E:29519 ||| -RRB-
,  ||| S:29519 E:29521 ||| ,
were  ||| S:29521 E:29526 ||| VBD
maintained  ||| S:29526 E:29537 ||| VBN
and  ||| S:29537 E:29541 ||| CC
mated  ||| S:29541 E:29557 ||| VBN
as  ||| S:29557 E:29560 ||| IN
previously  ||| S:29560 E:29571 ||| RB
described  ||| S:29571 E:29581 ||| VBN
[  ||| S:29581 E:29583 ||| -LRB-
60  ||| S:29583 E:29586 ||| CD
]  ||| S:29586 E:29588 ||| -RRB-
;  ||| S:29588 E:29590 ||| :
plug  ||| S:29590 E:29595 ||| JJ
day  ||| S:29595 E:29599 ||| NN
=  ||| S:29599 E:29601 ||| SYM
day  ||| S:29601 E:29605 ||| NN
0  ||| S:29605 E:29607 ||| CD
of  ||| S:29607 E:29620 ||| IN
gestation ||| S:29620 E:29629 ||| NN
.  ||| S:29629 E:29631 ||| .
Pregnant  ||| S:29631 E:29640 ||| JJ
females  ||| S:29640 E:29648 ||| NNS
were  ||| S:29648 E:29653 ||| VBD
anesthetized  ||| S:29653 E:29666 ||| VBN
on  ||| S:29666 E:29669 ||| IN
days  ||| S:29669 E:29684 ||| NNS
15-19  ||| S:29684 E:29690 ||| VBP
of  ||| S:29690 E:29693 ||| IN
gestation  ||| S:29693 E:29703 ||| NNS
( ||| S:29703 E:29704 ||| -LRB-
E15-18 ||| S:29704 E:29710 ||| NNP
)  ||| S:29710 E:29712 ||| -RRB-
with  ||| S:29712 E:29717 ||| IN
methoxyflurane  ||| S:29717 E:29742 ||| NNS
( ||| S:29742 E:29743 ||| -LRB-
metafane ||| S:29743 E:29751 ||| LS
)  ||| S:29751 E:29753 ||| -RRB-
and  ||| S:29753 E:29757 ||| CC
euthanized  ||| S:29757 E:29768 ||| NN
by  ||| S:29768 E:29771 ||| IN
cervical  ||| S:29771 E:29780 ||| JJ
dislocation ||| S:29780 E:29791 ||| NN
.  ||| S:29791 E:29803 ||| .
Embryos  ||| S:29803 E:29811 ||| NNP
were  ||| S:29811 E:29816 ||| VBD
dissected  ||| S:29816 E:29826 ||| VBN
in  ||| S:29826 E:29829 ||| IN
cold  ||| S:29829 E:29834 ||| JJ
phosphate  ||| S:29834 E:29844 ||| FW
buffered  ||| S:29844 E:29853 ||| FW
saline  ||| S:29853 E:29870 ||| FW
( ||| S:29870 E:29871 ||| -LRB-
PBS ||| S:29871 E:29874 ||| NNP
)  ||| S:29874 E:29876 ||| -RRB-
and  ||| S:29876 E:29880 ||| CC
staged  ||| S:29880 E:29887 ||| VBD
according  ||| S:29887 E:29897 ||| VBG
to  ||| S:29897 E:29900 ||| TO
Theiler  ||| S:29900 E:29908 ||| NNP
[  ||| S:29908 E:29910 ||| -LRB-
68  ||| S:29910 E:29913 ||| CD
]  ||| S:29913 E:29915 ||| -RRB-
.  ||| S:29915 E:29917 ||| .
SMGs  ||| S:29917 E:29922 ||| NNP
were  ||| S:29922 E:29937 ||| VBD
dissected  ||| S:29937 E:29947 ||| VBN
and  ||| S:29947 E:29951 ||| CC
cultured ||| S:29951 E:29959 ||| NN
,  ||| S:29959 E:29961 ||| ,
processed  ||| S:29961 E:29971 ||| VBN
for  ||| S:29971 E:29975 ||| IN
histology ||| S:29975 E:29984 ||| NN
,  ||| S:29984 E:29986 ||| ,
or  ||| S:29986 E:29999 ||| CC
stored  ||| S:29999 E:30006 ||| VBD
at  ||| S:30006 E:30009 ||| IN
-70°C ||| S:30009 E:30014 ||| CD
.  ||| S:30014 E:30016 ||| .
For  ||| S:30016 E:30020 ||| IN
cDNA  ||| S:30020 E:30025 ||| JJ
expression  ||| S:30025 E:30036 ||| NN
and  ||| S:30036 E:30040 ||| CC
proteomic  ||| S:30040 E:30060 ||| JJ
studies ||| S:30060 E:30067 ||| NNS
,  ||| S:30067 E:30069 ||| ,
E15  ||| S:30069 E:30073 ||| CD
+  ||| S:30073 E:30075 ||| CD
2  ||| S:30075 E:30077 ||| CD
explants  ||| S:30077 E:30086 ||| NNS
were  ||| S:30086 E:30091 ||| VBD
collected ||| S:30091 E:30100 ||| VBN
,  ||| S:30100 E:30102 ||| ,
pooled ||| S:30102 E:30108 ||| VBN
,  ||| S:30108 E:30110 ||| ,
and  ||| S:30110 E:30124 ||| CC
stored  ||| S:30124 E:30131 ||| VBD
at  ||| S:30131 E:30134 ||| IN
-70°C ||| S:30134 E:30139 ||| CD
.  ||| S:30139 E:30169 ||| .
Culture  ||| S:30169 E:30177 ||| NN
system  ||| S:30177 E:30194 ||| NN
E15  ||| S:30194 E:30198 ||| NNP
SMG  ||| S:30198 E:30202 ||| NNP
( ||| S:30202 E:30203 ||| -LRB-
mostly  ||| S:30203 E:30221 ||| RB
Canalicular  ||| S:30221 E:30233 ||| NNP
Stage ||| S:30233 E:30238 ||| NNP
)  ||| S:30238 E:30240 ||| -RRB-
primordia  ||| S:30240 E:30250 ||| NN
were  ||| S:30250 E:30265 ||| VBD
cultured  ||| S:30265 E:30274 ||| VBN
using  ||| S:30274 E:30280 ||| VBG
a  ||| S:30280 E:30282 ||| DT
modified  ||| S:30282 E:30291 ||| JJ
Trowell  ||| S:30291 E:30299 ||| JJ
method  ||| S:30299 E:30306 ||| NN
as  ||| S:30306 E:30309 ||| IN
previously  ||| S:30309 E:30330 ||| RB
described  ||| S:30330 E:30340 ||| VBN
[  ||| S:30340 E:30342 ||| -LRB-
13  ||| S:30342 E:30345 ||| CD
]  ||| S:30345 E:30347 ||| -RRB-
.  ||| S:30347 E:30349 ||| .
The  ||| S:30349 E:30353 ||| DT
medium  ||| S:30353 E:30360 ||| NN
consisted  ||| S:30360 E:30370 ||| VBD
of  ||| S:30370 E:30373 ||| IN
BGJb  ||| S:30373 E:30378 ||| NNP
( ||| S:30378 E:30379 ||| -LRB-
Life  ||| S:30379 E:30394 ||| NNP
Technologies ||| S:30394 E:30406 ||| NNPS
,  ||| S:30406 E:30408 ||| ,
Rockville ||| S:30408 E:30417 ||| NNP
,  ||| S:30417 E:30419 ||| ,
MD ||| S:30419 E:30421 ||| NNP
)  ||| S:30421 E:30423 ||| -RRB-
supplemented  ||| S:30423 E:30436 ||| NN
with  ||| S:30436 E:30441 ||| IN
0.5  ||| S:30441 E:30445 ||| CD
mg  ||| S:30445 E:30458 ||| FW
ascorbic  ||| S:30458 E:30467 ||| FW
acid ||| S:30467 E:30471 ||| FW
/ ||| S:30471 E:30472 ||| FW
ml  ||| S:30472 E:30475 ||| FW
and  ||| S:30475 E:30479 ||| CC
50  ||| S:30479 E:30482 ||| CD
units  ||| S:30482 E:30488 ||| NNS
penicillin ||| S:30488 E:30498 ||| VBD
/ ||| S:30498 E:30499 ||| CD
streptomycin  ||| S:30499 E:30522 ||| NNS
( ||| S:30522 E:30523 ||| -LRB-
Life  ||| S:30523 E:30528 ||| NNP
Technologies ||| S:30528 E:30540 ||| NNPS
) ||| S:30540 E:30541 ||| -RRB-
,  ||| S:30541 E:30543 ||| ,
pH  ||| S:30543 E:30546 ||| JJ
7.2 ||| S:30546 E:30549 ||| CD
,  ||| S:30549 E:30551 ||| ,
and  ||| S:30551 E:30555 ||| CC
replicate  ||| S:30555 E:30565 ||| JJ
cultures  ||| S:30565 E:30574 ||| NNS
were  ||| S:30574 E:30589 ||| VBD
changed  ||| S:30589 E:30597 ||| VBN
every  ||| S:30597 E:30603 ||| DT
other  ||| S:30603 E:30609 ||| JJ
day ||| S:30609 E:30612 ||| NN
.  ||| S:30612 E:30614 ||| .
Cultures  ||| S:30614 E:30623 ||| NNS
were  ||| S:30623 E:30628 ||| VBD
supplemented  ||| S:30628 E:30641 ||| VBN
on  ||| S:30641 E:30654 ||| IN
day  ||| S:30654 E:30658 ||| NN
0  ||| S:30658 E:30660 ||| CD
and  ||| S:30660 E:30664 ||| CC
maintained  ||| S:30664 E:30675 ||| VBN
for  ||| S:30675 E:30679 ||| IN
the  ||| S:30679 E:30683 ||| DT
duration  ||| S:30683 E:30692 ||| NN
of  ||| S:30692 E:30695 ||| IN
the  ||| S:30695 E:30699 ||| DT
experiments ||| S:30699 E:30710 ||| NNS
.  ||| S:30710 E:30722 ||| .
In  ||| S:30722 E:30725 ||| IN
each  ||| S:30725 E:30730 ||| DT
of  ||| S:30730 E:30733 ||| IN
the  ||| S:30733 E:30737 ||| DT
enumerated  ||| S:30737 E:30748 ||| JJ
studies ||| S:30748 E:30755 ||| NNS
,  ||| S:30755 E:30757 ||| ,
a  ||| S:30757 E:30759 ||| DT
minimum  ||| S:30759 E:30767 ||| NN
of  ||| S:30767 E:30770 ||| IN
12  ||| S:30770 E:30783 ||| CD
explants  ||| S:30783 E:30792 ||| NNS
were  ||| S:30792 E:30797 ||| VBD
cultured  ||| S:30797 E:30806 ||| VBN
for  ||| S:30806 E:30810 ||| IN
2  ||| S:30810 E:30812 ||| CD
or  ||| S:30812 E:30815 ||| CC
4  ||| S:30815 E:30817 ||| CD
days  ||| S:30817 E:30822 ||| NNS
in  ||| S:30822 E:30825 ||| IN
the  ||| S:30825 E:30829 ||| DT
cell  ||| S:30829 E:30844 ||| NN
permeable  ||| S:30844 E:30854 ||| FW
peptide  ||| S:30854 E:30862 ||| FW
SN50  ||| S:30862 E:30867 ||| FW
( ||| S:30867 E:30868 ||| -LRB-
Biomol  ||| S:30868 E:30875 ||| NNP
Research ||| S:30875 E:30883 ||| NNP
,  ||| S:30883 E:30885 ||| ,
Plymouth  ||| S:30885 E:30904 ||| NNP
Meeting ||| S:30904 E:30911 ||| NNP
,  ||| S:30911 E:30913 ||| ,
PA ||| S:30913 E:30915 ||| NNP
)  ||| S:30915 E:30917 ||| -RRB-
which  ||| S:30917 E:30923 ||| WDT
inhibits  ||| S:30923 E:30932 ||| VBZ
NF-κB  ||| S:30932 E:30938 ||| JJ
translocation  ||| S:30938 E:30952 ||| NN
into  ||| S:30952 E:30957 ||| IN
the  ||| S:30957 E:30971 ||| DT
nucleus  ||| S:30971 E:30979 ||| NN
[  ||| S:30979 E:30981 ||| -LRB-
24  ||| S:30981 E:30984 ||| CD
33  ||| S:30984 E:30987 ||| CD
34  ||| S:30987 E:30990 ||| CD
35  ||| S:30990 E:30993 ||| CD
]  ||| S:30993 E:30995 ||| -RRB-
.  ||| S:30995 E:30997 ||| .
The  ||| S:30997 E:31001 ||| DT
concentration  ||| S:31001 E:31015 ||| NN
used  ||| S:31015 E:31020 ||| VBN
( ||| S:31020 E:31021 ||| -LRB-
100  ||| S:31021 E:31035 ||| CD
μg ||| S:31035 E:31037 ||| CD
/ ||| S:31037 E:31038 ||| CD
ml ||| S:31038 E:31040 ||| CD
)  ||| S:31040 E:31042 ||| -RRB-
was  ||| S:31042 E:31046 ||| VBD
double  ||| S:31046 E:31053 ||| RB
that  ||| S:31053 E:31058 ||| IN
shown  ||| S:31058 E:31064 ||| VBN
to  ||| S:31064 E:31067 ||| TO
inhibit  ||| S:31067 E:31075 ||| VB
NF-κB  ||| S:31075 E:31091 ||| JJ
translocation  ||| S:31091 E:31105 ||| NN
in  ||| S:31105 E:31108 ||| IN
mouse  ||| S:31108 E:31114 ||| JJ
endothelial  ||| S:31114 E:31126 ||| JJ
LE-II  ||| S:31126 E:31132 ||| JJ
cells ||| S:31132 E:31137 ||| NNS
;  ||| S:31137 E:31139 ||| :
100  ||| S:31139 E:31143 ||| CD
μg ||| S:31143 E:31145 ||| FW
/ ||| S:31145 E:31146 ||| FW
ml  ||| S:31146 E:31159 ||| FW
mutant  ||| S:31159 E:31166 ||| FW
SN50  ||| S:31166 E:31171 ||| FW
( ||| S:31171 E:31172 ||| -LRB-
mSN50 ||| S:31172 E:31177 ||| NNP
)  ||| S:31177 E:31179 ||| -RRB-
peptide  ||| S:31179 E:31187 ||| NN
was  ||| S:31187 E:31191 ||| VBD
used  ||| S:31191 E:31196 ||| VBN
as  ||| S:31196 E:31199 ||| IN
a  ||| S:31199 E:31212 ||| DT
positive  ||| S:31212 E:31221 ||| JJ
control  ||| S:31221 E:31229 ||| NN
and  ||| S:31229 E:31233 ||| CC
control  ||| S:31233 E:31241 ||| VB
BGJb  ||| S:31241 E:31256 ||| JJ
medium  ||| S:31256 E:31263 ||| NN
as  ||| S:31263 E:31266 ||| IN
a  ||| S:31266 E:31279 ||| DT
negative  ||| S:31279 E:31288 ||| JJ
control ||| S:31288 E:31295 ||| NN
.  ||| S:31295 E:31297 ||| .
We  ||| S:31297 E:31300 ||| PRP
evaluated  ||| S:31300 E:31320 ||| VBD
their  ||| S:31320 E:31326 ||| PRP$
microanatomy  ||| S:31326 E:31339 ||| NN
by  ||| S:31339 E:31342 ||| IN
routine  ||| S:31342 E:31350 ||| JJ
hematoxylin  ||| S:31350 E:31362 ||| NN
and  ||| S:31362 E:31366 ||| CC
eosin  ||| S:31366 E:31382 ||| JJ
histology ||| S:31382 E:31391 ||| NN
.  ||| S:31391 E:31393 ||| .
We  ||| S:31393 E:31396 ||| PRP
report  ||| S:31396 E:31403 ||| VBP
a  ||| S:31403 E:31405 ||| DT
marked  ||| S:31405 E:31412 ||| JJ
difference  ||| S:31412 E:31423 ||| NN
between  ||| S:31423 E:31441 ||| IN
SN50-treated  ||| S:31441 E:31454 ||| NNP
and  ||| S:31454 E:31458 ||| CC
control  ||| S:31458 E:31466 ||| NN
explants  ||| S:31466 E:31475 ||| NNS
or  ||| S:31475 E:31478 ||| CC
SN50-and  ||| S:31478 E:31487 ||| CD
mSN50  ||| S:31487 E:31503 ||| CD
peptide-treated  ||| S:31503 E:31519 ||| JJ
explants ||| S:31519 E:31527 ||| NN
.  ||| S:31527 E:31529 ||| .
No  ||| S:31529 E:31532 ||| DT
differences  ||| S:31532 E:31544 ||| NNS
were  ||| S:31544 E:31549 ||| VBD
observed  ||| S:31549 E:31568 ||| VBN
between  ||| S:31568 E:31576 ||| IN
control  ||| S:31576 E:31584 ||| NN
and  ||| S:31584 E:31588 ||| CC
mSN50-treated  ||| S:31588 E:31602 ||| CD
explants ||| S:31602 E:31610 ||| NNS
.  ||| S:31610 E:31612 ||| .
Since  ||| S:31612 E:31618 ||| IN
these  ||| S:31618 E:31634 ||| DT
initial  ||| S:31634 E:31642 ||| JJ
studies  ||| S:31642 E:31650 ||| NNS
demonstrated  ||| S:31650 E:31663 ||| VBD
no  ||| S:31663 E:31666 ||| DT
difference  ||| S:31666 E:31677 ||| NN
between  ||| S:31677 E:31695 ||| IN
explants  ||| S:31695 E:31704 ||| JJ
cultured  ||| S:31704 E:31713 ||| NN
in  ||| S:31713 E:31716 ||| IN
control  ||| S:31716 E:31724 ||| NN
media  ||| S:31724 E:31730 ||| NNS
alone  ||| S:31730 E:31736 ||| RB
and  ||| S:31736 E:31740 ||| CC
in  ||| S:31740 E:31743 ||| IN
mutant  ||| S:31743 E:31760 ||| JJ
peptide ||| S:31760 E:31767 ||| NN
,  ||| S:31767 E:31769 ||| ,
control  ||| S:31769 E:31777 ||| NN
media  ||| S:31777 E:31783 ||| NNS
was  ||| S:31783 E:31787 ||| VBD
used  ||| S:31787 E:31792 ||| VBN
as  ||| S:31792 E:31795 ||| IN
the  ||| S:31795 E:31799 ||| DT
control  ||| S:31799 E:31807 ||| NN
in  ||| S:31807 E:31810 ||| IN
all  ||| S:31810 E:31824 ||| DT
subsequent  ||| S:31824 E:31835 ||| JJ
experiments ||| S:31835 E:31846 ||| NNS
.  ||| S:31846 E:31848 ||| .
Ten  ||| S:31848 E:31852 ||| CD
independent  ||| S:31852 E:31864 ||| JJ
experiments  ||| S:31864 E:31876 ||| NNS
of  ||| S:31876 E:31889 ||| IN
E15  ||| S:31889 E:31893 ||| CD
primordia  ||| S:31893 E:31903 ||| NNS
were  ||| S:31903 E:31908 ||| VBD
cultured  ||| S:31908 E:31917 ||| VBN
for  ||| S:31917 E:31921 ||| IN
2  ||| S:31921 E:31923 ||| CD
days  ||| S:31923 E:31928 ||| NNS
( ||| S:31928 E:31929 ||| -LRB-
E15  ||| S:31929 E:31933 ||| CD
+  ||| S:31933 E:31935 ||| CD
2 ||| S:31935 E:31936 ||| CD
)  ||| S:31936 E:31938 ||| -RRB-
in  ||| S:31938 E:31941 ||| IN
CONT  ||| S:31941 E:31956 ||| NNP
( ||| S:31956 E:31957 ||| -LRB-
control ||| S:31957 E:31964 ||| NN
)  ||| S:31964 E:31966 ||| -RRB-
or  ||| S:31966 E:31969 ||| CC
SN50-supplemented  ||| S:31969 E:31987 ||| CD
media ||| S:31987 E:31992 ||| NNS
,  ||| S:31992 E:31994 ||| ,
each  ||| S:31994 E:31999 ||| DT
group  ||| S:31999 E:32015 ||| NN
consisting  ||| S:32015 E:32026 ||| VBG
of  ||| S:32026 E:32029 ||| IN
a  ||| S:32029 E:32031 ||| DT
minimum  ||| S:32031 E:32039 ||| NN
of  ||| S:32039 E:32042 ||| IN
8  ||| S:32042 E:32044 ||| CD
explants  ||| S:32044 E:32053 ||| NN
per  ||| S:32053 E:32057 ||| IN
group ||| S:32057 E:32062 ||| NN
.  ||| S:32062 E:32064 ||| .
E15+2  ||| S:32064 E:32080 ||| NNP
explants  ||| S:32080 E:32089 ||| NN
were  ||| S:32089 E:32094 ||| VBD
collected  ||| S:32094 E:32104 ||| VBN
and  ||| S:32104 E:32108 ||| CC
processed  ||| S:32108 E:32118 ||| VBN
as  ||| S:32118 E:32121 ||| RB
described  ||| S:32121 E:32141 ||| VBN
below ||| S:32141 E:32146 ||| RB
.  ||| S:32146 E:32158 ||| .
To  ||| S:32158 E:32161 ||| TO
further  ||| S:32161 E:32169 ||| RB
demonstrate  ||| S:32169 E:32181 ||| VB
that  ||| S:32181 E:32186 ||| IN
SN50  ||| S:32186 E:32191 ||| CD
treatment  ||| S:32191 E:32201 ||| NN
inhibited  ||| S:32201 E:32221 ||| VBD
NB-κB  ||| S:32221 E:32227 ||| JJ
activation ||| S:32227 E:32237 ||| NN
,  ||| S:32237 E:32239 ||| ,
we  ||| S:32239 E:32242 ||| PRP
evaluated  ||| S:32242 E:32252 ||| VBD
if  ||| S:32252 E:32255 ||| IN
TNF  ||| S:32255 E:32259 ||| NNP
supplementation  ||| S:32259 E:32285 ||| NN
would  ||| S:32285 E:32291 ||| MD
induce  ||| S:32291 E:32298 ||| VB
NF-κB  ||| S:32298 E:32304 ||| JJ
translocation  ||| S:32304 E:32318 ||| NN
and  ||| S:32318 E:32322 ||| CC
SMG  ||| S:32322 E:32326 ||| NNP
morphogenesis ||| S:32326 E:32339 ||| NN
.  ||| S:32339 E:32351 ||| .
E15  ||| S:32351 E:32355 ||| NNP
SMGs  ||| S:32355 E:32360 ||| NNP
were  ||| S:32360 E:32365 ||| VBD
cultured  ||| S:32365 E:32374 ||| VBN
for  ||| S:32374 E:32378 ||| IN
4  ||| S:32378 E:32380 ||| CD
days  ||| S:32380 E:32385 ||| NNS
or  ||| S:32385 E:32388 ||| CC
longer  ||| S:32388 E:32395 ||| JJR
in  ||| S:32395 E:32398 ||| IN
10  ||| S:32398 E:32401 ||| CD
U ||| S:32401 E:32402 ||| NNP
/ ||| S:32402 E:32403 ||| FW
ml  ||| S:32403 E:32416 ||| FW
recombinant  ||| S:32416 E:32428 ||| FW
mouse  ||| S:32428 E:32434 ||| FW
TNF  ||| S:32434 E:32438 ||| FW
( ||| S:32438 E:32439 ||| -LRB-
rTNF ||| S:32439 E:32443 ||| NNP
,  ||| S:32443 E:32445 ||| ,
R  ||| S:32445 E:32447 ||| NNP
&  ||| S:32447 E:32449 ||| CC
D ||| S:32449 E:32450 ||| NNP
,  ||| S:32450 E:32452 ||| ,
Minneapolis ||| S:32452 E:32463 ||| NNP
,  ||| S:32463 E:32465 ||| ,
MN ||| S:32465 E:32467 ||| NNP
) ||| S:32467 E:32468 ||| -RRB-
,  ||| S:32468 E:32480 ||| ,
100  ||| S:32480 E:32484 ||| CD
μg ||| S:32484 E:32486 ||| CD
/ ||| S:32486 E:32487 ||| CD
ml  ||| S:32487 E:32490 ||| CD
SN50  ||| S:32490 E:32495 ||| CD
+  ||| S:32495 E:32497 ||| CD
10  ||| S:32497 E:32500 ||| CD
U ||| S:32500 E:32501 ||| NNP
/ ||| S:32501 E:32502 ||| NNP
ml  ||| S:32502 E:32505 ||| VBD
rTNF ||| S:32505 E:32509 ||| JJ
,  ||| S:32509 E:32511 ||| ,
or  ||| S:32511 E:32514 ||| CC
100  ||| S:32514 E:32518 ||| CD
μg ||| S:32518 E:32520 ||| CD
/ ||| S:32520 E:32521 ||| CD
ml  ||| S:32521 E:32524 ||| CD
mSN50  ||| S:32524 E:32530 ||| CD
+  ||| S:32530 E:32532 ||| CD
10  ||| S:32532 E:32545 ||| CD
U ||| S:32545 E:32546 ||| NNP
/ ||| S:32546 E:32547 ||| NNP
ml  ||| S:32547 E:32550 ||| VBD
rTNF ||| S:32550 E:32554 ||| JJ
,  ||| S:32554 E:32556 ||| ,
6-10  ||| S:32556 E:32561 ||| FW
explants  ||| S:32561 E:32570 ||| FW
per  ||| S:32570 E:32574 ||| FW
treatment  ||| S:32574 E:32584 ||| NN
group ||| S:32584 E:32589 ||| NN
.  ||| S:32589 E:32591 ||| .
This  ||| S:32591 E:32596 ||| DT
rTNF  ||| S:32596 E:32611 ||| JJ
concentration  ||| S:32611 E:32625 ||| NN
was  ||| S:32625 E:32629 ||| VBD
previously  ||| S:32629 E:32640 ||| RB
shown  ||| S:32640 E:32646 ||| VBN
in  ||| S:32646 E:32649 ||| IN
our  ||| S:32649 E:32653 ||| PRP$
laboratory  ||| S:32653 E:32664 ||| NN
to  ||| S:32664 E:32677 ||| TO
induce  ||| S:32677 E:32684 ||| VB
embryonic  ||| S:32684 E:32694 ||| JJ
SMG  ||| S:32694 E:32698 ||| NNP
morphogenesis  ||| S:32698 E:32712 ||| NN
and  ||| S:32712 E:32716 ||| CC
cell  ||| S:32716 E:32721 ||| NN
proliferation  ||| S:32721 E:32745 ||| NN
[  ||| S:32745 E:32747 ||| -LRB-
13  ||| S:32747 E:32750 ||| CD
]  ||| S:32750 E:32752 ||| -RRB-
.  ||| S:32752 E:32754 ||| .
Explants  ||| S:32754 E:32763 ||| NNP
were  ||| S:32763 E:32768 ||| VBD
collected  ||| S:32768 E:32778 ||| VBN
and  ||| S:32778 E:32782 ||| CC
evaluated  ||| S:32782 E:32792 ||| VBN
by  ||| S:32792 E:32805 ||| IN
histological  ||| S:32805 E:32818 ||| NN
and  ||| S:32818 E:32822 ||| CC
immunochemical  ||| S:32822 E:32837 ||| JJ
analyses  ||| S:32837 E:32846 ||| NNS
as  ||| S:32846 E:32849 ||| RB
described  ||| S:32849 E:32869 ||| VBN
below ||| S:32869 E:32874 ||| RB
.  ||| S:32874 E:32904 ||| .
Histology  ||| S:32904 E:32914 ||| NNP
and  ||| S:32914 E:32918 ||| CC
immunolocalization  ||| S:32918 E:32947 ||| JJ
SMGs  ||| S:32947 E:32952 ||| NN
were  ||| S:32952 E:32957 ||| VBD
fixed  ||| S:32957 E:32963 ||| VBN
in  ||| S:32963 E:32966 ||| IN
Carnoy ||| S:32966 E:32972 ||| NNP
's  ||| S:32972 E:32975 ||| POS
fixative ||| S:32975 E:32983 ||| NN
,  ||| S:32983 E:32985 ||| ,
processed ||| S:32985 E:32994 ||| VBN
,  ||| S:32994 E:33006 ||| ,
embedded  ||| S:33006 E:33015 ||| VBN
in  ||| S:33015 E:33018 ||| IN
low-melting  ||| S:33018 E:33030 ||| JJ
point  ||| S:33030 E:33036 ||| NN
paraplast ||| S:33036 E:33045 ||| NN
,  ||| S:33045 E:33047 ||| ,
and  ||| S:33047 E:33051 ||| CC
stored  ||| S:33051 E:33058 ||| VBD
for  ||| S:33058 E:33072 ||| IN
brief  ||| S:33072 E:33078 ||| JJ
periods  ||| S:33078 E:33086 ||| NNS
at  ||| S:33086 E:33089 ||| IN
4°C  ||| S:33089 E:33093 ||| CD
as  ||| S:33093 E:33096 ||| IN
previously  ||| S:33096 E:33107 ||| RB
described  ||| S:33107 E:33117 ||| VBN
[  ||| S:33117 E:33119 ||| -LRB-
13  ||| S:33119 E:33122 ||| CD
]  ||| S:33122 E:33124 ||| -RRB-
.  ||| S:33124 E:33136 ||| .
Cultured  ||| S:33136 E:33145 ||| JJ
explant  ||| S:33145 E:33153 ||| JJ
morphogenesis  ||| S:33153 E:33167 ||| NN
was  ||| S:33167 E:33171 ||| VBD
analyzed  ||| S:33171 E:33180 ||| VBN
by  ||| S:33180 E:33183 ||| IN
dissecting  ||| S:33183 E:33204 ||| JJ
microscopy  ||| S:33204 E:33215 ||| NN
and  ||| S:33215 E:33219 ||| CC
by  ||| S:33219 E:33222 ||| IN
light  ||| S:33222 E:33228 ||| JJ
microscopy  ||| S:33228 E:33239 ||| NN
of  ||| S:33239 E:33242 ||| IN
serial  ||| S:33242 E:33249 ||| JJ
sections  ||| S:33249 E:33268 ||| NNS
stained  ||| S:33268 E:33276 ||| VBN
with  ||| S:33276 E:33281 ||| IN
hematoxylin  ||| S:33281 E:33293 ||| NN
and  ||| S:33293 E:33297 ||| CC
eosin ||| S:33297 E:33302 ||| NN
.  ||| S:33302 E:33304 ||| .
A  ||| S:33304 E:33306 ||| DT
minimum  ||| S:33306 E:33314 ||| NN
of  ||| S:33314 E:33317 ||| IN
5  ||| S:33317 E:33329 ||| CD
explants  ||| S:33329 E:33338 ||| NN
per  ||| S:33338 E:33342 ||| IN
group  ||| S:33342 E:33348 ||| NN
was  ||| S:33348 E:33352 ||| VBD
evaluated  ||| S:33352 E:33362 ||| VBN
for  ||| S:33362 E:33366 ||| IN
all  ||| S:33366 E:33370 ||| DT
experimental  ||| S:33370 E:33393 ||| JJ
groups ||| S:33393 E:33399 ||| NNS
.  ||| S:33399 E:33401 ||| .
For  ||| S:33401 E:33405 ||| IN
immunochemistry ||| S:33405 E:33420 ||| NN
,  ||| S:33420 E:33422 ||| ,
the  ||| S:33422 E:33426 ||| DT
tissues  ||| S:33426 E:33434 ||| NNS
were  ||| S:33434 E:33439 ||| VBD
sectioned  ||| S:33439 E:33459 ||| VBN
at  ||| S:33459 E:33462 ||| IN
7  ||| S:33462 E:33464 ||| CD
μm ||| S:33464 E:33466 ||| NN
,  ||| S:33466 E:33468 ||| ,
placed  ||| S:33468 E:33475 ||| VBN
on  ||| S:33475 E:33478 ||| IN
cleaned ||| S:33478 E:33485 ||| NN
,  ||| S:33485 E:33487 ||| ,
gelatin-coated  ||| S:33487 E:33502 ||| JJ
slides  ||| S:33502 E:33509 ||| NNS
at  ||| S:33509 E:33512 ||| IN
37°C  ||| S:33512 E:33527 ||| CD
for  ||| S:33527 E:33531 ||| IN
3  ||| S:33531 E:33533 ||| CD
hr ||| S:33533 E:33535 ||| NN
,  ||| S:33535 E:33537 ||| ,
and  ||| S:33537 E:33541 ||| CC
immediately  ||| S:33541 E:33553 ||| RB
immunostained  ||| S:33553 E:33567 ||| VBN
as  ||| S:33567 E:33570 ||| IN
previously  ||| S:33570 E:33591 ||| RB
described  ||| S:33591 E:33601 ||| VBN
[  ||| S:33601 E:33603 ||| -LRB-
9  ||| S:33603 E:33605 ||| CD
13  ||| S:33605 E:33608 ||| CD
]  ||| S:33608 E:33610 ||| -RRB-
.  ||| S:33610 E:33612 ||| .
The  ||| S:33612 E:33616 ||| DT
sections  ||| S:33616 E:33625 ||| NNS
were  ||| S:33625 E:33630 ||| VBD
incubated  ||| S:33630 E:33640 ||| VBN
in  ||| S:33640 E:33653 ||| IN
polyclonal  ||| S:33653 E:33664 ||| FW
goat  ||| S:33664 E:33669 ||| FW
anti-NF-κB  ||| S:33669 E:33680 ||| FW
p65 ||| S:33680 E:33683 ||| FW
/ ||| S:33683 E:33684 ||| FW
RelA  ||| S:33684 E:33689 ||| FW
antibody  ||| S:33689 E:33698 ||| FW
( ||| S:33698 E:33699 ||| -LRB-
C-20 ||| S:33699 E:33703 ||| NNP
) ||| S:33703 E:33704 ||| -RRB-
( ||| S:33704 E:33705 ||| -LRB-
Santa  ||| S:33705 E:33721 ||| NNP
Cruz  ||| S:33721 E:33726 ||| NNP
Biotechnology ||| S:33726 E:33739 ||| NNP
,  ||| S:33739 E:33741 ||| ,
Santa  ||| S:33741 E:33747 ||| NNP
Cruz ||| S:33747 E:33751 ||| NNP
,  ||| S:33751 E:33753 ||| ,
CA ||| S:33753 E:33755 ||| NNP
) ||| S:33755 E:33756 ||| -RRB-
;  ||| S:33756 E:33758 ||| :
this  ||| S:33758 E:33763 ||| DT
antibody  ||| S:33763 E:33772 ||| NN
has  ||| S:33772 E:33786 ||| VBZ
been  ||| S:33786 E:33791 ||| VBN
shown  ||| S:33791 E:33797 ||| VBN
to  ||| S:33797 E:33800 ||| TO
cross-react  ||| S:33800 E:33812 ||| JJ
with  ||| S:33812 E:33817 ||| IN
mouse  ||| S:33817 E:33823 ||| CD
p65 ||| S:33823 E:33826 ||| CD
;  ||| S:33826 E:33828 ||| :
it  ||| S:33828 E:33831 ||| PRP
is  ||| S:33831 E:33834 ||| VBZ
not  ||| S:33834 E:33848 ||| RB
cross-reactive  ||| S:33848 E:33863 ||| JJ
with  ||| S:33863 E:33868 ||| IN
RelB  ||| S:33868 E:33873 ||| NNP
p68  ||| S:33873 E:33877 ||| NNP
or  ||| S:33877 E:33880 ||| CC
c-Rel  ||| S:33880 E:33886 ||| JJ
p75 ||| S:33886 E:33889 ||| NN
.  ||| S:33889 E:33891 ||| .
We  ||| S:33891 E:33894 ||| PRP
confirmed  ||| S:33894 E:33914 ||| VBD
the  ||| S:33914 E:33918 ||| DT
spatial  ||| S:33918 E:33926 ||| JJ
distribution  ||| S:33926 E:33939 ||| NN
of  ||| S:33939 E:33942 ||| IN
NF-κB  ||| S:33942 E:33948 ||| JJ
using  ||| S:33948 E:33954 ||| VBG
a  ||| S:33954 E:33956 ||| DT
polyclonal  ||| S:33956 E:33967 ||| FW
goat  ||| S:33967 E:33982 ||| FW
anti-NF-κB  ||| S:33982 E:33993 ||| FW
p50  ||| S:33993 E:33997 ||| FW
antibody  ||| S:33997 E:34006 ||| FW
( ||| S:34006 E:34007 ||| -LRB-
C-19 ||| S:34007 E:34011 ||| NNP
)  ||| S:34011 E:34013 ||| -RRB-
( ||| S:34013 E:34014 ||| -LRB-
Santa  ||| S:34014 E:34020 ||| NNP
Cruz  ||| S:34020 E:34035 ||| NNP
Biotechnology ||| S:34035 E:34048 ||| NNP
) ||| S:34048 E:34049 ||| -RRB-
;  ||| S:34049 E:34051 ||| :
this  ||| S:34051 E:34056 ||| DT
antibody  ||| S:34056 E:34065 ||| NN
has  ||| S:34065 E:34069 ||| VBZ
been  ||| S:34069 E:34074 ||| VBN
shown  ||| S:34074 E:34080 ||| VBN
to  ||| S:34080 E:34083 ||| TO
react  ||| S:34083 E:34099 ||| VB
with  ||| S:34099 E:34104 ||| IN
mouse  ||| S:34104 E:34110 ||| NN
p50  ||| S:34110 E:34114 ||| NN
or  ||| S:34114 E:34117 ||| CC
p105 ||| S:34117 E:34121 ||| NNP
;  ||| S:34121 E:34123 ||| :
it  ||| S:34123 E:34126 ||| PRP
is  ||| S:34126 E:34129 ||| VBZ
not  ||| S:34129 E:34133 ||| RB
cross-reactive  ||| S:34133 E:34148 ||| JJ
with  ||| S:34148 E:34163 ||| IN
NF-κB  ||| S:34163 E:34169 ||| NNP
p52 ||| S:34169 E:34172 ||| NNP
,  ||| S:34172 E:34174 ||| ,
p65 ||| S:34174 E:34177 ||| NNP
/ ||| S:34177 E:34178 ||| NNP
RelA  ||| S:34178 E:34183 ||| NNP
or  ||| S:34183 E:34186 ||| CC
p100 ||| S:34186 E:34190 ||| NNP
.  ||| S:34190 E:34192 ||| .
Controls  ||| S:34192 E:34201 ||| NNS
consisted  ||| S:34201 E:34211 ||| VBD
of  ||| S:34211 E:34224 ||| IN
sections  ||| S:34224 E:34233 ||| JJ
incubated  ||| S:34233 E:34243 ||| NN
with  ||| S:34243 E:34248 ||| IN
preimmune  ||| S:34248 E:34258 ||| JJ
serum  ||| S:34258 E:34264 ||| NN
or  ||| S:34264 E:34267 ||| CC
in  ||| S:34267 E:34270 ||| IN
the  ||| S:34270 E:34274 ||| DT
absence  ||| S:34274 E:34292 ||| NN
of  ||| S:34292 E:34295 ||| IN
primary  ||| S:34295 E:34303 ||| JJ
antibody ||| S:34303 E:34311 ||| NN
;  ||| S:34311 E:34313 ||| :
controls  ||| S:34313 E:34322 ||| NNS
were  ||| S:34322 E:34327 ||| VBD
routinely  ||| S:34327 E:34337 ||| RB
negative ||| S:34337 E:34345 ||| JJ
.  ||| S:34345 E:34357 ||| .
The  ||| S:34357 E:34361 ||| DT
spatial  ||| S:34361 E:34369 ||| JJ
distribution  ||| S:34369 E:34382 ||| NN
of  ||| S:34382 E:34385 ||| IN
NF-κB  ||| S:34385 E:34391 ||| NNP
p65  ||| S:34391 E:34395 ||| NNP
was  ||| S:34395 E:34399 ||| VBD
identical  ||| S:34399 E:34409 ||| JJ
to  ||| S:34409 E:34422 ||| TO
that  ||| S:34422 E:34427 ||| DT
of  ||| S:34427 E:34430 ||| IN
NF-κB  ||| S:34430 E:34436 ||| JJ
p50 ||| S:34436 E:34439 ||| NN
.  ||| S:34439 E:34441 ||| .
Therefore ||| S:34441 E:34450 ||| RB
,  ||| S:34450 E:34452 ||| ,
we  ||| S:34452 E:34455 ||| PRP
only  ||| S:34455 E:34460 ||| RB
show  ||| S:34460 E:34465 ||| VB
the  ||| S:34465 E:34469 ||| DT
results  ||| S:34469 E:34477 ||| NNS
of  ||| S:34477 E:34490 ||| IN
the  ||| S:34490 E:34494 ||| DT
anti-NF-κB  ||| S:34494 E:34505 ||| JJ
p65  ||| S:34505 E:34509 ||| CD
antibody  ||| S:34509 E:34518 ||| NN
experiments ||| S:34518 E:34529 ||| NNS
.  ||| S:34529 E:34559 ||| .
Quantitation  ||| S:34559 E:34572 ||| NNP
of  ||| S:34572 E:34575 ||| IN
activated  ||| S:34575 E:34585 ||| JJ
p53  ||| S:34585 E:34599 ||| NN
To  ||| S:34599 E:34602 ||| TO
quantitate  ||| S:34602 E:34613 ||| VB
differences  ||| S:34613 E:34625 ||| NNS
in  ||| S:34625 E:34639 ||| IN
activated  ||| S:34639 E:34649 ||| NNS
( ||| S:34649 E:34650 ||| -LRB-
phosphorylated ||| S:34650 E:34664 ||| LS
)  ||| S:34664 E:34666 ||| -RRB-
p53  ||| S:34666 E:34680 ||| NN
protein ||| S:34680 E:34687 ||| NN
,  ||| S:34687 E:34689 ||| ,
3  ||| S:34689 E:34691 ||| CD
SN50  ||| S:34691 E:34696 ||| CD
and  ||| S:34696 E:34700 ||| CC
control  ||| S:34700 E:34708 ||| NN
E15  ||| S:34708 E:34712 ||| CD
+  ||| S:34712 E:34714 ||| CD
2  ||| S:34714 E:34716 ||| CD
explants  ||| S:34716 E:34725 ||| NNS
were  ||| S:34725 E:34740 ||| VBD
sectioned ||| S:34740 E:34749 ||| CD
,  ||| S:34749 E:34751 ||| ,
preincubated  ||| S:34751 E:34764 ||| VBG
with  ||| S:34764 E:34769 ||| IN
unlabeled  ||| S:34769 E:34779 ||| JJ
goat-anti  ||| S:34779 E:34789 ||| JJ
mouse  ||| S:34789 E:34805 ||| NN
IgG  ||| S:34805 E:34809 ||| NN
as  ||| S:34809 E:34812 ||| IN
previously  ||| S:34812 E:34823 ||| RB
described  ||| S:34823 E:34833 ||| VBN
[  ||| S:34833 E:34835 ||| -LRB-
9  ||| S:34835 E:34837 ||| CD
]  ||| S:34837 E:34839 ||| -RRB-
and  ||| S:34839 E:34843 ||| CC
sequentially  ||| S:34843 E:34866 ||| JJ
incubated  ||| S:34866 E:34876 ||| NN
with  ||| S:34876 E:34881 ||| IN
a  ||| S:34881 E:34883 ||| DT
monoclonal  ||| S:34883 E:34894 ||| JJ
anti-phosphorylated  ||| S:34894 E:34914 ||| JJ
p53  ||| S:34914 E:34928 ||| NN
( ||| S:34928 E:34929 ||| -LRB-
Ser15 ||| S:34929 E:34934 ||| NNP
)  ||| S:34934 E:34936 ||| -RRB-
antibody  ||| S:34936 E:34945 ||| NN
( ||| S:34945 E:34946 ||| -LRB-
Cell  ||| S:34946 E:34951 ||| NNP
Signaling  ||| S:34951 E:34961 ||| NNP
Technology ||| S:34961 E:34971 ||| NNP
,  ||| S:34971 E:34973 ||| ,
Beverly ||| S:34973 E:34980 ||| NNP
,  ||| S:34980 E:34992 ||| ,
MA ||| S:34992 E:34994 ||| NNP
) ||| S:34994 E:34995 ||| -RRB-
,  ||| S:34995 E:34997 ||| ,
biotin-labeled  ||| S:34997 E:35012 ||| JJ
goat  ||| S:35012 E:35017 ||| JJ
anti-mouse  ||| S:35017 E:35028 ||| JJ
IgG ||| S:35028 E:35031 ||| NN
,  ||| S:35031 E:35033 ||| ,
and  ||| S:35033 E:35037 ||| CC
HRP-labeled  ||| S:35037 E:35059 ||| NNP
SA  ||| S:35059 E:35062 ||| NNP
( ||| S:35062 E:35063 ||| -LRB-
Zymed  ||| S:35063 E:35069 ||| NNP
Laboratories ||| S:35069 E:35081 ||| NNPS
,  ||| S:35081 E:35083 ||| ,
South  ||| S:35083 E:35089 ||| NNP
San  ||| S:35089 E:35093 ||| NNP
Francisco ||| S:35093 E:35102 ||| NNP
,  ||| S:35102 E:35104 ||| ,
CA ||| S:35104 E:35106 ||| NNP
) ||| S:35106 E:35107 ||| -RRB-
,  ||| S:35107 E:35109 ||| ,
and  ||| S:35109 E:35123 ||| CC
counterstained  ||| S:35123 E:35138 ||| NN
with  ||| S:35138 E:35143 ||| IN
hematoxylin ||| S:35143 E:35154 ||| NN
.  ||| S:35154 E:35156 ||| .
Controls  ||| S:35156 E:35165 ||| NNS
consisted  ||| S:35165 E:35175 ||| VBD
of  ||| S:35175 E:35188 ||| IN
preimmune  ||| S:35188 E:35198 ||| JJ
serum  ||| S:35198 E:35204 ||| NN
or  ||| S:35204 E:35207 ||| CC
PBS  ||| S:35207 E:35211 ||| NNP
alone ||| S:35211 E:35216 ||| RB
.  ||| S:35216 E:35218 ||| .
In  ||| S:35218 E:35221 ||| IN
this  ||| S:35221 E:35226 ||| DT
set  ||| S:35226 E:35230 ||| NN
of  ||| S:35230 E:35233 ||| IN
experiments ||| S:35233 E:35244 ||| NNS
,  ||| S:35244 E:35256 ||| ,
the  ||| S:35256 E:35260 ||| DT
cytoplasm  ||| S:35260 E:35270 ||| NN
appears  ||| S:35270 E:35278 ||| VBZ
blue  ||| S:35278 E:35283 ||| JJ
and  ||| S:35283 E:35298 ||| CC
activated  ||| S:35298 E:35308 ||| CD
p53-positive  ||| S:35308 E:35321 ||| CD
cells  ||| S:35321 E:35327 ||| NNS
appear  ||| S:35327 E:35344 ||| VBP
dark  ||| S:35344 E:35349 ||| JJ
brown ||| S:35349 E:35354 ||| NN
.  ||| S:35354 E:35356 ||| .
Three  ||| S:35356 E:35362 ||| CD
sections  ||| S:35362 E:35371 ||| NNS
per  ||| S:35371 E:35375 ||| IN
group  ||| S:35375 E:35381 ||| NN
were  ||| S:35381 E:35386 ||| VBD
selected  ||| S:35386 E:35395 ||| VBN
and  ||| S:35395 E:35399 ||| CC
3  ||| S:35399 E:35411 ||| CD
areas  ||| S:35411 E:35417 ||| NNS
per  ||| S:35417 E:35421 ||| IN
section  ||| S:35421 E:35429 ||| NN
was  ||| S:35429 E:35433 ||| VBD
photographed  ||| S:35433 E:35446 ||| VBN
at  ||| S:35446 E:35449 ||| IN
200×.  ||| S:35449 E:35455 ||| CD
p53-positive  ||| S:35455 E:35478 ||| CD
epithelial  ||| S:35478 E:35489 ||| CD
cells ||| S:35489 E:35494 ||| NNS
/ ||| S:35494 E:35495 ||| VBP
total  ||| S:35495 E:35501 ||| JJ
epithelial  ||| S:35501 E:35512 ||| JJ
cells  ||| S:35512 E:35518 ||| NNS
were  ||| S:35518 E:35523 ||| VBD
determined  ||| S:35523 E:35544 ||| VBN
per  ||| S:35544 E:35548 ||| IN
area  ||| S:35548 E:35553 ||| NN
and  ||| S:35553 E:35557 ||| CC
the  ||| S:35557 E:35561 ||| DT
mean  ||| S:35561 E:35566 ||| JJ
ratios  ||| S:35566 E:35573 ||| NNS
per  ||| S:35573 E:35577 ||| IN
section  ||| S:35577 E:35585 ||| NN
and  ||| S:35585 E:35589 ||| CC
per  ||| S:35589 E:35593 ||| IN
group  ||| S:35593 E:35609 ||| NN
were  ||| S:35609 E:35614 ||| VBD
determined ||| S:35614 E:35624 ||| VBN
.  ||| S:35624 E:35626 ||| .
Statistical  ||| S:35626 E:35638 ||| JJ
comparisons  ||| S:35638 E:35650 ||| NNS
were  ||| S:35650 E:35655 ||| VBD
made  ||| S:35655 E:35670 ||| VBN
between  ||| S:35670 E:35678 ||| IN
CONT  ||| S:35678 E:35683 ||| NNP
and  ||| S:35683 E:35687 ||| CC
SN50-treated  ||| S:35687 E:35700 ||| CD
E15  ||| S:35700 E:35704 ||| CD
+  ||| S:35704 E:35706 ||| CD
2  ||| S:35706 E:35708 ||| CD
explants  ||| S:35708 E:35717 ||| NNS
as  ||| S:35717 E:35730 ||| RB
described  ||| S:35730 E:35740 ||| VBN
below ||| S:35740 E:35745 ||| RB
.  ||| S:35745 E:35775 ||| .
Cell  ||| S:35775 E:35780 ||| NN
proliferation  ||| S:35780 E:35794 ||| NN
assay  ||| S:35794 E:35810 ||| VBD
E15  ||| S:35810 E:35814 ||| CD
+  ||| S:35814 E:35816 ||| CD
2  ||| S:35816 E:35818 ||| CD
CONT  ||| S:35818 E:35823 ||| NNP
or  ||| S:35823 E:35826 ||| CC
SN50-treated  ||| S:35826 E:35839 ||| CD
explants  ||| S:35839 E:35848 ||| NNS
were  ||| S:35848 E:35853 ||| VBD
sectioned ||| S:35853 E:35862 ||| CD
,  ||| S:35862 E:35874 ||| ,
incubated  ||| S:35874 E:35884 ||| VBG
with  ||| S:35884 E:35889 ||| IN
anti-PCNA  ||| S:35889 E:35899 ||| JJ
using  ||| S:35899 E:35905 ||| VBG
the  ||| S:35905 E:35909 ||| DT
Zymed  ||| S:35909 E:35915 ||| NNP
mouse  ||| S:35915 E:35921 ||| FW
PCNA  ||| S:35921 E:35926 ||| FW
kit  ||| S:35926 E:35940 ||| FW
( ||| S:35940 E:35941 ||| -LRB-
South  ||| S:35941 E:35947 ||| NNP
San  ||| S:35947 E:35951 ||| NNP
Francisco ||| S:35951 E:35960 ||| NNP
,  ||| S:35960 E:35962 ||| ,
CA ||| S:35962 E:35964 ||| NNP
) ||| S:35964 E:35965 ||| -RRB-
,  ||| S:35965 E:35967 ||| ,
and  ||| S:35967 E:35971 ||| CC
counterstained  ||| S:35971 E:35986 ||| NN
with  ||| S:35986 E:36001 ||| IN
hematoxylin  ||| S:36001 E:36013 ||| NN
as  ||| S:36013 E:36016 ||| IN
previously  ||| S:36016 E:36027 ||| RB
described  ||| S:36027 E:36037 ||| VBN
[  ||| S:36037 E:36039 ||| -LRB-
13  ||| S:36039 E:36042 ||| CD
]  ||| S:36042 E:36044 ||| -RRB-
.  ||| S:36044 E:36046 ||| .
In  ||| S:36046 E:36049 ||| IN
this  ||| S:36049 E:36054 ||| DT
set  ||| S:36054 E:36068 ||| NN
of  ||| S:36068 E:36071 ||| IN
experiments ||| S:36071 E:36082 ||| NNS
,  ||| S:36082 E:36084 ||| ,
the  ||| S:36084 E:36088 ||| DT
cytoplasm  ||| S:36088 E:36098 ||| NN
appears  ||| S:36098 E:36106 ||| VBZ
blue  ||| S:36106 E:36111 ||| JJ
and  ||| S:36111 E:36125 ||| CC
PCNA-positive  ||| S:36125 E:36139 ||| JJ
cells  ||| S:36139 E:36145 ||| NNS
appear  ||| S:36145 E:36152 ||| VBP
dark  ||| S:36152 E:36157 ||| JJ
brown ||| S:36157 E:36162 ||| NN
.  ||| S:36162 E:36164 ||| .
Quantitation  ||| S:36164 E:36177 ||| NNP
of  ||| S:36177 E:36190 ||| IN
cell  ||| S:36190 E:36195 ||| NN
proliferation  ||| S:36195 E:36209 ||| NN
was  ||| S:36209 E:36213 ||| VBD
conducted  ||| S:36213 E:36223 ||| VBN
as  ||| S:36223 E:36226 ||| RB
described  ||| S:36226 E:36236 ||| VBN
above  ||| S:36236 E:36242 ||| IN
for  ||| S:36242 E:36256 ||| IN
p53 ||| S:36256 E:36259 ||| NN
.  ||| S:36259 E:36261 ||| .
Cell  ||| S:36261 E:36266 ||| NN
proliferation  ||| S:36266 E:36280 ||| NN
is  ||| S:36280 E:36283 ||| VBZ
presented  ||| S:36283 E:36293 ||| VBN
as  ||| S:36293 E:36296 ||| IN
the  ||| S:36296 E:36300 ||| DT
ratio  ||| S:36300 E:36306 ||| NN
of  ||| S:36306 E:36319 ||| IN
PCNA-positive  ||| S:36319 E:36333 ||| JJ
epithelial  ||| S:36333 E:36344 ||| JJ
cells ||| S:36344 E:36349 ||| NNS
/ ||| S:36349 E:36350 ||| VBP
total  ||| S:36350 E:36356 ||| JJ
epithelial  ||| S:36356 E:36367 ||| JJ
cells ||| S:36367 E:36372 ||| NNS
.  ||| S:36372 E:36384 ||| .
Mean  ||| S:36384 E:36389 ||| JJ
ratios  ||| S:36389 E:36396 ||| NNS
per  ||| S:36396 E:36400 ||| IN
section  ||| S:36400 E:36408 ||| NN
and  ||| S:36408 E:36412 ||| CC
mean  ||| S:36412 E:36417 ||| VB
ratios  ||| S:36417 E:36424 ||| NNS
per  ||| S:36424 E:36428 ||| IN
group  ||| S:36428 E:36434 ||| NN
were  ||| S:36434 E:36449 ||| VBD
determined ||| S:36449 E:36459 ||| VBN
.  ||| S:36459 E:36461 ||| .
Statistical  ||| S:36461 E:36473 ||| JJ
comparisons  ||| S:36473 E:36485 ||| NNS
were  ||| S:36485 E:36490 ||| VBD
made  ||| S:36490 E:36495 ||| VBN
between  ||| S:36495 E:36513 ||| IN
CONT  ||| S:36513 E:36518 ||| NNP
and  ||| S:36518 E:36522 ||| CC
SN50-treated  ||| S:36522 E:36535 ||| CD
E15  ||| S:36535 E:36539 ||| CD
+  ||| S:36539 E:36541 ||| CD
2  ||| S:36541 E:36543 ||| CD
explants  ||| S:36543 E:36552 ||| NNS
as  ||| S:36552 E:36555 ||| RB
described  ||| S:36555 E:36575 ||| VBN
below ||| S:36575 E:36580 ||| RB
.  ||| S:36580 E:36610 ||| .
Apoptosis  ||| S:36610 E:36620 ||| JJ
assay  ||| S:36620 E:36636 ||| JJ
Apoptotic  ||| S:36636 E:36646 ||| JJ
cells  ||| S:36646 E:36652 ||| NNS
were  ||| S:36652 E:36657 ||| VBD
detected  ||| S:36657 E:36666 ||| VBN
using  ||| S:36666 E:36672 ||| VBG
a  ||| S:36672 E:36674 ||| DT
monoclonal  ||| S:36674 E:36695 ||| JJ
antibody  ||| S:36695 E:36704 ||| NN
to  ||| S:36704 E:36707 ||| TO
single-stranded  ||| S:36707 E:36723 ||| NNP
DNA  ||| S:36723 E:36727 ||| NNP
( ||| S:36727 E:36728 ||| -LRB-
ssDNA ||| S:36728 E:36733 ||| NNP
)  ||| S:36733 E:36735 ||| -RRB-
( ||| S:36735 E:36736 ||| -LRB-
Mab  ||| S:36736 E:36740 ||| NNP
F7-26 ||| S:36740 E:36745 ||| NNP
)  ||| S:36745 E:36757 ||| -RRB-
according  ||| S:36757 E:36767 ||| VBG
to  ||| S:36767 E:36770 ||| TO
the  ||| S:36770 E:36774 ||| DT
method  ||| S:36774 E:36781 ||| NN
of  ||| S:36781 E:36784 ||| IN
Apostain ||| S:36784 E:36792 ||| NNP
,  ||| S:36792 E:36794 ||| ,
Inc ||| S:36794 E:36797 ||| NNP
.  ||| S:36797 E:36799 ||| .
( ||| S:36799 E:36800 ||| -LRB-
Miami ||| S:36800 E:36805 ||| NNP
,  ||| S:36805 E:36807 ||| ,
FL ||| S:36807 E:36809 ||| NNP
)  ||| S:36809 E:36811 ||| -RRB-
[  ||| S:36811 E:36823 ||| -LRB-
13  ||| S:36823 E:36826 ||| CD
]  ||| S:36826 E:36828 ||| -RRB-
.  ||| S:36828 E:36830 ||| .
Selective  ||| S:36830 E:36840 ||| JJ
binding  ||| S:36840 E:36848 ||| NN
of  ||| S:36848 E:36851 ||| IN
anti-ssDNA  ||| S:36851 E:36862 ||| JJ
monoclonal  ||| S:36862 E:36883 ||| JJ
antibody  ||| S:36883 E:36892 ||| NN
F7-26  ||| S:36892 E:36898 ||| NN
to  ||| S:36898 E:36912 ||| TO
apoptotic  ||| S:36912 E:36922 ||| VB
nuclei  ||| S:36922 E:36929 ||| NN
reflects  ||| S:36929 E:36938 ||| VBZ
decreased  ||| S:36938 E:36958 ||| VBN
stability  ||| S:36958 E:36968 ||| NN
of  ||| S:36968 E:36971 ||| IN
DNA  ||| S:36971 E:36975 ||| NN
to  ||| S:36975 E:36978 ||| TO
thermal  ||| S:36978 E:36986 ||| JJ
denaturation ||| S:36986 E:36998 ||| NN
.  ||| S:36998 E:37000 ||| .
Four  ||| S:37000 E:37005 ||| CD
positive  ||| S:37005 E:37024 ||| JJ
and  ||| S:37024 E:37028 ||| CC
negative  ||| S:37028 E:37037 ||| JJ
controls  ||| S:37037 E:37046 ||| NNS
were  ||| S:37046 E:37051 ||| VBD
conducted ||| S:37051 E:37060 ||| VBN
.  ||| S:37060 E:37073 ||| .
Negative  ||| S:37073 E:37082 ||| JJ
controls ||| S:37082 E:37090 ||| NNS
:  ||| S:37090 E:37092 ||| :
( ||| S:37092 E:37093 ||| -LRB-
1 ||| S:37093 E:37094 ||| LS
)  ||| S:37094 E:37096 ||| -RRB-
Tissue  ||| S:37096 E:37113 ||| NNP
sections  ||| S:37113 E:37122 ||| NNS
were  ||| S:37122 E:37127 ||| VBD
heated  ||| S:37127 E:37134 ||| VBN
and  ||| S:37134 E:37138 ||| CC
treated  ||| S:37138 E:37146 ||| VBN
with  ||| S:37146 E:37151 ||| IN
S1  ||| S:37151 E:37154 ||| CD
nuclease  ||| S:37154 E:37173 ||| NNS
( ||| S:37173 E:37174 ||| -LRB-
Sigma ||| S:37174 E:37179 ||| NNP
) ||| S:37179 E:37180 ||| -RRB-
;  ||| S:37180 E:37182 ||| :
S1  ||| S:37182 E:37185 ||| CD
nuclease  ||| S:37185 E:37194 ||| NN
eliminates  ||| S:37194 E:37205 ||| VBZ
staining  ||| S:37205 E:37214 ||| VBN
of  ||| S:37214 E:37217 ||| IN
apoptotic  ||| S:37217 E:37237 ||| JJ
cells ||| S:37237 E:37242 ||| NNS
,  ||| S:37242 E:37244 ||| ,
thus  ||| S:37244 E:37249 ||| RB
demonstrating  ||| S:37249 E:37263 ||| VBG
that  ||| S:37263 E:37268 ||| IN
Mab  ||| S:37268 E:37272 ||| NNP
F7-26  ||| S:37272 E:37278 ||| NNP
binds  ||| S:37278 E:37294 ||| VBD
specifically  ||| S:37294 E:37307 ||| RB
to  ||| S:37307 E:37310 ||| TO
ssDNA.  ||| S:37310 E:37317 ||| CD
( ||| S:37317 E:37318 ||| -LRB-
2 ||| S:37318 E:37319 ||| LS
)  ||| S:37319 E:37321 ||| -RRB-
Sections  ||| S:37321 E:37330 ||| NNP
were  ||| S:37330 E:37335 ||| VBD
pretreated  ||| S:37335 E:37346 ||| VBN
in  ||| S:37346 E:37359 ||| IN
PBS  ||| S:37359 E:37363 ||| NNP
containing  ||| S:37363 E:37374 ||| VBG
lysine-rich  ||| S:37374 E:37386 ||| JJ
histone  ||| S:37386 E:37394 ||| NNS
( ||| S:37394 E:37395 ||| -LRB-
Sigma ||| S:37395 E:37400 ||| NNP
)  ||| S:37400 E:37402 ||| -RRB-
prior  ||| S:37402 E:37408 ||| RB
to  ||| S:37408 E:37421 ||| TO
heating  ||| S:37421 E:37429 ||| NN
and  ||| S:37429 E:37433 ||| CC
immunostaining ||| S:37433 E:37447 ||| NNS
;  ||| S:37447 E:37449 ||| :
reconstitution  ||| S:37449 E:37464 ||| NN
with  ||| S:37464 E:37469 ||| IN
histone  ||| S:37469 E:37487 ||| JJ
restores  ||| S:37487 E:37496 ||| JJ
DNA  ||| S:37496 E:37500 ||| NN
stability  ||| S:37500 E:37510 ||| NN
in  ||| S:37510 E:37513 ||| IN
apoptotic  ||| S:37513 E:37523 ||| JJ
nuclei ||| S:37523 E:37529 ||| NN
,  ||| S:37529 E:37531 ||| ,
thus  ||| S:37531 E:37546 ||| RB
preventing  ||| S:37546 E:37557 ||| VBG
DNA  ||| S:37557 E:37561 ||| NN
denaturation  ||| S:37561 E:37574 ||| NNS
and  ||| S:37574 E:37578 ||| CC
eliminating  ||| S:37578 E:37590 ||| VBG
Mab  ||| S:37590 E:37594 ||| JJ
staining  ||| S:37594 E:37613 ||| NN
of  ||| S:37613 E:37616 ||| IN
apoptotic  ||| S:37616 E:37626 ||| JJ
cells ||| S:37626 E:37631 ||| NNS
.  ||| S:37631 E:37644 ||| .
Positive  ||| S:37644 E:37653 ||| JJ
controls ||| S:37653 E:37661 ||| NNS
:  ||| S:37661 E:37663 ||| :
( ||| S:37663 E:37664 ||| -LRB-
1 ||| S:37664 E:37665 ||| LS
)  ||| S:37665 E:37667 ||| -RRB-
Sections  ||| S:37667 E:37686 ||| NNP
were  ||| S:37686 E:37691 ||| VBD
heated  ||| S:37691 E:37698 ||| VBN
in  ||| S:37698 E:37701 ||| IN
water  ||| S:37701 E:37707 ||| NN
and  ||| S:37707 E:37711 ||| CC
treated  ||| S:37711 E:37719 ||| VBN
with  ||| S:37719 E:37724 ||| IN
Mab ||| S:37724 E:37727 ||| NNP
;  ||| S:37727 E:37729 ||| :
bright  ||| S:37729 E:37746 ||| JJ
staining  ||| S:37746 E:37755 ||| NN
of  ||| S:37755 E:37758 ||| IN
all  ||| S:37758 E:37762 ||| DT
non-apoptotic  ||| S:37762 E:37776 ||| JJ
nuclei  ||| S:37776 E:37783 ||| NN
with  ||| S:37783 E:37788 ||| IN
low  ||| S:37788 E:37792 ||| JJ
apoptotic  ||| S:37792 E:37812 ||| JJ
indexes  ||| S:37812 E:37820 ||| NNS
demonstrates  ||| S:37820 E:37833 ||| VBZ
that  ||| S:37833 E:37838 ||| IN
the  ||| S:37838 E:37842 ||| DT
procedure  ||| S:37842 E:37852 ||| NN
is  ||| S:37852 E:37855 ||| VBZ
adequate  ||| S:37855 E:37864 ||| JJ
to  ||| S:37864 E:37877 ||| TO
detect  ||| S:37877 E:37884 ||| VB
ssDNA.  ||| S:37884 E:37891 ||| NNP
( ||| S:37891 E:37892 ||| -LRB-
2 ||| S:37892 E:37893 ||| LS
)  ||| S:37893 E:37895 ||| -RRB-
Sections  ||| S:37895 E:37904 ||| NNP
were  ||| S:37904 E:37909 ||| VBD
pretreated  ||| S:37909 E:37920 ||| VBN
with  ||| S:37920 E:37935 ||| IN
proteinase  ||| S:37935 E:37946 ||| JJ
K  ||| S:37946 E:37948 ||| NN
before  ||| S:37948 E:37955 ||| IN
heating ||| S:37955 E:37962 ||| NN
;  ||| S:37962 E:37964 ||| :
intensive  ||| S:37964 E:37974 ||| JJ
staining  ||| S:37974 E:37983 ||| NN
of  ||| S:37983 E:37996 ||| IN
non-apoptotic  ||| S:37996 E:38010 ||| JJ
nuclei  ||| S:38010 E:38017 ||| NN
demonstrates  ||| S:38017 E:38030 ||| VBZ
that  ||| S:38030 E:38035 ||| IN
the  ||| S:38035 E:38039 ||| DT
procedure  ||| S:38039 E:38059 ||| NN
detects  ||| S:38059 E:38067 ||| NNS
decreased  ||| S:38067 E:38077 ||| VBD
DNA  ||| S:38077 E:38081 ||| NNP
stability  ||| S:38081 E:38091 ||| NN
induced  ||| S:38091 E:38099 ||| NN
by  ||| S:38099 E:38102 ||| IN
the  ||| S:38102 E:38106 ||| DT
digestion  ||| S:38106 E:38126 ||| NN
of  ||| S:38126 E:38129 ||| IN
nuclear  ||| S:38129 E:38137 ||| JJ
proteins ||| S:38137 E:38145 ||| NNS
.  ||| S:38145 E:38147 ||| .
Mab  ||| S:38147 E:38151 ||| NNP
F7-26  ||| S:38151 E:38157 ||| NNP
was  ||| S:38157 E:38161 ||| VBD
purchased  ||| S:38161 E:38171 ||| VBN
from  ||| S:38171 E:38186 ||| IN
Apostain ||| S:38186 E:38194 ||| NNP
,  ||| S:38194 E:38196 ||| ,
Inc ||| S:38196 E:38199 ||| NNP
.  ||| S:38199 E:38211 ||| .
Apoptotic  ||| S:38211 E:38221 ||| JJ
nuclei  ||| S:38221 E:38228 ||| NNS
appear  ||| S:38228 E:38235 ||| VBP
as  ||| S:38235 E:38238 ||| RB
dark  ||| S:38238 E:38243 ||| JJ
brown ||| S:38243 E:38248 ||| NN
.  ||| S:38248 E:38250 ||| .
Since  ||| S:38250 E:38256 ||| IN
the  ||| S:38256 E:38270 ||| DT
sections  ||| S:38270 E:38279 ||| NNS
were  ||| S:38279 E:38284 ||| VBD
not  ||| S:38284 E:38288 ||| RB
counterstained  ||| S:38288 E:38303 ||| VBN
with  ||| S:38303 E:38308 ||| IN
hematoxylin  ||| S:38308 E:38320 ||| NN
in  ||| S:38320 E:38323 ||| IN
this  ||| S:38323 E:38338 ||| DT
set  ||| S:38338 E:38342 ||| NN
of  ||| S:38342 E:38345 ||| IN
experiments ||| S:38345 E:38356 ||| NNS
,  ||| S:38356 E:38358 ||| ,
epithelial  ||| S:38358 E:38369 ||| JJ
cell  ||| S:38369 E:38374 ||| NN
cytoplasm  ||| S:38374 E:38384 ||| NN
appears  ||| S:38384 E:38392 ||| VBZ
as  ||| S:38392 E:38405 ||| RB
light  ||| S:38405 E:38411 ||| JJ
brown ||| S:38411 E:38416 ||| NN
.  ||| S:38416 E:38418 ||| .
Only  ||| S:38418 E:38423 ||| RB
apoptotic  ||| S:38423 E:38433 ||| JJ
( ||| S:38433 E:38434 ||| -LRB-
variously  ||| S:38434 E:38444 ||| RB
intense  ||| S:38444 E:38452 ||| JJ
dark  ||| S:38452 E:38467 ||| JJ
brown ||| S:38467 E:38472 ||| NN
)  ||| S:38472 E:38474 ||| -RRB-
nuclei  ||| S:38474 E:38481 ||| NN
were  ||| S:38481 E:38486 ||| VBD
counted  ||| S:38486 E:38494 ||| VBN
in  ||| S:38494 E:38497 ||| IN
control  ||| S:38497 E:38505 ||| NN
and  ||| S:38505 E:38509 ||| CC
SN50-treated  ||| S:38509 E:38532 ||| CD
sections ||| S:38532 E:38540 ||| NNS
.  ||| S:38540 E:38542 ||| .
Apoptosis  ||| S:38542 E:38552 ||| NNP
was  ||| S:38552 E:38556 ||| VBD
evaluated  ||| S:38556 E:38566 ||| VBN
in  ||| S:38566 E:38569 ||| IN
a  ||| S:38569 E:38571 ||| DT
minimum  ||| S:38571 E:38579 ||| NN
of  ||| S:38579 E:38582 ||| IN
4  ||| S:38582 E:38594 ||| CD
explants  ||| S:38594 E:38603 ||| NN
per  ||| S:38603 E:38607 ||| IN
experimental  ||| S:38607 E:38620 ||| JJ
group ||| S:38620 E:38625 ||| NN
.  ||| S:38625 E:38627 ||| .
Quantitation  ||| S:38627 E:38640 ||| NNP
of  ||| S:38640 E:38653 ||| IN
apoptotic  ||| S:38653 E:38663 ||| JJ
nuclei  ||| S:38663 E:38670 ||| NN
was  ||| S:38670 E:38674 ||| VBD
conducted  ||| S:38674 E:38684 ||| VBN
as  ||| S:38684 E:38687 ||| RB
described  ||| S:38687 E:38697 ||| VBN
above  ||| S:38697 E:38703 ||| IN
for  ||| S:38703 E:38717 ||| IN
p53 ||| S:38717 E:38720 ||| NN
.  ||| S:38720 E:38722 ||| .
Apoptosis  ||| S:38722 E:38732 ||| NNP
is  ||| S:38732 E:38735 ||| VBZ
presented  ||| S:38735 E:38745 ||| VBN
as  ||| S:38745 E:38748 ||| IN
the  ||| S:38748 E:38752 ||| DT
ratio  ||| S:38752 E:38758 ||| NN
of  ||| S:38758 E:38771 ||| IN
apoptotic-positive  ||| S:38771 E:38790 ||| FW
epithelial  ||| S:38790 E:38801 ||| FW
cell  ||| S:38801 E:38806 ||| FW
nuclei ||| S:38806 E:38812 ||| FW
/ ||| S:38812 E:38813 ||| FW
total  ||| S:38813 E:38829 ||| FW
epithelial  ||| S:38829 E:38840 ||| FW
cell  ||| S:38840 E:38845 ||| FW
nuclei ||| S:38845 E:38851 ||| FW
.  ||| S:38851 E:38853 ||| .
Mean  ||| S:38853 E:38858 ||| JJ
ratios  ||| S:38858 E:38865 ||| NNS
per  ||| S:38865 E:38869 ||| IN
section  ||| S:38869 E:38877 ||| NN
and  ||| S:38877 E:38881 ||| CC
mean  ||| S:38881 E:38896 ||| VB
ratios  ||| S:38896 E:38903 ||| NNS
per  ||| S:38903 E:38907 ||| IN
group  ||| S:38907 E:38913 ||| NN
were  ||| S:38913 E:38918 ||| VBD
determined ||| S:38918 E:38928 ||| VBN
.  ||| S:38928 E:38930 ||| .
Statistical  ||| S:38930 E:38942 ||| JJ
comparisons  ||| S:38942 E:38964 ||| NNS
were  ||| S:38964 E:38969 ||| VBD
made  ||| S:38969 E:38974 ||| VBN
between  ||| S:38974 E:38982 ||| IN
CONT  ||| S:38982 E:38987 ||| NNP
and  ||| S:38987 E:38991 ||| CC
SN50-treated  ||| S:38991 E:39004 ||| CD
E15  ||| S:39004 E:39008 ||| CD
+  ||| S:39008 E:39010 ||| CD
2  ||| S:39010 E:39012 ||| CD
explants  ||| S:39012 E:39031 ||| NNS
as  ||| S:39031 E:39034 ||| RB
described  ||| S:39034 E:39044 ||| VBD
below.  ||| S:39044 E:39079 ||| CD
cDNA  ||| S:39079 E:39084 ||| JJ
expression  ||| S:39084 E:39095 ||| NN
arrays  ||| S:39095 E:39112 ||| NN
For  ||| S:39112 E:39116 ||| IN
cDNA  ||| S:39116 E:39121 ||| NNP
Expression  ||| S:39121 E:39132 ||| NNP
Array  ||| S:39132 E:39138 ||| NNP
analysis ||| S:39138 E:39146 ||| NN
,  ||| S:39146 E:39148 ||| ,
E15  ||| S:39148 E:39152 ||| NNP
SMG  ||| S:39152 E:39156 ||| NNP
primordia  ||| S:39156 E:39176 ||| NN
were  ||| S:39176 E:39181 ||| VBD
cultured  ||| S:39181 E:39190 ||| VBN
in  ||| S:39190 E:39193 ||| IN
the  ||| S:39193 E:39197 ||| DT
presence  ||| S:39197 E:39206 ||| NN
or  ||| S:39206 E:39209 ||| CC
absence  ||| S:39209 E:39217 ||| NN
of  ||| S:39217 E:39220 ||| IN
SN50  ||| S:39220 E:39225 ||| CD
peptide  ||| S:39225 E:39243 ||| NN
for  ||| S:39243 E:39247 ||| IN
2  ||| S:39247 E:39249 ||| CD
days  ||| S:39249 E:39254 ||| NNS
( ||| S:39254 E:39255 ||| -LRB-
E15  ||| S:39255 E:39259 ||| CD
+  ||| S:39259 E:39261 ||| CD
2 ||| S:39261 E:39262 ||| CD
) ||| S:39262 E:39263 ||| -RRB-
,  ||| S:39263 E:39265 ||| ,
collected  ||| S:39265 E:39275 ||| VBN
in  ||| S:39275 E:39278 ||| IN
cold  ||| S:39278 E:39283 ||| JJ
PBS  ||| S:39283 E:39287 ||| NNP
containing  ||| S:39287 E:39308 ||| VBG
0.02 ||| S:39308 E:39312 ||| CD
%  ||| S:39312 E:39314 ||| NN
DEPC ||| S:39314 E:39318 ||| NNP
,  ||| S:39318 E:39320 ||| ,
snap  ||| S:39320 E:39325 ||| VBP
frozen ||| S:39325 E:39331 ||| VBN
,  ||| S:39331 E:39333 ||| ,
and  ||| S:39333 E:39337 ||| CC
stored  ||| S:39337 E:39344 ||| VBD
at  ||| S:39344 E:39347 ||| IN
-70°C ||| S:39347 E:39352 ||| CD
.  ||| S:39352 E:39354 ||| .
Clontech  ||| S:39354 E:39373 ||| NNP
( ||| S:39373 E:39374 ||| -LRB-
Clontech  ||| S:39374 E:39383 ||| NNP
Laboratories ||| S:39383 E:39395 ||| NNPS
,  ||| S:39395 E:39397 ||| ,
Inc. ||| S:39397 E:39401 ||| NNP
,  ||| S:39401 E:39403 ||| ,
Palo  ||| S:39403 E:39408 ||| NNP
Alto ||| S:39408 E:39412 ||| NNP
,  ||| S:39412 E:39414 ||| ,
CA ||| S:39414 E:39416 ||| NNP
)  ||| S:39416 E:39418 ||| -RRB-
Mouse  ||| S:39418 E:39424 ||| NNP
1.2  ||| S:39424 E:39438 ||| CD
cDNA  ||| S:39438 E:39443 ||| JJ
Expression  ||| S:39443 E:39454 ||| NNP
Arrays  ||| S:39454 E:39461 ||| NNP
were  ||| S:39461 E:39466 ||| VBD
used  ||| S:39466 E:39471 ||| VBN
to  ||| S:39471 E:39474 ||| TO
analyze  ||| S:39474 E:39482 ||| VB
each  ||| S:39482 E:39487 ||| DT
sample ||| S:39487 E:39493 ||| NN
.  ||| S:39493 E:39505 ||| .
These  ||| S:39505 E:39511 ||| DT
arrays  ||| S:39511 E:39518 ||| NNS
include  ||| S:39518 E:39526 ||| VBP
1176  ||| S:39526 E:39531 ||| CD
mouse  ||| S:39531 E:39537 ||| NN
cDNAs ||| S:39537 E:39542 ||| NN
,  ||| S:39542 E:39544 ||| ,
9  ||| S:39544 E:39546 ||| CD
housekeeping  ||| S:39546 E:39569 ||| JJ
control  ||| S:39569 E:39577 ||| NN
cDNAs ||| S:39577 E:39582 ||| NN
,  ||| S:39582 E:39584 ||| ,
and  ||| S:39584 E:39588 ||| CC
negative  ||| S:39588 E:39597 ||| JJ
controls  ||| S:39597 E:39606 ||| NNS
immobilized  ||| S:39606 E:39618 ||| VBN
on  ||| S:39618 E:39621 ||| IN
a  ||| S:39621 E:39633 ||| DT
nylon  ||| S:39633 E:39639 ||| JJ
membrane  ||| S:39639 E:39648 ||| JJ
www.clontech.com ||| S:39648 E:39664 ||| NN
.  ||| S:39664 E:39666 ||| .
Briefly ||| S:39666 E:39673 ||| RB
,  ||| S:39673 E:39675 ||| ,
total  ||| S:39675 E:39681 ||| JJ
RNA  ||| S:39681 E:39685 ||| NNP
was  ||| S:39685 E:39699 ||| VBD
isolated  ||| S:39699 E:39708 ||| VBN
and  ||| S:39708 E:39712 ||| CC
cDNA  ||| S:39712 E:39717 ||| JJ
probes  ||| S:39717 E:39724 ||| NNS
were  ||| S:39724 E:39729 ||| VBD
synthesized  ||| S:39729 E:39741 ||| VBN
using  ||| S:39741 E:39747 ||| VBG
the  ||| S:39747 E:39751 ||| DT
Atlas  ||| S:39751 E:39767 ||| NNP
Pure  ||| S:39767 E:39772 ||| NNP
Total  ||| S:39772 E:39778 ||| NNP
RNA  ||| S:39778 E:39782 ||| NNP
Labeling  ||| S:39782 E:39791 ||| NNP
System  ||| S:39791 E:39798 ||| NNP
and  ||| S:39798 E:39802 ||| CC
32P ||| S:39802 E:39805 ||| NNP
.  ||| S:39805 E:39807 ||| .
The  ||| S:39807 E:39811 ||| DT
labeled  ||| S:39811 E:39819 ||| JJ
cDNA  ||| S:39819 E:39834 ||| JJ
probes  ||| S:39834 E:39841 ||| NNS
were  ||| S:39841 E:39846 ||| VBD
hybridized  ||| S:39846 E:39857 ||| VBN
to  ||| S:39857 E:39860 ||| TO
the  ||| S:39860 E:39864 ||| DT
Atlas  ||| S:39864 E:39870 ||| NNP
Array  ||| S:39870 E:39876 ||| NNP
using  ||| S:39876 E:39892 ||| VBG
ExpressHyb  ||| S:39892 E:39903 ||| JJ
Solution ||| S:39903 E:39911 ||| NN
.  ||| S:39911 E:39913 ||| .
Hybridization  ||| S:39913 E:39927 ||| JJ
signals  ||| S:39927 E:39935 ||| NNS
were  ||| S:39935 E:39940 ||| VBD
revealed  ||| S:39940 E:39959 ||| VBN
by  ||| S:39959 E:39962 ||| IN
phosphorimaging  ||| S:39962 E:39978 ||| NN
and  ||| S:39978 E:39982 ||| CC
quantitated  ||| S:39982 E:39994 ||| VBP
using  ||| S:39994 E:40000 ||| VBG
the  ||| S:40000 E:40004 ||| DT
Clontech  ||| S:40004 E:40023 ||| NNP
Atlas  ||| S:40023 E:40029 ||| NNP
Image  ||| S:40029 E:40035 ||| NNP
1.01  ||| S:40035 E:40040 ||| CD
software  ||| S:40040 E:40049 ||| NN
package ||| S:40049 E:40056 ||| NN
,  ||| S:40056 E:40058 ||| ,
which  ||| S:40058 E:40064 ||| WDT
allows  ||| S:40064 E:40071 ||| VBZ
for  ||| S:40071 E:40085 ||| IN
unbiased  ||| S:40085 E:40094 ||| JJ
normalization  ||| S:40094 E:40108 ||| NN
of  ||| S:40108 E:40111 ||| IN
transcript  ||| S:40111 E:40122 ||| JJ
abundance  ||| S:40122 E:40132 ||| NN
to  ||| S:40132 E:40135 ||| TO
overall  ||| S:40135 E:40153 ||| JJ
signal ||| S:40153 E:40159 ||| NN
.  ||| S:40159 E:40161 ||| .
We  ||| S:40161 E:40164 ||| PRP
generated  ||| S:40164 E:40174 ||| VBD
pseudocolored  ||| S:40174 E:40188 ||| JJ
images  ||| S:40188 E:40195 ||| NNS
indicating  ||| S:40195 E:40206 ||| VBG
up  ||| S:40206 E:40219 ||| RP
and  ||| S:40219 E:40223 ||| CC
down  ||| S:40223 E:40228 ||| JJ
gene  ||| S:40228 E:40233 ||| NN
regulation ||| S:40233 E:40243 ||| NN
.  ||| S:40243 E:40245 ||| .
The  ||| S:40245 E:40249 ||| DT
probe  ||| S:40249 E:40255 ||| NN
set  ||| S:40255 E:40259 ||| NN
intensity  ||| S:40259 E:40279 ||| NN
( ||| S:40279 E:40280 ||| -LRB-
average  ||| S:40280 E:40288 ||| JJ
difference ||| S:40288 E:40298 ||| NN
)  ||| S:40298 E:40300 ||| -RRB-
is  ||| S:40300 E:40303 ||| VBZ
proportional  ||| S:40303 E:40316 ||| VBN
to  ||| S:40316 E:40319 ||| TO
the  ||| S:40319 E:40323 ||| DT
abundance  ||| S:40323 E:40333 ||| NN
of  ||| S:40333 E:40346 ||| IN
the  ||| S:40346 E:40350 ||| DT
specific  ||| S:40350 E:40359 ||| JJ
mRNA  ||| S:40359 E:40364 ||| NN
it  ||| S:40364 E:40367 ||| PRP
represents  ||| S:40367 E:40378 ||| VBZ
and  ||| S:40378 E:40382 ||| CC
was  ||| S:40382 E:40386 ||| VBD
calculated  ||| S:40386 E:40397 ||| VBN
by  ||| S:40397 E:40410 ||| IN
comparing  ||| S:40410 E:40420 ||| VBG
hybridization  ||| S:40420 E:40434 ||| JJ
signal  ||| S:40434 E:40441 ||| NN
of  ||| S:40441 E:40444 ||| IN
the  ||| S:40444 E:40448 ||| DT
control  ||| S:40448 E:40466 ||| NN
oligonucleotide  ||| S:40466 E:40482 ||| NN
to  ||| S:40482 E:40485 ||| TO
that  ||| S:40485 E:40490 ||| DT
of  ||| S:40490 E:40493 ||| IN
the  ||| S:40493 E:40497 ||| DT
treated ||| S:40497 E:40504 ||| NN
.  ||| S:40504 E:40506 ||| .
Total  ||| S:40506 E:40512 ||| JJ
signal  ||| S:40512 E:40529 ||| NN
intensity  ||| S:40529 E:40539 ||| NN
of  ||| S:40539 E:40542 ||| IN
different  ||| S:40542 E:40552 ||| JJ
probes  ||| S:40552 E:40559 ||| NNS
was  ||| S:40559 E:40563 ||| VBD
scaled  ||| S:40563 E:40570 ||| VBN
to  ||| S:40570 E:40573 ||| TO
the  ||| S:40573 E:40577 ||| DT
same  ||| S:40577 E:40592 ||| JJ
value  ||| S:40592 E:40598 ||| NN
before  ||| S:40598 E:40605 ||| IN
comparison ||| S:40605 E:40615 ||| NN
.  ||| S:40615 E:40617 ||| .
Fold  ||| S:40617 E:40622 ||| JJ
changes  ||| S:40622 E:40630 ||| NNS
were  ||| S:40630 E:40635 ||| VBD
calculated  ||| S:40635 E:40646 ||| VBN
by  ||| S:40646 E:40659 ||| IN
AtlasImage  ||| S:40659 E:40670 ||| JJ
1.0  ||| S:40670 E:40674 ||| CD
software  ||| S:40674 E:40683 ||| NN
by  ||| S:40683 E:40686 ||| IN
pair-wise  ||| S:40686 E:40696 ||| JJ
comparisons  ||| S:40696 E:40708 ||| NNS
of  ||| S:40708 E:40721 ||| IN
corresponding  ||| S:40721 E:40735 ||| JJ
probe  ||| S:40735 E:40741 ||| NN
pairs  ||| S:40741 E:40747 ||| NNS
from  ||| S:40747 E:40752 ||| IN
experimental  ||| S:40752 E:40765 ||| JJ
and  ||| S:40765 E:40769 ||| CC
control ||| S:40769 E:40776 ||| NN
.  ||| S:40776 E:40788 ||| .
Three  ||| S:40788 E:40794 ||| CD
independent  ||| S:40794 E:40806 ||| JJ
experiments  ||| S:40806 E:40818 ||| NNS
were  ||| S:40818 E:40823 ||| VBD
conducted  ||| S:40823 E:40833 ||| VBN
per  ||| S:40833 E:40847 ||| IN
experimental  ||| S:40847 E:40860 ||| JJ
group  ||| S:40860 E:40866 ||| NN
and  ||| S:40866 E:40870 ||| CC
the  ||| S:40870 E:40874 ||| DT
composite  ||| S:40874 E:40884 ||| JJ
array  ||| S:40884 E:40890 ||| NN
determined ||| S:40890 E:40900 ||| VBN
.  ||| S:40900 E:40912 ||| .
Relevant  ||| S:40912 E:40921 ||| JJ
genes  ||| S:40921 E:40927 ||| NNS
with  ||| S:40927 E:40932 ||| IN
altered  ||| S:40932 E:40940 ||| JJ
expression  ||| S:40940 E:40951 ||| NN
were  ||| S:40951 E:40956 ||| VBD
then  ||| S:40956 E:40961 ||| RB
assigned  ||| S:40961 E:40980 ||| VBN
to  ||| S:40980 E:40983 ||| TO
functional  ||| S:40983 E:40994 ||| VB
groups ||| S:40994 E:41000 ||| NNS
.  ||| S:41000 E:41002 ||| .
Specifically ||| S:41002 E:41014 ||| RB
,  ||| S:41014 E:41016 ||| ,
we  ||| S:41016 E:41019 ||| PRP
assigned  ||| S:41019 E:41028 ||| VBD
those  ||| S:41028 E:41044 ||| DT
genes  ||| S:41044 E:41050 ||| NNS
related  ||| S:41050 E:41058 ||| VBN
to  ||| S:41058 E:41061 ||| TO
the  ||| S:41061 E:41076 ||| DT
Connections  ||| S:41076 E:41088 ||| NNP
Map  ||| S:41088 E:41092 ||| NNP
( ||| S:41092 E:41093 ||| -LRB-
Fig.  ||| S:41093 E:41098 ||| CD
1 ||| S:41098 E:41099 ||| CD
)  ||| S:41099 E:41101 ||| -RRB-
that  ||| S:41101 E:41106 ||| WDT
have  ||| S:41106 E:41121 ||| VBP
a  ||| S:41121 E:41123 ||| DT
1.5  ||| S:41123 E:41127 ||| CD
or  ||| S:41127 E:41130 ||| CC
greater  ||| S:41130 E:41138 ||| JJR
fold-change  ||| S:41138 E:41150 ||| JJ
to  ||| S:41150 E:41153 ||| TO
functional  ||| S:41153 E:41164 ||| VB
groups  ||| S:41164 E:41171 ||| NNS
(  ||| S:41171 E:41184 ||| -LRB-
i.e. ||| S:41184 E:41188 ||| FW
,  ||| S:41188 E:41190 ||| ,
cell  ||| S:41190 E:41195 ||| NN
cycle ||| S:41195 E:41200 ||| NN
,  ||| S:41200 E:41202 ||| ,
apoptosis ||| S:41202 E:41211 ||| NN
,  ||| S:41211 E:41213 ||| ,
signal  ||| S:41213 E:41230 ||| NN
transduction ||| S:41230 E:41242 ||| NN
,  ||| S:41242 E:41244 ||| ,
etc. ||| S:41244 E:41248 ||| FW
)  ||| S:41248 E:41250 ||| -RRB-
which  ||| S:41250 E:41256 ||| WDT
have  ||| S:41256 E:41261 ||| VBP
biological  ||| S:41261 E:41282 ||| JJ
significance.  ||| S:41282 E:41324 ||| CD
2-D  ||| S:41324 E:41328 ||| CD
western  ||| S:41328 E:41336 ||| JJ
array  ||| S:41336 E:41342 ||| NN
screening  ||| S:41342 E:41362 ||| VBG
The  ||| S:41362 E:41366 ||| DT
expression  ||| S:41366 E:41377 ||| NN
of  ||| S:41377 E:41380 ||| IN
signaling  ||| S:41380 E:41390 ||| VBG
proteins  ||| S:41390 E:41399 ||| NNS
was  ||| S:41399 E:41403 ||| VBD
analyzed  ||| S:41403 E:41412 ||| VBN
by  ||| S:41412 E:41425 ||| IN
Powerblot  ||| S:41425 E:41435 ||| NNP
Western  ||| S:41435 E:41443 ||| NNP
Array  ||| S:41443 E:41449 ||| NNP
Screening  ||| S:41449 E:41459 ||| NNP
( ||| S:41459 E:41460 ||| -LRB-
BD  ||| S:41460 E:41463 ||| NNP
Transduction  ||| S:41463 E:41486 ||| NNP
Laboratories ||| S:41486 E:41498 ||| NNPS
,  ||| S:41498 E:41500 ||| ,
Lexington ||| S:41500 E:41509 ||| NNP
,  ||| S:41509 E:41511 ||| ,
KY ||| S:41511 E:41513 ||| NNP
) ||| S:41513 E:41514 ||| -RRB-
.  ||| S:41514 E:41516 ||| .
This  ||| S:41516 E:41521 ||| DT
2-D  ||| S:41521 E:41525 ||| NNP
Western  ||| S:41525 E:41533 ||| NNP
Blot  ||| S:41533 E:41538 ||| NNP
Array  ||| S:41538 E:41554 ||| NNP
methodology  ||| S:41554 E:41566 ||| VBD
simultaneously  ||| S:41566 E:41581 ||| RB
examines  ||| S:41581 E:41590 ||| VBZ
relative  ||| S:41590 E:41599 ||| JJ
changes  ||| S:41599 E:41607 ||| NNS
in  ||| S:41607 E:41620 ||| IN
protein  ||| S:41620 E:41628 ||| NN
expression  ||| S:41628 E:41639 ||| NN
in  ||| S:41639 E:41642 ||| IN
~600  ||| S:41642 E:41647 ||| CD
proteins  ||| S:41647 E:41656 ||| NNS
in  ||| S:41656 E:41659 ||| IN
a  ||| S:41659 E:41661 ||| DT
given  ||| S:41661 E:41667 ||| VBN
sample ||| S:41667 E:41673 ||| NN
.  ||| S:41673 E:41685 ||| .
Using  ||| S:41685 E:41691 ||| VBG
highly  ||| S:41691 E:41698 ||| RB
specific  ||| S:41698 E:41707 ||| JJ
monoclonal  ||| S:41707 E:41718 ||| JJ
antibodies  ||| S:41718 E:41729 ||| NNS
in  ||| S:41729 E:41732 ||| IN
antibody  ||| S:41732 E:41751 ||| NN
combinations  ||| S:41751 E:41764 ||| NNS
carefully  ||| S:41764 E:41774 ||| RB
formulated  ||| S:41774 E:41785 ||| VBN
by  ||| S:41785 E:41788 ||| IN
BD  ||| S:41788 E:41791 ||| NNP
Transduction  ||| S:41791 E:41814 ||| NNP
Laboratories ||| S:41814 E:41826 ||| NNPS
,  ||| S:41826 E:41828 ||| ,
this  ||| S:41828 E:41833 ||| DT
multiprotein  ||| S:41833 E:41846 ||| JJ
assay  ||| S:41846 E:41852 ||| JJ
detects  ||| S:41852 E:41860 ||| JJ
proteins  ||| S:41860 E:41869 ||| NNS
to  ||| S:41869 E:41882 ||| TO
the  ||| S:41882 E:41886 ||| DT
nanogram  ||| S:41886 E:41895 ||| JJ
levels  ||| S:41895 E:41902 ||| NNS
and  ||| S:41902 E:41906 ||| CC
can  ||| S:41906 E:41910 ||| MD
distinguish  ||| S:41910 E:41922 ||| VB
closely  ||| S:41922 E:41930 ||| RB
related  ||| S:41930 E:41948 ||| VBN
members  ||| S:41948 E:41956 ||| NNS
of  ||| S:41956 E:41959 ||| IN
many  ||| S:41959 E:41964 ||| JJ
important  ||| S:41964 E:41974 ||| JJ
signaling  ||| S:41974 E:41984 ||| JJ
families ||| S:41984 E:41992 ||| NNS
.  ||| S:41992 E:41994 ||| .
E15+2  ||| S:41994 E:42000 ||| NNP
CONT  ||| S:42000 E:42015 ||| NNP
and  ||| S:42015 E:42019 ||| CC
SN50-treated  ||| S:42019 E:42032 ||| CD
explants  ||| S:42032 E:42041 ||| NNS
were  ||| S:42041 E:42046 ||| VBD
collected  ||| S:42046 E:42056 ||| VBN
and  ||| S:42056 E:42060 ||| CC
processed  ||| S:42060 E:42080 ||| VBN
according  ||| S:42080 E:42090 ||| VBG
to  ||| S:42090 E:42093 ||| TO
the  ||| S:42093 E:42097 ||| DT
protocol  ||| S:42097 E:42106 ||| NN
of  ||| S:42106 E:42109 ||| IN
BD  ||| S:42109 E:42112 ||| NNP
Transduction  ||| S:42112 E:42135 ||| NNP
Laboratories ||| S:42135 E:42147 ||| NNPS
.  ||| S:42147 E:42149 ||| .
Each  ||| S:42149 E:42154 ||| DT
sample  ||| S:42154 E:42161 ||| NN
( ||| S:42161 E:42162 ||| -LRB-
CONT  ||| S:42162 E:42167 ||| NNP
and  ||| S:42167 E:42171 ||| CC
SN50-treated ||| S:42171 E:42183 ||| CD
)  ||| S:42183 E:42185 ||| -RRB-
was  ||| S:42185 E:42199 ||| VBD
analyzed  ||| S:42199 E:42208 ||| VBN
on  ||| S:42208 E:42211 ||| IN
4  ||| S:42211 E:42213 ||| CD
separate  ||| S:42213 E:42222 ||| JJ
2-D  ||| S:42222 E:42226 ||| CD
gels  ||| S:42226 E:42231 ||| NNS
which  ||| S:42231 E:42237 ||| WDT
were  ||| S:42237 E:42242 ||| VBD
then  ||| S:42242 E:42257 ||| RB
transferred  ||| S:42257 E:42269 ||| VBN
onto  ||| S:42269 E:42274 ||| IN
4  ||| S:42274 E:42276 ||| CD
blots ||| S:42276 E:42281 ||| NNS
.  ||| S:42281 E:42283 ||| .
Each  ||| S:42283 E:42288 ||| DT
blot  ||| S:42288 E:42293 ||| NN
was  ||| S:42293 E:42297 ||| VBD
then  ||| S:42297 E:42302 ||| RB
incubated  ||| S:42302 E:42322 ||| VBN
with  ||| S:42322 E:42327 ||| IN
a  ||| S:42327 E:42329 ||| DT
different  ||| S:42329 E:42339 ||| JJ
mixture  ||| S:42339 E:42347 ||| NN
of  ||| S:42347 E:42350 ||| IN
~150  ||| S:42350 E:42355 ||| CD
monoclonal  ||| S:42355 E:42366 ||| CD
antibodies  ||| S:42366 E:42387 ||| NNS
and  ||| S:42387 E:42391 ||| CC
proteins  ||| S:42391 E:42400 ||| NNS
were  ||| S:42400 E:42405 ||| VBD
detected  ||| S:42405 E:42414 ||| VBN
by  ||| S:42414 E:42417 ||| IN
chemiluminescence ||| S:42417 E:42434 ||| NNS
;  ||| S:42434 E:42436 ||| :
~600  ||| S:42436 E:42451 ||| CD
( ||| S:42451 E:42452 ||| -LRB-
150  ||| S:42452 E:42456 ||| CD
antibodies  ||| S:42456 E:42467 ||| CD
×  ||| S:42467 E:42469 ||| CD
4  ||| S:42469 E:42471 ||| CD
blots ||| S:42471 E:42476 ||| CD
)  ||| S:42476 E:42478 ||| -RRB-
proteins  ||| S:42478 E:42487 ||| NNS
were  ||| S:42487 E:42492 ||| VBD
evaluated  ||| S:42492 E:42502 ||| VBN
in  ||| S:42502 E:42505 ||| IN
a  ||| S:42505 E:42517 ||| DT
given  ||| S:42517 E:42523 ||| VBN
sample ||| S:42523 E:42529 ||| NN
.  ||| S:42529 E:42531 ||| .
For  ||| S:42531 E:42535 ||| IN
this  ||| S:42535 E:42540 ||| DT
set  ||| S:42540 E:42544 ||| NN
of  ||| S:42544 E:42547 ||| IN
experiments ||| S:42547 E:42558 ||| NNS
,  ||| S:42558 E:42560 ||| ,
two  ||| S:42560 E:42574 ||| CD
independent  ||| S:42574 E:42586 ||| JJ
samples  ||| S:42586 E:42594 ||| NNS
were  ||| S:42594 E:42599 ||| VBD
analyzed  ||| S:42599 E:42608 ||| VBN
The  ||| S:42608 E:42612 ||| DT
relative  ||| S:42612 E:42621 ||| JJ
level  ||| S:42621 E:42627 ||| NN
of  ||| S:42627 E:42640 ||| IN
proteins  ||| S:42640 E:42649 ||| NNS
were  ||| S:42649 E:42654 ||| VBD
determined  ||| S:42654 E:42665 ||| VBN
by  ||| S:42665 E:42668 ||| IN
phosphor  ||| S:42668 E:42677 ||| JJ
imaging  ||| S:42677 E:42685 ||| NN
and  ||| S:42685 E:42699 ||| CC
normalized  ||| S:42699 E:42710 ||| JJ
to  ||| S:42710 E:42713 ||| TO
overall  ||| S:42713 E:42721 ||| JJ
signal ||| S:42721 E:42727 ||| NN
.  ||| S:42727 E:42729 ||| .
We  ||| S:42729 E:42732 ||| PRP
then  ||| S:42732 E:42737 ||| RB
assigned  ||| S:42737 E:42746 ||| VBN
those  ||| S:42746 E:42763 ||| DT
Connections  ||| S:42763 E:42775 ||| NNP
Map  ||| S:42775 E:42779 ||| NNP
proteins  ||| S:42779 E:42788 ||| NNS
with  ||| S:42788 E:42793 ||| IN
a  ||| S:42793 E:42795 ||| DT
1.5  ||| S:42795 E:42809 ||| CD
or  ||| S:42809 E:42812 ||| CC
greater  ||| S:42812 E:42820 ||| JJR
fold-change  ||| S:42820 E:42832 ||| JJ
to  ||| S:42832 E:42835 ||| TO
functional  ||| S:42835 E:42846 ||| VB
groups  ||| S:42846 E:42853 ||| NNS
as  ||| S:42853 E:42856 ||| RB
described  ||| S:42856 E:42876 ||| VBD
above.  ||| S:42876 E:42911 ||| CD
1-D  ||| S:42911 E:42915 ||| CD
western  ||| S:42915 E:42923 ||| JJ
blot  ||| S:42923 E:42928 ||| JJ
analysis  ||| S:42928 E:42947 ||| NN
To  ||| S:42947 E:42950 ||| TO
determine  ||| S:42950 E:42960 ||| VB
which  ||| S:42960 E:42966 ||| WDT
key  ||| S:42966 E:42970 ||| JJ
pathways  ||| S:42970 E:42979 ||| NN
were  ||| S:42979 E:42984 ||| VBD
activated ||| S:42984 E:42993 ||| VBN
,  ||| S:42993 E:43005 ||| ,
Western  ||| S:43005 E:43013 ||| JJ
blot  ||| S:43013 E:43018 ||| JJ
analyses  ||| S:43018 E:43027 ||| NNS
of  ||| S:43027 E:43030 ||| IN
phosphorylated  ||| S:43030 E:43045 ||| NN
or  ||| S:43045 E:43048 ||| CC
cleaved  ||| S:43048 E:43066 ||| JJ
proteins  ||| S:43066 E:43075 ||| NNS
in  ||| S:43075 E:43078 ||| IN
E15+2  ||| S:43078 E:43084 ||| NNP
CONT  ||| S:43084 E:43089 ||| NNP
and  ||| S:43089 E:43093 ||| CC
SN50-treated  ||| S:43093 E:43106 ||| CD
explants  ||| S:43106 E:43115 ||| NNS
were  ||| S:43115 E:43130 ||| VBD
conducted  ||| S:43130 E:43140 ||| VBN
as  ||| S:43140 E:43143 ||| IN
previously  ||| S:43143 E:43154 ||| RB
described  ||| S:43154 E:43164 ||| VBN
[  ||| S:43164 E:43166 ||| -LRB-
5  ||| S:43166 E:43168 ||| LS
]  ||| S:43168 E:43170 ||| -RRB-
.  ||| S:43170 E:43172 ||| .
For  ||| S:43172 E:43176 ||| IN
this  ||| S:43176 E:43181 ||| DT
set  ||| S:43181 E:43185 ||| NN
of  ||| S:43185 E:43198 ||| IN
experiments ||| S:43198 E:43209 ||| NNS
,  ||| S:43209 E:43211 ||| ,
we  ||| S:43211 E:43214 ||| PRP
first  ||| S:43214 E:43220 ||| RB
determined  ||| S:43220 E:43231 ||| VBN
the  ||| S:43231 E:43235 ||| DT
specificity  ||| S:43235 E:43247 ||| NN
for  ||| S:43247 E:43251 ||| IN
each  ||| S:43251 E:43266 ||| DT
of  ||| S:43266 E:43269 ||| IN
the  ||| S:43269 E:43273 ||| DT
following  ||| S:43273 E:43283 ||| JJ
antibodies  ||| S:43283 E:43294 ||| NNS
purchased  ||| S:43294 E:43304 ||| VBN
from  ||| S:43304 E:43309 ||| IN
Cell  ||| S:43309 E:43314 ||| NNP
Signaling  ||| S:43314 E:43334 ||| NNP
Technology  ||| S:43334 E:43345 ||| NNP
( ||| S:43345 E:43346 ||| -LRB-
Beverly ||| S:43346 E:43353 ||| NNP
,  ||| S:43353 E:43355 ||| ,
MA ||| S:43355 E:43357 ||| NNP
)  ||| S:43357 E:43359 ||| -RRB-
using  ||| S:43359 E:43365 ||| VBG
E15  ||| S:43365 E:43369 ||| NNP
and  ||| S:43369 E:43373 ||| CC
E17  ||| S:43373 E:43377 ||| NNP
SMG  ||| S:43377 E:43391 ||| NNP
homogenates ||| S:43391 E:43402 ||| NN
:  ||| S:43402 E:43404 ||| :
anti-phosphorylated  ||| S:43404 E:43424 ||| JJ
Erk1 ||| S:43424 E:43428 ||| CD
/ ||| S:43428 E:43429 ||| CD
2  ||| S:43429 E:43431 ||| CD
[ ||| S:43431 E:43432 ||| -LRB-
phospho-p44 ||| S:43432 E:43443 ||| CD
/ ||| S:43443 E:43444 ||| CD
42  ||| S:43444 E:43457 ||| CD
MAP  ||| S:43457 E:43461 ||| NN
kinase  ||| S:43461 E:43468 ||| NNS
( ||| S:43468 E:43469 ||| -LRB-
Thr202 ||| S:43469 E:43475 ||| CD
/ ||| S:43475 E:43476 ||| CD
Tyr204 ||| S:43476 E:43482 ||| CD
) ||| S:43482 E:43483 ||| -RRB-
]  ||| S:43483 E:43485 ||| -RRB-
antibody ||| S:43485 E:43493 ||| NN
,  ||| S:43493 E:43495 ||| ,
anti-phosphorylated  ||| S:43495 E:43525 ||| NNP
c-Raf ||| S:43525 E:43530 ||| NNP
( ||| S:43530 E:43531 ||| -LRB-
Ser259 ||| S:43531 E:43537 ||| NNP
)  ||| S:43537 E:43539 ||| -RRB-
antibody ||| S:43539 E:43547 ||| NN
,  ||| S:43547 E:43549 ||| ,
anti-cleaved  ||| S:43549 E:43562 ||| NNP
Caspase  ||| S:43562 E:43570 ||| NNP
3  ||| S:43570 E:43572 ||| CD
( ||| S:43572 E:43573 ||| -LRB-
D  ||| S:43573 E:43575 ||| NNP
175 ||| S:43575 E:43578 ||| CD
)  ||| S:43578 E:43590 ||| -RRB-
antibody ||| S:43590 E:43598 ||| NN
,  ||| S:43598 E:43600 ||| ,
and  ||| S:43600 E:43604 ||| CC
anti-cleaved  ||| S:43604 E:43617 ||| NNP
PARP  ||| S:43617 E:43622 ||| NNP
( ||| S:43622 E:43623 ||| -LRB-
D214 ||| S:43623 E:43627 ||| NNP
)  ||| S:43627 E:43629 ||| -RRB-
antibody ||| S:43629 E:43637 ||| NN
.  ||| S:43637 E:43639 ||| .
Each  ||| S:43639 E:43654 ||| DT
antibody  ||| S:43654 E:43663 ||| NN
had  ||| S:43663 E:43667 ||| VBD
previously  ||| S:43667 E:43678 ||| RB
been  ||| S:43678 E:43683 ||| VBN
shown  ||| S:43683 E:43689 ||| VBN
to  ||| S:43689 E:43692 ||| TO
be  ||| S:43692 E:43695 ||| VB
specific  ||| S:43695 E:43704 ||| JJ
for  ||| S:43704 E:43708 ||| IN
the  ||| S:43708 E:43722 ||| DT
activated  ||| S:43722 E:43732 ||| NN
( ||| S:43732 E:43733 ||| -LRB-
phosphorylated ||| S:43733 E:43747 ||| FW
/ ||| S:43747 E:43748 ||| FW
cleaved ||| S:43748 E:43755 ||| FW
)  ||| S:43755 E:43757 ||| -RRB-
protein  ||| S:43757 E:43765 ||| NN
and  ||| S:43765 E:43769 ||| CC
not  ||| S:43769 E:43773 ||| RB
to  ||| S:43773 E:43786 ||| TO
cross  ||| S:43786 E:43792 ||| VB
react  ||| S:43792 E:43798 ||| VBN
with  ||| S:43798 E:43803 ||| IN
inactive  ||| S:43803 E:43812 ||| JJ
protein ||| S:43812 E:43819 ||| NN
.  ||| S:43819 E:43821 ||| .
Once  ||| S:43821 E:43826 ||| RB
optimal  ||| S:43826 E:43844 ||| JJ
experimental  ||| S:43844 E:43857 ||| JJ
conditions  ||| S:43857 E:43868 ||| NNS
were  ||| S:43868 E:43873 ||| VBD
established  ||| S:43873 E:43885 ||| VBN
for  ||| S:43885 E:43889 ||| IN
each  ||| S:43889 E:43904 ||| DT
antibody ||| S:43904 E:43912 ||| NN
,  ||| S:43912 E:43914 ||| ,
we  ||| S:43914 E:43917 ||| PRP
then  ||| S:43917 E:43922 ||| RB
incubated  ||| S:43922 E:43932 ||| JJ
blots  ||| S:43932 E:43938 ||| NN
of  ||| S:43938 E:43941 ||| IN
E15  ||| S:43941 E:43945 ||| NNP
and  ||| S:43945 E:43949 ||| CC
E17  ||| S:43949 E:43953 ||| CD
SMGs  ||| S:43953 E:43958 ||| NN
in  ||| S:43958 E:43971 ||| IN
a  ||| S:43971 E:43973 ||| DT
mixture  ||| S:43973 E:43981 ||| NN
of  ||| S:43981 E:43984 ||| IN
these  ||| S:43984 E:43990 ||| DT
4  ||| S:43990 E:43992 ||| CD
antibodies  ||| S:43992 E:44003 ||| NNS
and  ||| S:44003 E:44007 ||| CC
determined  ||| S:44007 E:44018 ||| VBN
that  ||| S:44018 E:44023 ||| IN
we  ||| S:44023 E:44036 ||| PRP
could  ||| S:44036 E:44042 ||| MD
identify  ||| S:44042 E:44051 ||| VB
all  ||| S:44051 E:44055 ||| DT
proteins  ||| S:44055 E:44064 ||| NNS
in  ||| S:44064 E:44067 ||| IN
a  ||| S:44067 E:44069 ||| DT
single  ||| S:44069 E:44076 ||| JJ
sample  ||| S:44076 E:44083 ||| NN
by  ||| S:44083 E:44086 ||| IN
M  ||| S:44086 E:44099 ||| NNP
r  ||| S:44099 E:44101 ||| NN
.  ||| S:44101 E:44103 ||| .
This  ||| S:44103 E:44108 ||| DT
methodology  ||| S:44108 E:44120 ||| NN
using  ||| S:44120 E:44126 ||| VBG
a  ||| S:44126 E:44128 ||| DT
mixture  ||| S:44128 E:44146 ||| NN
of  ||| S:44146 E:44149 ||| IN
antibodies  ||| S:44149 E:44160 ||| NNS
has  ||| S:44160 E:44164 ||| VBZ
been  ||| S:44164 E:44169 ||| VBN
successfully  ||| S:44169 E:44182 ||| RB
used  ||| S:44182 E:44187 ||| VBN
by  ||| S:44187 E:44190 ||| IN
Cell  ||| S:44190 E:44205 ||| NNP
Signaling  ||| S:44205 E:44215 ||| NNP
Technology  ||| S:44215 E:44226 ||| NNP
and  ||| S:44226 E:44230 ||| CC
BD  ||| S:44230 E:44233 ||| NNP
Signal  ||| S:44233 E:44240 ||| NNP
Transduction  ||| S:44240 E:44253 ||| NNP
for  ||| S:44253 E:44257 ||| IN
2-D  ||| S:44257 E:44271 ||| NNP
and  ||| S:44271 E:44275 ||| CC
1-D  ||| S:44275 E:44279 ||| NNP
Western  ||| S:44279 E:44287 ||| NNP
blot  ||| S:44287 E:44292 ||| NN
analyses ||| S:44292 E:44300 ||| NNS
.  ||| S:44300 E:44302 ||| .
Controls  ||| S:44302 E:44311 ||| NNS
consisted  ||| S:44311 E:44321 ||| VBD
of  ||| S:44321 E:44334 ||| IN
blots  ||| S:44334 E:44340 ||| JJ
incubated  ||| S:44340 E:44350 ||| NN
in  ||| S:44350 E:44353 ||| IN
preimmune  ||| S:44353 E:44363 ||| JJ
rabbit  ||| S:44363 E:44370 ||| NN
serum  ||| S:44370 E:44376 ||| NNS
or  ||| S:44376 E:44379 ||| CC
in  ||| S:44379 E:44382 ||| IN
the  ||| S:44382 E:44396 ||| DT
absence  ||| S:44396 E:44404 ||| NN
of  ||| S:44404 E:44407 ||| IN
primary  ||| S:44407 E:44415 ||| JJ
antibodies ||| S:44415 E:44425 ||| NNS
;  ||| S:44425 E:44427 ||| :
controls  ||| S:44427 E:44436 ||| NNS
were  ||| S:44436 E:44441 ||| VBD
routinely  ||| S:44441 E:44461 ||| RB
negative ||| S:44461 E:44469 ||| JJ
.  ||| S:44469 E:44471 ||| .
In  ||| S:44471 E:44474 ||| IN
each  ||| S:44474 E:44479 ||| DT
sample ||| S:44479 E:44485 ||| NN
,  ||| S:44485 E:44487 ||| ,
each  ||| S:44487 E:44503 ||| DT
activated  ||| S:44503 E:44513 ||| JJ
protein  ||| S:44513 E:44521 ||| NN
was  ||| S:44521 E:44525 ||| VBD
identified  ||| S:44525 E:44536 ||| VBN
by  ||| S:44536 E:44549 ||| IN
M  ||| S:44549 E:44562 ||| NNP
r  ||| S:44562 E:44564 ||| NN
and  ||| S:44564 E:44568 ||| CC
the  ||| S:44568 E:44572 ||| DT
relative  ||| S:44572 E:44581 ||| JJ
level  ||| S:44581 E:44587 ||| NN
of  ||| S:44587 E:44601 ||| IN
activated  ||| S:44601 E:44611 ||| JJ
proteins  ||| S:44611 E:44620 ||| NNS
in  ||| S:44620 E:44623 ||| IN
CONT  ||| S:44623 E:44628 ||| NNP
and  ||| S:44628 E:44642 ||| CC
SN50-treated  ||| S:44642 E:44655 ||| CD
explants  ||| S:44655 E:44664 ||| NNS
was  ||| S:44664 E:44668 ||| VBD
determined  ||| S:44668 E:44679 ||| VBN
by  ||| S:44679 E:44682 ||| IN
densitometry ||| S:44682 E:44694 ||| NN
.  ||| S:44694 E:44696 ||| .
The  ||| S:44696 E:44710 ||| DT
SN50  ||| S:44710 E:44715 ||| CD
results  ||| S:44715 E:44723 ||| NNS
are  ||| S:44723 E:44727 ||| VBP
presented  ||| S:44727 E:44737 ||| VBN
as  ||| S:44737 E:44740 ||| IN
fold  ||| S:44740 E:44745 ||| JJ
change  ||| S:44745 E:44752 ||| NN
relative  ||| S:44752 E:44761 ||| JJ
to  ||| S:44761 E:44774 ||| TO
CONT  ||| S:44774 E:44779 ||| NNP
protein ||| S:44779 E:44786 ||| NN
.  ||| S:44786 E:44788 ||| .
Two  ||| S:44788 E:44792 ||| CD
independent  ||| S:44792 E:44804 ||| JJ
samples  ||| S:44804 E:44812 ||| NNS
per  ||| S:44812 E:44816 ||| IN
group  ||| S:44816 E:44822 ||| NN
was  ||| S:44822 E:44836 ||| VBD
analyzed ||| S:44836 E:44844 ||| VBN
.  ||| S:44844 E:44846 ||| .
Statistical  ||| S:44846 E:44858 ||| JJ
comparisons  ||| S:44858 E:44870 ||| NNS
were  ||| S:44870 E:44875 ||| VBD
made  ||| S:44875 E:44880 ||| VBN
between  ||| S:44880 E:44888 ||| IN
CONT  ||| S:44888 E:44903 ||| NNP
and  ||| S:44903 E:44907 ||| CC
SN50-treated  ||| S:44907 E:44920 ||| CD
E15  ||| S:44920 E:44924 ||| CD
+  ||| S:44924 E:44926 ||| CD
2  ||| S:44926 E:44928 ||| CD
explants  ||| S:44928 E:44937 ||| NNS
as  ||| S:44937 E:44940 ||| RB
described  ||| S:44940 E:44950 ||| VBN
below ||| S:44950 E:44955 ||| RB
.  ||| S:44955 E:44985 ||| .
Probabilistic  ||| S:44985 E:44999 ||| JJ
neural  ||| S:44999 E:45006 ||| JJ
network  ||| S:45006 E:45014 ||| NN
analysis  ||| S:45014 E:45033 ||| NN
We  ||| S:45033 E:45036 ||| PRP
used  ||| S:45036 E:45041 ||| VBD
PNN  ||| S:45041 E:45045 ||| NNP
analyses  ||| S:45045 E:45054 ||| NNS
to  ||| S:45054 E:45057 ||| TO
determine  ||| S:45057 E:45067 ||| VB
which  ||| S:45067 E:45084 ||| WDT
Connection  ||| S:45084 E:45095 ||| NNP
Map  ||| S:45095 E:45099 ||| NNP
( ||| S:45099 E:45100 ||| -LRB-
Fig.  ||| S:45100 E:45105 ||| CD
1 ||| S:45105 E:45106 ||| CD
)  ||| S:45106 E:45108 ||| -RRB-
transcripts  ||| S:45108 E:45130 ||| NNS
or  ||| S:45130 E:45133 ||| CC
proteins  ||| S:45133 E:45142 ||| NNS
with  ||| S:45142 E:45147 ||| IN
altered  ||| S:45147 E:45155 ||| JJ
expression  ||| S:45155 E:45166 ||| NN
best  ||| S:45166 E:45171 ||| RBS
discriminate  ||| S:45171 E:45194 ||| JJ
CONT  ||| S:45194 E:45199 ||| NN
from  ||| S:45199 E:45204 ||| IN
SN50-treated  ||| S:45204 E:45217 ||| CD
explants  ||| S:45217 E:45226 ||| NN
with  ||| S:45226 E:45231 ||| IN
100 ||| S:45231 E:45234 ||| CD
%  ||| S:45234 E:45236 ||| NN
sensitivity  ||| S:45236 E:45248 ||| NN
and  ||| S:45248 E:45262 ||| CC
specificity  ||| S:45262 E:45274 ||| NNS
[  ||| S:45274 E:45276 ||| -LRB-
69  ||| S:45276 E:45279 ||| CD
]  ||| S:45279 E:45281 ||| -RRB-
.  ||| S:45281 E:45283 ||| .
PNN  ||| S:45283 E:45287 ||| NNP
analyses  ||| S:45287 E:45296 ||| NNS
identify  ||| S:45296 E:45305 ||| VBP
the  ||| S:45305 E:45309 ||| DT
relative  ||| S:45309 E:45328 ||| JJ
importance  ||| S:45328 E:45339 ||| NN
( ||| S:45339 E:45340 ||| -LRB-
0-1 ||| S:45340 E:45343 ||| NNP
,  ||| S:45343 E:45345 ||| ,
with  ||| S:45345 E:45350 ||| IN
0  ||| S:45350 E:45352 ||| CD
being  ||| S:45352 E:45358 ||| VBG
of  ||| S:45358 E:45361 ||| IN
no  ||| S:45361 E:45364 ||| DT
relative  ||| S:45364 E:45373 ||| JJ
importance  ||| S:45373 E:45394 ||| NN
and  ||| S:45394 E:45398 ||| CC
1  ||| S:45398 E:45400 ||| CD
being  ||| S:45400 E:45406 ||| VBG
relatively  ||| S:45406 E:45417 ||| RB
most  ||| S:45417 E:45422 ||| RBS
important ||| S:45422 E:45431 ||| JJ
)  ||| S:45431 E:45433 ||| -RRB-
of  ||| S:45433 E:45436 ||| IN
gene  ||| S:45436 E:45441 ||| NN
and  ||| S:45441 E:45455 ||| CC
protein  ||| S:45455 E:45463 ||| NN
expression  ||| S:45463 E:45474 ||| NN
changes  ||| S:45474 E:45482 ||| NNS
in  ||| S:45482 E:45485 ||| IN
defining  ||| S:45485 E:45494 ||| VBG
the  ||| S:45494 E:45498 ||| DT
SN50  ||| S:45498 E:45513 ||| JJ
phenotype ||| S:45513 E:45522 ||| NN
.  ||| S:45522 E:45524 ||| .
It  ||| S:45524 E:45527 ||| PRP
is  ||| S:45527 E:45530 ||| VBZ
the  ||| S:45530 E:45534 ||| DT
change  ||| S:45534 E:45541 ||| NN
in  ||| S:45541 E:45544 ||| IN
expression ||| S:45544 E:45554 ||| NN
,  ||| S:45554 E:45556 ||| ,
not  ||| S:45556 E:45560 ||| RB
the  ||| S:45560 E:45574 ||| DT
direction  ||| S:45574 E:45584 ||| NN
of  ||| S:45584 E:45587 ||| IN
change ||| S:45587 E:45593 ||| NN
,  ||| S:45593 E:45595 ||| ,
that  ||| S:45595 E:45600 ||| WDT
is  ||| S:45600 E:45603 ||| VBZ
important  ||| S:45603 E:45613 ||| JJ
in  ||| S:45613 E:45616 ||| IN
defining  ||| S:45616 E:45625 ||| VBG
the  ||| S:45625 E:45639 ||| DT
phenotype ||| S:45639 E:45648 ||| NN
.  ||| S:45648 E:45650 ||| .
The  ||| S:45650 E:45654 ||| DT
algorithm  ||| S:45654 E:45664 ||| NN
we  ||| S:45664 E:45667 ||| PRP
used  ||| S:45667 E:45672 ||| VBD
( ||| S:45672 E:45673 ||| -LRB-
Ward  ||| S:45673 E:45678 ||| NNP
Systems  ||| S:45678 E:45686 ||| NNPS
Group ||| S:45686 E:45691 ||| NNP
,  ||| S:45691 E:45703 ||| ,
Frederick ||| S:45703 E:45712 ||| NNP
,  ||| S:45712 E:45714 ||| ,
MD ||| S:45714 E:45716 ||| NNP
)  ||| S:45716 E:45718 ||| -RRB-
is  ||| S:45718 E:45721 ||| VBZ
based  ||| S:45721 E:45727 ||| VBN
upon  ||| S:45727 E:45732 ||| IN
the  ||| S:45732 E:45736 ||| DT
work  ||| S:45736 E:45741 ||| NN
of  ||| S:45741 E:45744 ||| IN
Specht  ||| S:45744 E:45751 ||| NNP
and  ||| S:45751 E:45765 ||| CC
colleagues  ||| S:45765 E:45776 ||| NNS
[  ||| S:45776 E:45778 ||| -LRB-
69  ||| S:45778 E:45781 ||| CD
70  ||| S:45781 E:45784 ||| CD
71  ||| S:45784 E:45787 ||| CD
72  ||| S:45787 E:45790 ||| CD
]  ||| S:45790 E:45792 ||| -RRB-
.  ||| S:45792 E:45794 ||| .
Utilizing  ||| S:45794 E:45804 ||| JJ
proprietary  ||| S:45804 E:45826 ||| JJ
software  ||| S:45826 E:45835 ||| NN
designed  ||| S:45835 E:45844 ||| VBN
by  ||| S:45844 E:45847 ||| IN
Ward  ||| S:45847 E:45852 ||| NNP
Systems  ||| S:45852 E:45860 ||| NNPS
Group  ||| S:45860 E:45866 ||| NNP
( ||| S:45866 E:45867 ||| -LRB-
Frederick ||| S:45867 E:45876 ||| NNP
,  ||| S:45876 E:45878 ||| ,
MD ||| S:45878 E:45880 ||| NNP
) ||| S:45880 E:45881 ||| -RRB-
,  ||| S:45881 E:45893 ||| ,
we  ||| S:45893 E:45896 ||| PRP
made  ||| S:45896 E:45901 ||| VBD
comparisons  ||| S:45901 E:45913 ||| NNS
among  ||| S:45913 E:45930 ||| IN
Connections  ||| S:45930 E:45942 ||| NNP
Map  ||| S:45942 E:45946 ||| NNP
transcripts  ||| S:45946 E:45958 ||| NNS
or  ||| S:45958 E:45971 ||| CC
proteins  ||| S:45971 E:45980 ||| NNS
with  ||| S:45980 E:45985 ||| IN
altered  ||| S:45985 E:45993 ||| JJ
expression  ||| S:45993 E:46004 ||| NN
in  ||| S:46004 E:46007 ||| IN
a  ||| S:46007 E:46009 ||| DT
given  ||| S:46009 E:46015 ||| VBN
group ||| S:46015 E:46020 ||| NN
.  ||| S:46020 E:46050 ||| .
Statistical  ||| S:46050 E:46062 ||| JJ
analysis  ||| S:46062 E:46081 ||| NN
Means  ||| S:46081 E:46087 ||| VBZ
differences  ||| S:46087 E:46099 ||| NNS
were  ||| S:46099 E:46104 ||| VBD
analyzed  ||| S:46104 E:46113 ||| VBN
by  ||| S:46113 E:46116 ||| IN
t-test  ||| S:46116 E:46123 ||| JJ
in  ||| S:46123 E:46126 ||| IN
the  ||| S:46126 E:46130 ||| DT
usual  ||| S:46130 E:46146 ||| JJ
manner  ||| S:46146 E:46153 ||| NN
[  ||| S:46153 E:46155 ||| -LRB-
73  ||| S:46155 E:46158 ||| CD
]  ||| S:46158 E:46160 ||| -RRB-
.  ||| S:46160 E:46162 ||| .
To  ||| S:46162 E:46165 ||| TO
meet  ||| S:46165 E:46170 ||| VB
the  ||| S:46170 E:46174 ||| DT
assumptions  ||| S:46174 E:46186 ||| NNS
of  ||| S:46186 E:46189 ||| IN
this  ||| S:46189 E:46194 ||| DT
analysis ||| S:46194 E:46202 ||| NN
,  ||| S:46202 E:46214 ||| ,
namely  ||| S:46214 E:46221 ||| RB
normality  ||| S:46221 E:46231 ||| JJ
and  ||| S:46231 E:46235 ||| CC
homoscedasticity  ||| S:46235 E:46252 ||| NNS
( ||| S:46252 E:46253 ||| -LRB-
homogeneity  ||| S:46253 E:46265 ||| NN
of  ||| S:46265 E:46278 ||| IN
variances ||| S:46278 E:46287 ||| CD
) ||| S:46287 E:46288 ||| -RRB-
,  ||| S:46288 E:46290 ||| ,
counts ||| S:46290 E:46296 ||| NNS
,  ||| S:46296 E:46298 ||| ,
ratios ||| S:46298 E:46304 ||| NNS
,  ||| S:46304 E:46306 ||| ,
and  ||| S:46306 E:46310 ||| CC
percentages  ||| S:46310 E:46322 ||| NNS
were  ||| S:46322 E:46327 ||| VBD
log  ||| S:46327 E:46331 ||| JJ
or  ||| S:46331 E:46344 ||| CC
arcsin  ||| S:46344 E:46351 ||| JJ
transformed  ||| S:46351 E:46363 ||| NNS
[  ||| S:46363 E:46365 ||| -LRB-
74  ||| S:46365 E:46368 ||| CD
]  ||| S:46368 E:46370 ||| -RRB-
.  ||| S:46370 E:46372 ||| .
This  ||| S:46372 E:46377 ||| DT
allows  ||| S:46377 E:46384 ||| VBZ
for  ||| S:46384 E:46388 ||| IN
parametric  ||| S:46388 E:46409 ||| JJ
statistical  ||| S:46409 E:46421 ||| JJ
testing ||| S:46421 E:46428 ||| NN
.  ||| S:46428 E:46454 ||| .
